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There is a desperate need for new antibacterials to combat the growing threat of antimicrobial 
resistant infections. One of the most common causes of such infections is the Gram-positive 
pathogen Staphylococcus aureus. S. aureus is responsible for the majority of hospital based 
infective deaths, with strains resistant to even last resort antibacterial agents. To combat these 
infections novel antibiotic agents are required. However, few novel antibacterial agents have 
been approved in the past 4 decades, with most products being derivatives of previously used 
chemical classes. As a result, resistance mechanisms are often already present in bacteria, or 
develop rapidly after introduction. Antibacterial agents with novel mechanism of action 
against S. aureus are needed to address this crisis. 
One potential target for the development of novel antibacterials is the essential enzyme biotin 
protein ligase (BPL). The BPL of S. aureus serves two major functions. Firstly, BPL catalyses 
attachment of the vitamin biotin onto biotin-dependent enzymes, such as acetyl-CoA (ACC) 
and pyruvate carboxylase (PC). Secondly BPL is a transcriptional repressor that regulates 
expression of proteins required for biotin biosynthesis and biotin transport. Previous work in 
our laboratory and others has sought to generate inhibitors that target BPL catalytic activity, 
however little is known about their effect on transcriptional repression.  As a result, several 
BPL inhibitors with a variety of chemical scaffolds are described in the literature focusing on 
creating mimics of the reaction intermediate biotinyl-5′-AMP. Despite success in creating 
antibacterial inhibitors, a selective compound that completely inhibits bacterial growth has 
proved elusive. The most potent and selective anti-staphyloccocal compound, biotin-triazole, 
shows promising inhibitory activity (Ki = 90 nM) but is unable to completely inhibit bacterial 
growth.  
The first aim of this thesis is to characterise three distinct chemical classes of BPL inhibitors 
designed to improve whole cell antibacterial activity. Each series of inhibitors was tested to 
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determine in vitro potency and whole cell efficacy through enzyme and antibacterial 
susceptibility assays. The first and second compound series are modifications of the 
previously described biotin-triazole pharmacophore. Series 1 describes the shortening of the 
triazole pharmacophore with a view to producing a refined pharmacophore with greater drug 
like properties. For a similar purpose series 2 was created by halogenation of the C5 position 
on the triazole ring. Improvements in whole cell activity were achieved in series 2, yielding 
our first biotin-triazole inhibitor to completely inhibit bacterial growth (MIC = 8μg/ml). The 
third series tested a separate sulfonyl based compound series and provided the most potent 
BPL inhibitor and antibacterial to date. This compound, BPL 199, exhibited a sub-nanomolar 
Ki (0.7 nM) and an MIC of < 0.5 μg/ml against a panel of S. aureus isolates. Importantly, 
BPL199 also showed no cytotoxicity against two human cell lines, HepG2 and HEK293, and 
was well tolerated in mouse models.  
The second aim of this thesis was to validate the mechanism of antibacterial action of BPL 
inhibitors and investigate potential mechanisms of resistance in S. aureus. To validate the 
mechanism of action, a BPL overexpression strain was constructed in S. aureus strain 
RN4220 and used to test the effect of increased BPL on compound efficacy. This system was 
used against the most potent compounds from all three series. The assay confirmed that BPL 
inhibitors exerted antibacterial effects through inhibition of the BPL enzyme for the most 
potent antibacterial compounds. To determine resistance mechanisms to BPL inhibitors in S. 
aureus several individual isolates of S. aureus NCTC 8325 were exposed to sub-optimal 
concentrations of BPL199 to evolve resistance. Whole genome sequencing of the strains 
resistant to BPL199 was then undertaken to identify potential resistance mechanisms. The 
mutations present occurred in a diverse range of genes including BPL and the biotin 
dependent enzyme pyruvate carboxylase. The one missense mutation in BPL (D200E) was 
further explored with both in vitro and in vivo testing. This amino acid substitution was found 
to not greatly affect catalytic activity, reducing the affinity for biotin by 2-fold (Km wt =  1.8 ± 
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0.3 μM , D200E = 3.8 ± 0.4 μM) and did not affect repression by the inhibitor (Ki wt = 4.8 ± 
2.1 nM   , D200E =10.9 ± 3.5 nM).  However native mass spectrometry was able to show that 
the substitution abolished dimerization of the BPL in vitro and EMSA showed that this 
resulted in reduced DNA binding activity. Further in vivo testing, with a chromosomally 
integrated lacZ reporter assay in E. coli, demonstrated that the mutation was sufficient for 
dysregulation of the biotin transport and synthesis genes with a greater than 50 – fold 
increased biotin concentration required to facilitate repression of biotin transport. Several of 
the other mutations identified, such as the one in PC, were likely to induce loss of function. 
The individual effect of a loss of function in these genes was further explored using 
transposon mutagenesis knock-out strains. The effect of individual loss of function mutations 
in pyruvate carboxylase in S. aureus JE2 determined that this mutation alone was sufficient 
for a four-fold decrease in susceptibility to BPL199.   
In summary this thesis has looked at the development of BPL inhibitors for the purpose of 
antibacterial drug discovery. Using the most potent compounds the mechanism of action and 
resistance to BPL inhibitors was also characterised. This work will help in the future design of 
BPL inhibitors with the resistance mechanisms suggesting potential pathways that are 
important for BPL inhibitor resistance. 
Thesis layout: 
The thesis will be presented as a series of manuscripts either published, submitted or to be 
submitted for publication. Each manuscript will be a chapter with its own references. 
Supplementary material for published manuscripts is available online with citation 
information. A general introduction and discussion will also be included to link together all 
the research conducted during candidature. A publishing agreement with all co-authors 
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1.1 Need for new antibiotic agents 
There is a dire need for new agents to target antimicrobial resistance in hospital, community 
and agricultural settings. With deaths due to drug resistant pathogens expected to exceed 10 
million per year by 2050, and trillions of dollars in associated loss of GDP through lost 
productivity [1], there is a desperate need for action to combat the rise in resistance. Of these 
drug resistant bacteria some of the most concerning are the so called ‘ESKAPE’ pathogens 
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumanii, Pseudomonas aeruginosa, and Enterobacter species) [2] which exhibit extensive 
drug resistance (XDR). Multidrug resistance presents infections that are unresponsive to even 
antibiotics of last resort [3] leading to treatment failure and in many cases mortality. Despite 
the need for treatments to combat these XDR strains there has been a decrease in successful 
new antimicrobials being discovered. In the past 40 years only four novel antibacterial classes 
have received FDA approval [4, 5] with few candidates in the development pipeline [6]. This 
is largely attributed to the high risk, low financial rewards and punishing regulations that has 
led many large pharmaceutical companies to downsize their antibiotic drug discovery 
programs or leave the space entirely, opting to pursue more lucrative options [7, 8]. As the 
threat of antimicrobial resistance (AMR) increases, further research must be pursued to 
develop new chemotherapies. The winding back of large scale and, as discussed later on in 
this review, largely unsuccessful early stage research and development by industry has made 
publically funded university level research an important part of this development.  
1.2 Staphylococcus aureus is a pathogen of concern 
The bacterial pathogen S. aureus is a Gram-positive bacterial species that is one of the most 
common nosocomial infections and a leading cause of hospital based mortality [7]. Typically 




implicated in several serious disease states including skin infections, bacteraemia and 
meningitis [10]. AMR in S. aureus is a major concern  with many strains resistant to β-lactam 
antibiotics, such as methicillin [11]. According to a recent survey 20% of all cases of S. 
aureus bacteraemia worldwide are due to MRSA, with certain countries having rates 
exceeding 40% [4]. As patients with MRSA have a 64% higher risk of infection based 
mortality than those with susceptible strains [4], this increased resistance is highly 
concerning. Clinicians are forced to use treatments previously considered as ‘last resort’ such 
as vancomycin, daptomycin, linezolid and colistin. These treatments often have significant 
dose limiting toxicity, and for the case of colistin little information is available for dosing 
regimens [4, 7, 12, 13]. However resistance to these agents is emerging, with some strains 
now resistant to all frontline antibacterial classes [14, 15]. 
1.3 Project aims 
One strategy to combat increasing AMR is to develop new antibacterial classes with novel 
mechanisms of action and that function through new targets. To take an antibacterial agent 
from discovery to preclinical studies requires overcoming many hurdles. Some of the key 
steps in early stage antibiotic discovery include: identifying compounds with whole cell 
antibacterial activity, devoid of cytotoxic effects and favourable pharmacology, confirming 
the mechanism of action, and determining both the rate and potential mechanisms of 
resistance. Failure at any of these milestones can be a serious roadblock for a new antibiotic. 
The bolded sections above highlights my role in our laboratory’s antibiotic project targeting 
the inhibition of biotin protein ligase (BPL) [16-19]. Below I discuss the literature 
surrounding the decision to target BPL, the previous antibacterial discovery that has been 
pursued, the importance of discovering resistance mechanisms early in development and the 
new technologies that enable such an approach. In particular I will introduce 3 chemical series 




and 4 respectively, detail the chemical optimisation of the previously described biotin-
triazoles chemical scaffold [16] with a focus on improvement of whole cell antibacterial 
activity. Series 3 (figure 6, compound 10), in chapter 5, details a sulphonamide chemical 
scaffold [20]. One compound using this scaffold was particularly potent leading to further 
investigation of its mechanism of action and resistance. Chapter 6 addresses these 
mechanisms of resistance further, with whole genome sequencing used to discover resistance 
causing mutations. 
1.4 Biotin 
Biotin, also known as vitamin H or B7, is a micronutrient essential for all life. Biotin 
serves as a co-factor for biotin-dependent enzymes, which catalyse key carboxylation, 
decarboxylation or trans-carboxylation reactions [21]. Despite its ubiquitous biological role, 
biotin is only produced by plants, bacteria and some fungi. Other organisms scavenge biotin 
from exogenous sources [22]. Mammals primarily obtain biotin from either dietary sources or 
from gut microflora that produce the vitamin. Recycling of protein bound biotin is also 
possible through the activity of biotinidase  [23]. No equivalent biotinidase activity  has been 
identified in bacteria [24]. In S. aureus there are two biotin dependent enzymes acetyl-CoA 
carboxylase (ACC) and pyruvate carboxylase (PC). The biological roles of these important 
bacterial biotin-dependent enzymes is described below, as is their activation by the covalent 
attachment of biotin. 
Acetyl-CoA carboxylase function in S. aureus 
ACC catalyses the first step in fatty acid synthesis (FAS), converting acetyl-CoA to 
malonyl-CoA, and is required for cell wall maintenance and replication [25]. This reaction 
occurs by carboxylation of acetyl-CoA and is facilitated by biotin attached to a key lysine 
residue on ACC. Cell membrane biogenesis is essential for the continued growth and 




should both impede growth of the organism and prevent its proliferation. This is true of all 
Gram-negative organisms where the FAS pathway is essential (reviewed [26, 27]). However, 
there is debate as to whether FAS inhibition is a viable target for Gram-positive pathogens. 
Unlike Gram-negative organisms which have a specific lipid A core that cannot be 
synthesised from host derived fatty acids [26], exogenous fatty acids can be used to 
circumvent the inhibition of the FAS pathway in certain Gram-positive organisms [28, 29]. 
This is not the case in S. aureus as exogenous fatty acids cannot fully ameliorate the 
knockdown of the FabI enzyme in the FASII pathway [26, 27, 29]. This is due to the different 
levels that exogenous fatty acids can be incorporated in the S. aureus membrane. Only 50% of  
phospholipids in the S. aureus membrane can be incorporated from exogenous sources 
compared to 100% in the Gram positive S. pneumoniae [30]. This, and the fact that ACC 
inhibitors have shown efficacy in vitro as well as in mouse models of S. aureus bacteraemia 
[25, 31, 32], supports that antibiotics targeting fatty acid synthesis are viable for S. aureus .  
Pyruvate Carboxylase is important for several biosynthetic pathways 
The effect of inhibiting pyruvate carboxylase (PC) activity through reduced protein 
biotinylation is less well understood in comparison to the inhibition of ACC. PC catalyses the 
conversion of pyruvate to oxaloacetate, a molecule that plays a vital role in the tri-citric acid 
(TCA) cycle and hence, cellular energy production. Oxaloacetate is also a precursor molecule 
to the synthesis of several amino acids (aspartate, lysine, threonine and methionine), and 
pyrimidine nucleotides [33].  As a result inhibiting PC activity should impact upon bacterial 
growth and protein synthesis. This is supported by studies showing that addition of exogenous 
biotin improves growth rates [34, 35] and protein synthesis in S. aureus (reviewed [36]). Of 
particular interest is lysine biosynthesis. In S. aureus lysine is utilised in both peptidoglycan 
cell wall synthesis and in modifying lipids in the cell membrane [37]. Bacterial adaptation to 




peptides, require these membrane incorporated lysines. Therefore the inability to synthesise 
sufficient lysine has the potential to increase bacterial susceptibility to these antibiotics [38].  
Roles of TCA cycle metabolism on virulence in S. aureus 
Despite its important role PC is not essential for bacterial growth in the laboratory. PC 
does not appear in genome wide screens for essential genes [39, 40]. However, genetic 
knockout studies showed that PC is required for virulence in a murine model of infection [41]. 
Knockouts of several TCA cycle enzymes have also been shown to decrease virulence in a 
nematode killing model [42]. Conversely, one study showed increased virulence as a result of 
reduced TCA cycle activity in a biofilm model of infection [43]. These conflicting results 
highlight that the mechanism for regulation of virulence by PC and the TCA cycle is poorly 
understood, making it difficult to predict the effect of PC inhibition. Understanding the effects 
of PC inhibition on virulence is important for determining appropriate usage of BPL 
inhibitors. Metabolic pathways, such as TCA cycle activity, in staphylococci have previously 
been shown to regulate virulence factor expression in response to environmental conditions 
(reviewed [44]). One such regulation is increased synthesis of polysaccharide intracellular 
adhesins (PIA), involved in biofilm formation, that results from repression of TCA cycle 
activity [44]. Recently a transcriptional regulator, catabolite control protein E (CCPE), was 
identified that is positively regulated by the TCA cycle intermediate citrate, offering one 
mechanism for some of the roles of the TCA cycle intermediate enzymes in virulence [45-48]. 
Deletion of the CCPE gene in S. aureus strain Newman caused a ≥ 2-fold change in mRNA 
for 126 target genes, including several gene products required for virulence and pathogenesis 
[45]. The upregulated genes included those involved in synthesising capsular polysaccharides, 
consistent with the observation that decreased TCA cycle activity increased this metabolic 
pathway [44]. Downregulated factors however were also involved in virulence, though largely 




that cells adapt in response to their environment, through production of various virulence 
factors and this adaptation is mediated by signals such as changes in the TCA cycle [45, 46]. 
Disrupting the cycle by inhibiting PC will therefore disrupt the ability of the pathogen to 
adapt to better suit its environment. As a result, understanding how PC inhibition effects the 
bacteria in the niche habitats it colonises may be important for clinical use of BPL inhibitors. 
Biotin protein ligase 
Biotin protein ligase reaction  
Biotin protein ligase is the enzyme which catalyses the attachment of biotin onto 
biotin dependent enzymes [49]. BPL is present in all organisms alongside at least one biotin 
dependent enzyme. The biotinylated enzymes in S. aureus are ACC and PC [50]. 
Biotinylation of these enzymes occurs through two partial reactions. In the first partial 
reaction, biotin and ATP bind to the enzyme in adjacent ligand binding pockets and react to 
produce an adenylated reaction intermediate, biotinyl-5′-AMP (figure 1, compound 2) and 
pyrophosphate. This reaction intermediate adopts a V-shaped geometry which is required to 
occupy both biotin and ATP binding sites (see figure 4). The second partial reaction involves 
the hydrolysis of this reaction intermediate, resulting in attachment of biotin to a specific 
lysine residue on the biotin-accepting domain of the biotin-dependent enzymes [49] and 
release of adenosine monophosphate (AMP) (figure 1). Protein bound biotin then serves as a 
cofactor to transfer carbon dioxide to small molecules such as acetyl-CoA (for ACC) or 
pyruvate (for PC).  Without protein biotinylation neither ACC nor PC is capable of fulfilling 








Figure 1. Reaction mechanism of biotin protein ligase. Equation 1, biotin interacts with ATP 
in the binding pockets of BPL to produce and adenylated reaction intermediate, biotinyl-5′-
AMP. Equation 2, biotinyl-5′-AMP interacts with the specific lysine on the biotin domain of 
biotin dependent enzymes to biotinylate the protein. Adapted from trisubstituted triazole 
paper 
 
Structural classes of BPL 
Three distinct structural classes of BPL exist, with each containing a highly conserved 
catalytic domain and C-terminal cap (figure 2) [36]. S. aureus and E. coli belong to the Class 
II BPLs which contain an additional N-terminal DNA binding domain. This allows the BPL 
to serve as a transcriptional repressor when they form a homodimer (reviewed [51, 52]). The 
class I BPLs, with notable member Mycobacterium tuberculosis, lack this domain. Class III 
BPLs, including human and fungi, contain a distinct N-terminal extension. Though a high 
resolution X-ray structure remains elusive, this N-terminal extension has been shown to be 
important for aiding recognition of the target domain of biotin dependent enzymes, but does 







Figure 2: Structural classes of BPL. Three distinct structural classes of BPL exist with a 
conserved catalytic function. All classes contain a conserved catalytic domain with Class II 
BPLs additionally contain an N-terminal DNA binding domain and class III BPLs a large N-
terminal domain with unknown function. (adapted from Paparella et al.) 
 
BPL transcriptional repression 
The transcriptional repressor capability of class II BPLs has the potential to play a role 
in antibacterial activity. The BPL of S. aureus acts to transcriptionally repress expression of 
transcripts for both the biotin synthesis enzymes and biotin import protein, BioY, in response 
to biotin levels in the cell. This transcriptional repressor function of the class II BPLs relies on 
the homo-dimerisation of the enzyme and binding to two independent half-site recognition 
sequences. The dimerisation is stabilised through interactions of side chains R122 and F123 
with D200 of the opposing monomer (figure 4) on S. aureus BPL (SaBPL) [50, 55, 56] and 




requirements for DNA-binding to occur are still unclear with recent evidence that S. aureus 
BPL may bind recognition sequences as a monomer [55] and recruit a second BPL subunit 
(Jiulia Satiaputra, Thesis 2017). This is in contrast with the E. coli BPL where dimerization 
proceeds prior to DNA binding (reviewed [51, 52]). For both enzymes dimerisation is induced 
by the presence of the reaction intermediate, biotinyl-5′-AMP, (figure 1, compound 2). Many 
successful BPL inhibitors described in the literature are chemical analogues of 2, making it 
likely that BPL inhibitors could similarly induce dimerisation. This has been shown with two 
separate reaction intermediate mimics with E. coli BPL [58]. As BPL inhibitors can act as a 
co-repressor the DNA binding function may play a role in the antibacterial effect of BPL 
inhibitors, making understanding this process important for the future design of BPL 
inhibitors. Recent studies investigating the DNA binding of SaBPL show SaBPL represses 
expression of the biotin biosynthesis operon (bioO), transporter (bioY) [59] and putative long 
chain fatty acid ligases (yhfT/ yhfS) (Jiulia Satiaputra, Thesis 2017) [60]  in response to 
increasing biotin levels.  The respective half sites for these binding sites differ slightly, 
establishing a hierarchy of the three targets in response to biotin stress (Jiulia Satiaputra, 
Thesis 2017). This results in more rapid and complete repression of biotin synthesis enzymes 
than biotin import protein BioY at the same (10 nM) biotin concentrations (Jiulia Satiaputra, 
Thesis 2017). This is thought to be a result of the prioritisation of the less metabolically 
expensive transport system to prevent excess energy usage, as each biotin molecule 
synthesised requires the energetic equivalent of 20 ATP molecules (Jiulia Satiaputra, Thesis 
2017). [61]. The presence of an inhibitor that induces dimerization could, therefore, feasibly 
maintain constitutive repression of either biotin synthesis or both biotin synthesis and 
transport genes. This would be expected to either reduce biotin competing for binding sites or 
lead to biotin starvation. This function was explored in depth by Jiulia Satiaputra, a PhD 





Essential nature of BPL 
Several lines of evidence support targeting BPL for the creation of a new antibiotic 
class. BPL and ACC have been identified as an essential enzyme in S. aureus [39, 40] and 
other organisms [20, 62, 63]. Additionally chemical inhibition of protein biotinylation has 
also been demonstrated, with two mechanisms described in the literature. One, a natural biotin 
mimic with antibacterial activity acts by incorporating into and crippling biotin dependent 
enzymes [64]. The other, which is the focus of this thesis, are synthetic mimics of the reaction 
intermediate which have been produced to block BPL activity with antibacterial effect [16, 
17, 19, 20, 36, 65, 66]. This antibacterial activity occurs through indirectly inhibiting the 
activity of biotin-dependent enzymes which in S. aureus are important for the cellular 
processes of both fatty acid synthesis (FAS), and the tri-citric acid (TCA) cycle (figure 3) 
[67]. The drug design approaches used to inhibit BPL and their antibacterial effect against S. 










Figure 3: Roles of BPL in S. aureus. BPL catalyses the attachment of biotin and 
activation of biotin dependent enzymes acetyl-CoA carboxylase (ACC) and pyruvate 
carboxylase (PC) which are involved in fatty acid synthesis (FAS) and replenishment of the 
tri-citric acid (TCA) cycle respectively (green arrows). As a homodimer BPL also represses 
expression of genes involved in biotin transport and synthesis in response to increasing biotin 






1.5 Drug design approach 
Structure based approaches can succeed where HTS has failed 
Despite the genetic evidence to suggest that the inhibition of BPL provides a route to 
new antibacterials, GSK failed to identify  inhibitors in a high throughput screen with a 
library of 260,000-530,000 compounds [68]. This lack of success highlights a major difficulty 
in antibacterial drug discovery, namely poor sampling of chemical space even in large 
compound libraries. As it is impossible to sample all of chemical space with these ‘shotgun’ 
approaches, structural data is vital to direct compound discovery.  Poor entry of compounds 
into bacteria also contributes to failure. Using the same library of 260,000-530,000 
compounds only three anti-staphylococcal compounds were identified [68]. This highlights 
why whole cell testing is important for compound development. Additional to these general 
concerns, the desire for a broad spectrum antibiotic that lacks toxicity is particularly 
challenging in the case of BPL, due to the presence of a human BPL homologue. The failures 
discussed above indicate the problems with high-throughput screening approaches. Hence, 
our group and others have attempted structure based drug design. The success of BPL 
inhibition attempts recently, using structure guided drug design, suggest the approach is more 
likely to produce a successful antibiotic. 
Targeting BPL by probing the active site/ compound progression 
Using X-ray crystal structures of BPL, structure guided drug design of BPL inhibitors 
has been performed by our laboratory [16-19], and others [20, 66, 69]. The BPL of S. aureus 
undergoes an ordered reaction mechanisms to catalyse protein biotinylation (figure 2). In the 
first step biotin binds to the enzyme and induces a disordered to ordered transition for 
residues 118 to 129 known as the biotin binding loop. This conformational change results in 
the positioning of W127 in the active site such that it can accommodate a π-π stacking 





Figure 4: S. aureus BPL dimer with biotinol-5′-AMP bound (PDB 3RIR). The biotin 
binding loop 118-129 (red) is present initially allowing the biotin moiety (orange) to bind. 
This causes a conformational change ordering the nucleotides involved in nucleotide binding 
I224, A228 (light green) as well as positioning the tryptophan W127 involved in π-π stacking 
with the ATP. This allows the binding of ATP or adenine moeity (purple). Binding of ATP 
and biotin in adjacent pockets leads to the formation of the reaction intermediate which binds 
with a V-shaped geometry. The DNA binding domains of SaBPL are also highlighted at the 
N-terminal end (blue). Inset the residues involved in dimerisation of the BPL are highlighted: 





biotin  to form an adenylated reaction intermediate, 2 [70]. Consequently, the enzyme must 
bind biotin first, then ATP. Initial attempts to inhibit BPL with analogues of biotin, such as 
biotin acetylene (figure 5, compound 3), were pursued. However, highly conserved amino 
acids in the biotin-binding pocket made selectivity difficult [17]. On the other hand, the 
nucleotide binding pockets of human and S. aureus enzymes show greater diversity in amino 
acid sequence [16, 71]. As a result of this, the knowledge of the reaction mechanism has 
impacted inhibitor design. Inhibitors that target the active site must contain a biotin moiety, as 
biotin is required for the formation of the nucleotide-binding pocket. The biotinyl 
pharmacophore can then be elaborated with groups that can occupy the ATP site. This allows 
selectivity to be engineered into the compound.  
Phosphodiester linker and creation of the pan inhibitor biotinol-5′-AMP 
Replacing the labile phosphoanhydride linker of the reaction intermediate 2 with more 
stable bioisosteres yields competitive inhibitors that target the active site. Several 
modifications to the linker have improved selectivity and potency (figure 5). First, replacing 
the phosphoanhydride group from the reaction intermediate with a non-hydrolysable 
phosphodiester bioisostere, produced a potent inhibitor biotinol-5′-AMP (MIC 1-4μg/ml) with 
no observed cell toxicity against HepG2 cells (CC50 < 200 μg/mL) (figure 5, compound 4) 
[19, 57]. Unfortunately, 4 still exhibited poor selectivity, inhibiting the human enzyme (Ki = 
182 nM) as well as that of S. aureus (Ki = 18 nM, MIC 1-4μg/ml) and M. tuberculosis (Ki = 
52 nM, MIC 0.5-2.5μg/ml). Subsequent attempts to produce a selective inhibitor have focused 
on replacing the phosphoanhydride linker with a triazole bioisostere in S. aureus (figure 5, 








Figure 5: Previously described compounds used to inhibit BPL. 3) biotin acetylene, 4) 
biotinol-5′-AMP, 5) biotin triazole without modifications to the adenosine moiety, 6) removal 
of the ribosyl moiety and 7) replacement of adenine with a benzoxalone of 5 improved 





Figure 6: Representative compounds of the 3 series addressed in this thesis. Series 1, Benzyl 
biotin-triazoles, were attempts to shorten the triazole pharmacophore and probe the ribose 
binding pocket to improve activity. Series 2, halogenation at the 5C position on the triazole 
ring of both biotin-triazole 6 and series 1 was attempted to improve whole cell activity. Series 
3, removal of the ribose and other modifications to the biotin sulfonamide Bio-AMS produced 






Biotin triazoles- Series 1 and 2  
Our group has focused on designing selective BPL inhibitors using a triazole based 
linker. The triazole heterocycle has several desirable features for drug discovery of BPL 
inhibitors: 1. The linker is stable to enzymatic degradation, including biotinidase [72], 2. 
hydrogen bonding interactions are available through the nitrogens of the triazole heterocycle, 
and 3. the linker can impart the same V-shaped geometry observed in the natural substrate 2 
[16]. Using the 1,2,3-triazole 5 (figure 5) yielded activity against the SaBPL (Ki 1.17 μM) but 
not the human homologue.  Development of this compound series to improve potency was 
undertaken with removal of the ribosyl moiety 6 (figure 5). Further replacement of the 
adenine with a benzoxalone, as in 7 (figure 5) produced the most potent (Ki 0.09 μM) and 
selective compound with  >1100 fold selectivity over the human homologue. However, the 
compound failed to completely inhibit bacterial growth, with only 80% inhibition observed at 
8 μg/ml [16]. Chapters 3 and 4 will focus on our attempts to improve the whole cell 
antibacterial activity of the biotin-triazole inhibitors. Series 1 (figure 6, compound 8), in 
chapter 3, focuses on shortening the biotin-triazole pharmacophore, by appending a benzyl 
moiety to probe binding in the ribose pocket of BPL. Series 2 (figure 6, compound 9), in 
chapter 4, explores halogenation on the C5 position of the triazole ring as an alternative route 
to improve whole cell activity.  
Sulfonamide linker-series 3 
Another chemical scaffold that has been described in the literature are the biotin 
sulphonamides. Replacement of the phosphoanhydride linker of 2 with a sulfonyl bioisostere 
was first used to produce a series of inhibitors targeting the BPL of M. tuberculosis [20]. The 
most potent of this series, Bio-AMS demonstrated efficacy against M. tuberculosis BPL in 
vitro and possessed whole cell antibacterial activity (MIC= 0.31–0.78 μM) [20]. Despite the 




S. aureus and had cytotoxicity against one of two cell lines, with 50% inhibition of a Vero 
liver cell line at 58 μM [20]. As the ribose on biotin-triazole was shown to be dispensable for 
anti-staphylococcal activity [16], Series 3 (figure 6, compound 10) in chapter 5, focuses on 
compounds based around the Bio-AMS sulfonyl linker with no ribose moiety to create new 
selective SaBPL inhibitors. The Bio-AMS compound is also the only BPL inhibitor described 
in literature that has a confirmed mechanism of antibacterial action through inhibition of 
biotinylation activity [20]. A similar approach to that adopted for this compound is used in 
this thesis to characterise promising compounds from Series 1, 2 and 3. 
1.6 Resistance mechanisms and detection 
Trying to understand the evolution and dispersal of drug resistant pathogens is an 
important part of modern healthcare. Although AMR can occur through many independent 
mechanisms, they broadly fall into 4 categories: 1) The antibiotic is prevented from entering 
the cell through modification of the cell membrane, 2) is actively removed from the cell by 
efflux pumps, 3) the antibiotic is degraded enzymatically, or 4) the antibiotic target is 
modified through mutation to prevent activity [73]. Understanding these resistance 
mechanisms can help guide further drug development by determining if new analogues avoid 
obvious mechanisms or if new approaches are needed. Additionally, discovery of pre-existing 
resistance mechanisms, or rapid spontaneous resistance rates during development, can prevent 
costly failures in clinical trials [74, 75].  Cross-resistance to existing antibacterial agents 
should also be investigated as often patients treated with last line treatments will have 
previously been subjected to other antibacterial agents [76, 77]. Understanding what cross-
resistance may be present for BPL inhibitors is therefore important information for eventual 
clinical use.  
AMR has been reported for every antibiotic released to clinic [7, 78]. The advent of 




genomes, has greatly enhanced the quantity of biological data surrounding these resistant 
strains. This has allowed for faster and easier identification of resistance conveying mutations 
in the lab through parallel evolution studies [79-83] and determining how resistance may 
develop and disseminate in the clinic [84-86]. Parallel evolution studies expose bacteria to 
sub-inhibitory concentrations of an antibiotic for extended periods of time, allowing 
resistance to evolve. The resistant strains can then be compared through whole genome 
sequencing. Several studies in S. aureus and other organisms reported only 1-6 mutations are 
required for a strain to become resistant to certain antibiotics [79-81, 87]. These studies have 
also shown that in parallel isolates, most mutations occur in the same regions of the genome 
and, for some antibiotics, with a defined order. In combination with the use of sequencing in 
diagnosis of infections, such studies could be used to predict a strains resistance potential  in 
clinical settings as is already the case for some resistance determinants [88-90]. The clinical 
relevance of such studies has also been explored with comparison of resistance evolution in 
clinical and laboratory settings. To address how the evolution of resistance differs in vitro vs 
in the clinic, one study looked at M. tuberculosis strains [86].  Using whole genome 
sequencing (WGS) conserved resistance mechanisms were observed in both cohorts. 
However, the clinical strains also contained additional compensatory mutations not selected 
for in the controlled evolution experiment  [86]. This highlights that whilst such in vitro 
studies are valuable for understanding mutational hotspots and resistance mechanisms they 
may not necessarily fully explore all possible mechanisms. As fitness deficits associated with 
resistance can be detrimental in a competitive environment, resistance often is slower and 
requires additional mutations to flourish in vivo. Similarly, adaptive resistance that requires 
particular environmental conditions will not be discovered, as described for one Pseudomonas 
aeruginosa resistance mechanism [75]. In chapter 6 of this thesis parallel evolution studies of 
the mutational hotspots involved in S. aureus resistance to BPL inhibitors were undertaken 




1.7 Research described in this thesis. 
This thesis focuses on characterising the next generation of BPL inhibitors for 
antibacterial drug discovery. Three different pharmacophores are presented the benzyl 
triazoles, C5-halogenated triazoles and sulfonyl-linked compounds. Their potency, whole cell 
antibacterial activity and mechanism of action are studied, providing valuable information for 
future compound development. Each series undergoes the same compound progression plan, 
summarised in figure 7. This encompasses initial screening undertaken against the target 
enzyme, subsequent analysis of active compounds in cell based systems, both for efficacy 
against bacteria and lack of toxic side effects against human cell lines, and finally 
investigation of the mechanisms of action and resistance for the most promising compounds. 
The first paper in this thesis “A new series of BPL inhibitors to probe the ribose-
binding pocket of Staphylococcus aureus biotin protein ligase” addresses attempts to improve 
the activity of triazole based BPL inhibitors as well as create a smaller pharmacophore for 
further development and optimisation. My contribution to this paper was cytotoxicity testing 
of the most potent compounds as well as generation of a BPL overexpression system in S. 
aureus RN4220 which I subsequently used to test the mechanism of action of compounds. 
The second manuscript in progress “Halogenation of biotin protein ligase inhibitors improves 
whole cell activity against Staphylococcus aureus” addresses the hypothesis that halogenation 
at the C5 position on triazole inhibitors would improve whole cell antibacterial activity. My 
contribution to this paper was assisting in antibacterial susceptibility testing of the second 
halogenated series and undertaking mechanism of action studies against the most potent 
compound in the first series. The third manuscript in preparation “Sulfonyl based mimic of 
biotinyl-5′-AMP as antibacterial agents against Staphylococcus aureus” addresses 
modification of a sulfonyl based linked BPL inhibitor described in literature to improve 




further investigation into the mechanism of action and resistance was undertaken with a 
particular focus on the transcriptional co-repressor function of the compound. My 
contribution to this work was to perform: antibacterial susceptibility against ATCC49775 and 
RN4220, cytotoxicity assays, mechanism of action and advanced resistance studies, and 
expression, purification and characterisation of the D200E mutant BPL. The final manuscript 
in preparation in this thesis “Mutations associated with reduced susceptibility to a novel 
antibacterial class, Biotin Protein Ligase inhibitors, in Staphylococcus aureus” addresses the 
mutations associated with resistance to BPL inhibitors in strains generated in the previous 
manuscript. All of the experiments described in the manuscript were performed by myself 
with the exception of the whole genome sequencing run. The aim of this thesis is to help 
guide the development of BPL inhibitors as antibacterial agents, in particular highlighting the 
role of the co-repressor function of BPL inhibitors in antibacterial activity. The studies into 
resistance mechanisms further address concerns of rapid resistance, as well as providing 
indicative mutations that lead to resistance, helping understand what pathways are required to 









Figure 7: General progression of compounds used for series 1-3 in this thesis, red boxes 
represent work that was directly undertaken by me as part of this thesis (adapted from slide 
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2.1.1 General materials 
Materials Suppliers 
CoStar 96 well flat bottom clear plate  Corning Life Sciences, USA 
CoStar 96 well round bottom clear plate  Corning Life Sciences, USA 
96 well LUMITRAC 600 white plate  Greiner Bio One, Germany 
Thermo Scientific™ centrifuge tubes (10 mL) Thermofisher Scientific 
BD Falcon™ conical centrifuge tubes (50 mL)  
epT.I.P.S.® Standard 50-1250μL  Eppendorf, Hamburg, Germany 
epT.I.P.S.® Standard 20-300μL  Eppendorf, Hamburg, Germany 
Eclipse Pipette Tip refill System  Labcon, North America 
Thermo Scientific™ QSP filtered pipette tips 
(0.1 - 10 µL) 
Thermofisher Scientific 
ART® self-sealing barrier pipette tips 
(20,200,1000 µL) 
 
SealPlate® Plate seals  Excel Scientific Inc., Victorville, USA 
T25/T75/T175 Corning Flask  Corning Life Science, USA 
Eppendorf® UVette® disposable cuvettes  
Parafilm M® laboratory film  
PVDF membrane (HybondTM-C extra)  Ammersham Pharmacia Biotech, CA, USA 
Gel blotting paper  Schleicher & Schuell Bioscience GmbH, Germany 
Whatman® qualitative filter paper  
Amicon® centrifugal devices  Millipore, MA, USA 
Satorius VIVASPIN20, 10000 MWCO  Sartorius, Goettingen, Germany 
Cellu.SepT2 MWCO 6000-8000 dialysis tubing  Membrane Filtration Products Inc., Seguin, TX, 
USA 
BD precise syringes (5 mL, 50 mL)  
Ministart syringe filter 0.2μM, 0.45μM and 
0.8μM  
Sartorius, Goettingen, Germany 
5 mL Profinia® IMAC cartridge  Bio-Rad Laboratories Inc., CA, USA 
NuPage® 4-12% Bis-Tris polyacrylamide gels  Invitrogen, CA, USA 






2.1.2 Chemical reagents 
 
function Reagents Supplier 
antibiotics 
 
Ampicillin  Sigma-Aldrich, MO, USA 
Chloramphenicol  Sigma-Aldrich, MO, USA 
Erythromycin  Sigma-Aldrich, MO, USA 
Streptomycin sulfate salt  Sigma-Aldrich, MO, USA 
Chloramphenicol  Amresco Inc., OH, USA 
Daptomycin Sigma-Aldrich Inc., MO, USA  
Methicillin Sodium Salt  Sigma-Aldrich Inc., MO, USA  
Tetracycline University of Adelaide, SA, 
Australia 
Vancomycin Hydrochloride from Streptomyces 
orientalis  
Sigma-Aldrich Inc., MO, USA  
assay 
reagents 
Biotin  Sigma-Aldrich inc., CA, USA 
Dithiothreitol (DTT)  Sigma-Aldrich, MO, USA 
Dissociation-Enhanced Lanthanide Fluorescence 
Immunoassay (DELFIA
®
)  Enhancement Solution  
Perkin Elmer, Boston, MA, 
USA 
Eu-Streptavidin  Perkin Elmer, Boston, MA, 
USA 
Anti-Glutathione-S-transferase Antibody (Anti-GST 
Ab) Produced in Rabbit 
Sigma-Aldrich Inc., MO, USA  
ATP Sigma-Aldrich Inc., MO, USA  
bacterial 
reagents 
Bacto™ Agar  Becton, Dickinson and 
Company, MD, USA  
BBL™ Mueller Hinton II Broth, Cation-Adjusted 
(CAMHB) 
Becton, Dickinson and 
Company, MD, USA 
Defibrillated Sheep’s Blood  Institute of Medical and 
Veterinary Science, SA, 
Australia  




Foetal Calf Serum  Sigma- Aldrich Inc, MO, USA 
Trypan blue  
Sodium pyruvate (100mM)  
Glutamine  
WST-1 cell proliferation reagent  Roche Diagnostics, IN, USA 
DNA 
analysis 
2-log DNA ladder  New England Biolabs, MA, 
USA 
Agarose, DNA grade  Probiogen Biochemicals, 
Australia 
GelRED™ Nucleic acid gel stain  Biotium Inc., CA, USA 
BigDye (version 3) reaction mix  Perkin Elmer, CA, USA 
RNA  
analysis 
DNAsaI (RNAse free) Life technology, Carlsbad, USA 
RNAse free water Life technology, Carlsbad, USA 
RNAprotect Bacteria reagent Qiagen, GmbH, Germany 
protein 
work 
Bradford protein reagent concentrate Bio-Rad Laboratories Inc., CA, 
USA 
Phenylmethanesulfonyl fluoride (PMSF) Sigma-Aldrich, MO, USA 




MOPS/MES SDS running buffer Invitrogen Life Technologies 
Inc., NY, USA 
Precision Plus Protein Kaleidoscope standards Bio-Rad Laboratories Inc., CA, 
USA 
Bovine Serum Albumin Roche Diagnostics, IN, USA 




Dimethyl Sulfoxide (DMSO) Sigma-Aldrich Inc., MO, USA  
Ethylenediaminetetraacetic Acid (EDTA) University of Adelaide, SA, 
Australia 




Water (MQ-H2O) University of Adelaide, SA, 
Australia 
Polyoxyethylene Sorbitan Monolaurate (Tween
®
 20) Sigma-Aldrich Inc., MO, USA  
Potassium Chloride (KCl) University of Adelaide, SA, 
Australia 
Trisaminomethane (Tris) University of Adelaide, SA, 
Australia 




2.1.3 DNA modifying enzymes 
All enzymes were all obtained from New England Biolabs, MA, USA unless otherwise stated 
Enzymes Used  






Polymerases Phusion DNA polymerase 
Taq DNA polymerase 
Ligases T4 DNA ligase 
Phosphatases Antarctic DNA phosphatase 
 
 
2.1.4 Commercial Kits 
Kit Suppliers 
QIAprep miniprep kit QIAGEN, GmbH, Germany 
QIAquick gel extraction kit  QIAGEN, GmbH, Germany 
Qiaquick PCR purification kit QIAGEN, GmbH, Germany 
RNeasy mini Kit QIAGEN, GmbH, Germany 
Wizard genomic DNA purification kit Promega, Wisconsin, USA 





2.1.5 Buffers and Media 
Reagents recipe 
CAMHB 3 % (w/v) Beef Extract, 17.5 % (w/v) Acid Hydrolysate of Casein, 
1.5 % (w/v) Starch, supplemented to contain 20-25 mg/L calcium 
and 10-12.5 mg/L magnesium. 
CAMHB Agar CAMHB supplemented with 1.25 % (w/v) Bacto™ agar 
CAMHB Blood Agar CAMHB supplemented with 1.25 % (w/v) Bacto™ agar and 5 % 
Defibrillated Sheep’s Blood  
Luria Broth (LB):  1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl, 
adjusted to pH 7.0 with NaOH 
LB agar: LB supplemented with 1.5% (w/v) bacto-agar 
SOC Broth 2% w/v tryptone, 0.5% w/v Yeast extract, 10mM NaCl, 2.5mM KCl, 
10mM MgCl2 and 10mM MgSO4 
DMEM   
Trypsin EDTA  
Blocking Buffer (For Western 
analysis):  
1% (w/v) BSA in PBS 
Cell Lysis Buffer:  10% (v/v) β-mercaptoethanol, 2% (w/v) SDS 
Cleaning solution 1 (2x):  100 mM NaCl, 100 mM Tris, at pH 8.0 
Cleaning solution 2 (4x):  2M NaCl, 0.4 M sodium acetate, at pH 4.5 
DNA loading buffer (6X):  0.5x Tris-borate-EDTA (TBE) buffer, 40% (v/v) glycerol, 1mg/ml 
bromophenol blue 
Native IMAC lysis 
buffer/wash buffer 1:  
300 mM KCl, 50 mM Tris at pH 8.0, 5 mM imidazole 
Native IMAC wash buffer 2 :  300 mM KCl, 50 mM Tris at pH 8.0, 10 mM imidazole 
Native elution buffer :  300 mM KCl, 50 mM Tris at pH 8.0, 250 mM imidazole 
SDS-PAGE loading buffer:  0.1 M Tris (pH 7), 4% (w/v) SDS, 0.2% (w/v) bromophenol blue 
SDS-PAGE Coomassie Blue 
staining solution:  




10% (v/v) Methanol, 10% (v/v) Acetic acid 
PBS:  0.136 M NaCl, 2.7 mM KCl, 1.46 mM KH2PO4 at pH 7.4 
PBS-Tween:  PBS, 0.1% (v/v) Tween 20 
TAE:  40mM tris pH 8.2, 20 mM sodium acetate, 1 mM EDTA 
TBS:  25 mM Tris pH 7.5, 150 mM NaCl 
TE:  10 mM Tris pH 7.5, 1 mM EDTA 
Transfer Buffer:  39 mM glycine, 48 mM Tris, 0.037% (w/v) SDS, 20% (v/v) 
methanol 
Transformation buffer 1:  30 mM potassium acetate, 100 mM RbCl, 10 mM CaCl2, 50 mM 
MnCl2 , 15% glycerol 
Transformation buffer 2: 10 mM MOPS, 10 mM RbCl, 75 mM CaCl2, 15% glycerol 
BPL storage buffer:  50 mM Tris pH 8.0, 100 mM KCI, 5% glycerol, 0.1 mM EDTA pH 







2.1.6 General bacterial strains 
E. coli DH5α (supEΔlac169 (p80lacZΔM15) hsdR17 recA1 end AA1 gyrA96 thi-1 relA1): For 
routine molecular cloning (New England Biolabs, MA, USA)  
E. coli BL21-CodonPlus(DE3)-RIPL strain (B F- ompT hsdS(rB- mB-) dcm+ Tetr gal λ(DE3) 
endA The [argU proL Camr ] [argU ileY leuW Sterp/Specr]: E. coli BL21 carrying (λDE3) 
insertion and contains plasmids encoding extra copies of genes for rare tRNAs in E. coli. This strain 
was used for recombinant expression of pET expression vector encoding the gene for Staphylococcus 
aureus wild type and D200E mutant biotin protein ligases (Aglient Technologies, CA, USA).  
Methicillin Sensitive Staphylococcus aureus ATCC 49775: Purchased from the American Tissue 
Culture Collection. This strain was used for antimicrobial susceptibility assays. 
Staphylococcus aureus NCTC8325: Purchased from the American Tissue Culture Collection. This 
strain was used for antimicrobial susceptibility assays and resistance studies. 
Staphylococcus aureus RN4220: Obtained from Dr Alistair Standish, University of Adelaide. This 




Plasmid Description  Source 
pGEMT-SaBPL(6xHis) pGEMT plasmid containing saBPL with 6x his-tag [1] 
pGEMT-SaBPL-
D200E-(6xHis) 
pGEMT plasmid containing saBPL D200E with 6x his-tag This 
study 
pIT4_TL_152002 Chromosomal integration plasmid  (λ-attP, Tc
R









pCN51 Shuttle vector for E. coli to S. aureus transformation with 
cadmium inducible promoter 
[3] 
pCN51-NcoI Negative control vector with NcoI site for cloning This 
study 













All custom oligonucleotides were ordered from Geneworks, Adelaide, SA, Australia 
 
 
2.1.9 General Software: 
software function 
graphpad prism 7 data analysis 
UCSF Chimera 1.10.2 protein structure analysis 
APE A plasmid editor plasmid viewing and primer design 
SnapGene Viewer plasmid viewing and diagram creation 
Ugene biological data viewer 
Applied biosystems SeqScanner 2 analysis of sanger sequencing data 
IGV Next generation sequencing alignment viewer 
Mauve Progressive aligner genome alignment 
































B493 5′ -TAGGTGATGAACATATCAGGC-3′  pCN51 MCS sequencing 
primer 
This Study  
594 5′-TGCGATGCATGCGCACTTATTC 
AAGTGTATTT-3′  





pCN51 Cd cassette reverse 
primer with NcoI site and PstI 




5′-GGCATCACGGCAATATAC-3′  attp-λ PCR screening primer  [2] 
Lambda 
P2 
5′ -ACTTAACGGCTGACATGG-3′  attp-λ PCR screening primer  [2] 
Lambda 
P3 
5′-GGGAATTAATTCTTGAAGACG-3′  attp-λ PCR screening primer  [2] 
Lambda 
P4 




2.1.10 Web based services 
service address function 
NCBI  (http://www.ncbi.nlm.nih.gov/)  Used to access protein, nucleotide, and 
PubMed databases. 








(www.ebi.ac.uk/Tools/psa/emboss_needle/) dual sequence alignment (protein and 
nucleotide) 
bioCyc (biocyc.org/) genomic annotation viewer 
Prodoric (www.prodoric.de/) Promoter region prediction software 









2.2.1 Microbiological methods 
2.2.1.1 Antibiotic selection 
Unless stated otherwise the following concentrations were used to select for plasmids 
or chromosomal integration events. Tetracycline (4 μg/ml), Chloramphenicol (34 μg/ml), 
Ampicillin (100 μg/ml), Erythromycin (10 μg/ml plasmid, 5 μg/ml chromosomal), 
Streptomycin (75 μg/ml). 
2.2.1.2 Antibacterial susceptibility evaluation 
Antibacterial activity was determined by the microdilution broth method as 
recommended by the CLSI (Clinical and Laboratory Standards Institute, Document M07-A8, 
2009, Wayne, Pa.) using cation-adjusted Mueller-Hinton broth (CAMHB) (Trek Diagnostics 
Systems, U.K.). Overnight cultures of bacteria were subcultured 1:1000 and grown to mid log 
phase (OD600 of approximately 1.2 = 10
9
CFU/ml). Cultures were further diluted 1:1000 into 
CAMHB and used to inoculate 96 well plates containing diluted compound. Compound 
dilution plates were prepared by serial two-fold dilution of DMSO dissolved compounds into 
CAMHB such that the concentration of DMSO was consistently 50%. This master stock was 
further diluted, 6.4 μl into 43.5 μl of CAMHB, into a 96 well flat bottom plates. An equal 
volume, 50 µL, of the diluted cell suspension was added to each well. After addition of the 
cell inoculum each well contained ≈ 5 x 10
4 
 CFU with a concentration range of 64 to 0.06 
μg/ml in 3.2% DMSO. Plates were incubated at 37°C for 20-22 hours with shaking. Growth 
of the culture was quantified after this time by measuring the absorbance at 620 nm using a 







2.2.1.3 Mechanism of action studies  
Antibacterial activity was determined on S. aureus RN4220 containing either pCN51-
NcoI (parent vector) or pCN51-BPL (BPL over-expression). Compounds, dissolved in 
DMSO, were serially diluted from 64 to 0.0625 µg/ml in Mueller Hinton broth (3.2% (v/v) 
DMSO) supplemented with 10 µg/ml erythromycin for plasmid selection and 25 nM CdCl2 to 
induce BPL expression. Log phase cultures of transformed S. aureus RN4220 strains, grown 
in the absence of compound, were diluted 1:1000 into media containing compound. Growth 
of the cultures at 37°C with shaking was then monitored with absorbance at 630 nm every 30 
mins for 16 hours using an EL808™ Absorbance Microplate Reader (BioTek Instruments Inc, 
Winooski, VT, USA). S. aureus harbouring pCN51-BPL grown in the absence of compound 
served as a negative control. The mechanism of action assays were performed in triplicate.  
 
2.2.1.4 Bacterial Cell enumeration 
Cell density of a growing culture was estimated by using optical density (OD600 1.2 = 
10
9
 CFU/ml) to determine an appropriate dilution series. The culture was then serially diluted 
1 in 10 and aliquots of the dilution (20 μL) applied to pre-warmed LB Agar plates in 
duplicate. The plates were incubated at 37°C overnight and colonies enumerated from the first 








2.2.2 Tissue culture methods 
2.2.2.1 Culturing of HepG2 and HEK293 cells 
Mammalian cell lines were propagated and incubated at 37°C with constant 5% CO2. 
Cells were seeded at approximately 10
5
 cells/ml and grown to 80% confluence in DMEM (+ 
10%FCS, 1 mM sodium pyruvate and 2 mM glutamine), in a T75 flask before media was 
removed and cells washed twice with 10 ml of PBS. Cells were subsequently treated for 5 
minutes with 1mL of trypsin EDTA at 37
o
C. Following this 9mL of DMEM was added, cells 
were centrifuged, supernatant removed and cells resuspended in 4mL of DMEM. An aliquot 
of the cell suspension was viewed under the microscope at this stage to ensure proper cell 
dispersion, and the cell density determined using a haemocytometer following trypan blue 
staining. Cells were centrifuged 2 minutes and resuspended in DMEM such that the 
concentration of cells was 10
5 
cells/ml for seeding either 96 well plates or a second flask. 
 
2.2.2.2 Cytotoxicity Assay 
HepG2 or HEK293 cells were seeded in 96-well tissue culture plates at 10
4
 cells per 
well (protocol 2.2.2.1). After 24 hours growth, cells were treated with varying concentrations 
of test compound. Dilutions of compound were prepared by two fold serial dilution of 
compound in DMEM, maintaining a constant DMSO concentration, 2% (v/v) for HepG2 or 
0.5% (v/v) for HEK293. After treatment for 48 hours, 10 μl WST-1 cell proliferation reagent 
(Roche) was added to each well and incubated for 30 minutes at 37°C. The WST-1 assay 
quantitatively monitors the metabolic activity of cells by measuring the hydrolysis of the 






2.2.3 Protein methods 
2.2.3.1 Protein expression 
Histidine tagged proteins were expressed using the following protocol, antibiotics 
were used as required by plasmid selection. E. coli BL21 (DE3) colonies containing the 
desired expression plasmid were streaked out onto LB Agar. A single colony was used to 
inoculate a 50 ml overnight culture and grown overnight at 37°C. This culture was diluted 
1:50 into 2 L (4× 500 mL) and grown until an OD of approximately 0.6-0.8. Recombinant 
protein expression was then induced by addition of IPTG to a concentration of 0.5 mM. Cells 
were induced for 2-3 hours before being harvested by centrifugation at 5000 × g for 5 minutes 
at 4°C. The cell pellets were washed with 100 mL of 1× PBS and then further pelleted at 5000 







2.2.3.2 Purification of recombinantly expressed SaBPL 
Cell pellets were resuspended in 30 mL ice cold native IMAC lysis buffer containing 1 
mM PMSF. Cells were disrupted by at least 5 passages through a M110L homogenizer 
(Microfluidics, USA) until the solution became clear and homogenous. Cellular debris was 
removed by two centrifugation steps each at 20 000 x g for 10 minutes at 4 ºC and then the 
solution was passed through 0.8 μm and 0.45 μm filters. His-tagged BPL proteins were 
purified by immobilized nickel affinity chromatography (IMAC). The filtered lysate was 
applied at 5 mL/min onto a 5 mL Profinia IMAC cartridge that was pre-equilibrated with 10 
column volumes of milliQ water then 10 column volumes of native IMAC lysis buffer. The 
column was washed with 6 column volumes of native IMAC lysis buffer (300 mM KCl, 50 
mM Tris pH 8.0, 5 mM imidazole) followed by 6 column volumes of native IMAC wash 
buffer 2 (300 mM, 50 mM Tris pH 8.0, 10 mM imidazole). His-tagged BPL was eluted with 
native elution buffer (300 mM KCl, 50 mM Tris pH 8.0, 250 mM imidazole). Material eluting 
from the column was detected by UV absorbance at 280 nm and pooled and subsequently 
exchanged into storage buffer (50 mM tris pH 8.0, 100 mM KCl, 5% glycerol, 1 mM EDTA, 
1mM DTT) using overnight dialysis at 4 °C. For SPR experiments SaBPL was dialysed into 
storage buffer containing 1× PBS, 100 mM KCl, 5 % glycerol, 1 mM EDTA and 1 mM DTT. 
Protein concentrations were determined using a Bradford protein assay (BioRad) using bovine 
serum albumin (Sigma Aldrich®) as a standard (section 2.2.3.5). The fractions containing 
BPL were confirmed using SDS-PAGE gel electrophoresis and the in vitro biotin 







2.2.3.3 Preparation of bacterial cell lysates 
For cell lysates 1ml of OD600 = 1 culture was resuspended in 40 μl of lysis buffer 
(2% SDS, 10% BME) and vortexed to resuspend cells before boiling for 5 minutes. Samples 
were then centrifuged and boiled as per SDS PAGE analysis procedure (2.2.3.4). S. aureus 
cell lysates were prepared by first incubating cells in TE buffer containing 1 mg/mL lysozyme 
and 0.5 mg/ml lysostaphin for 30 minutes at 37°C before addition of 2% SDS and 10% βME. 
Concentration was quantified prior to SDS and βME addition by Bradford assay (2.2.3.5). 
 
2.2.3.4 SDS PAGE analysis 
Protein, 10μL (approximately 5μg), was added to an equal volume of 2× SDS loading 
buffer containing 5% βME. The samples were then boiled at 100°C for 5 min and centrifuged 
briefly before being loaded and fractioned on a NuPage® 4-12% Bis-Tris polyacrylamide 
precast gel (Invitrogen) using 1X NuPAGE® MES running buffer (Invitrogen) at 200 V for 
approximately 40 min or until the dye front reached the bottom of the gel. The gel was stained 
with Coomassie blue for 1 hour and destained overnight or transferred onto a PVDF 
membrane (HybondTM-LFP) using a semi dry transfer unit (Hoefer Semiphor, Amersham 










2.2.3.5 Determination of protein concentration 
Protein concentration was assayed using the Bradford Reagent (Bio-Rad Laboratories 
Inc., CA, USA). A standard curve of bovine serum albumin (BSA) was generated from 0 to 1 
mg/mL and a linear regression was used to calculate protein concentration. For the Bradford 
assay 10 μL of sample was mixed with 200 μL of 1x Bradford Reagent in a 96 well plate 
(Corning Life Sciences, USA). Absorbance at 620 nm wavelength was measured on a 
microplate reader (Molecular Devices, CA, USA). 
 
2.2.3.6 Concentration of proteins 
Concentration of protein solutions was performed using Amicon® centrifugal filter 
devices (10000 MWCO) (Millipore, MA, USA) following manufacturer’s instruction manual. 
The columns were rinsed with MilliQ water and then equilibrated in the appropriate buffer by 
centrifugation at 5000 x g at 4 °C for 20 minutes or until reaching a required retentate volume. 
The buffer was discarded prior to adding protein sample into the spin column. Likewise, 
protein was concentrated by centrifugation at 5000 x g at 4 °C until reaching a required 
retentate volume. For retentate recovery, the concentrate was collected using a pipette with 
200 microliter tip to new pre-cold microcentrifuge tube. The protein was kept at -80 ºC until 
needed. For storage of using Amicon® centrifugal filter devices, the centrifuge tube was 








2.2.3.7 Streptavidin blot analysis of biotinylated protein 
For detection of biotinylated protein from either an in vitro biotinylation reaction or 
bacterial cell lysates the following protocol was performed. After biotinylation reaction 
(2.2.3.8) or cell lysate preparation (2.2.3.3) an appropriate volume of 2X SDS loading dye 
was added to each preparation. The samples were then boiled at 100 °C for 5 min and 
centrifuged briefly before being loaded and fractioned on a NuPage® 4-12% Bis-Tris 
polyacrylamide precast gel (Invitrogen) using 1X NuPAGE® MES running buffer 
(Invitrogen) at 200 V for approximately 40 min or until the dye front reached the bottom of 
the gel. The proteins fractionated by SDS-PAGE were transferred onto a PVDF membrane 
(HybondTM-LFP) using a semi dry transfer unit (Hoefer Semiphor, Amersham Pharmacia 
Biotech, CA, USA). The PVDF membrane was pre-soaked briefly in methanol, then milliQ 
water, followed by transfer buffer. The transfer was run for 1 hour at 80 mA per gel. The 
membrane was then soaked with blocking buffer (1% (w/v) BSA in PBS) for at least 1 hour at 
room temperature and washed 3 times with PBS-Tween before being probed with streptavidin 
conjugated - Alexa-488 (Life Technologies, 1:1000 dilution, PBS-Tween) for another hour at 
room temperature. The membrane was washed another 3 times with PBS-Tween then 










2.2.3.8 In vitro protein biotinylation assay 
 Enzymatic biotinylation of an acceptor subtrate protein (GST-SaPC90) was 
performed with 2 μl of a BPL stock (6 nM in storage buffer: 50 mM Tris (pH 8.0), 100 mM 
KCL, 1 mM EDTA, 1 mM DTT *added fresh each time, 5% (w/v) glycerol) added to 14 μl of 
pre-warmed reaction mix (50 mM Tris pH 8.0, 5.5 mM MgCl2, 100 mM KCl, 5 μM biotin, 3 
mM ATP, 0.1 μM DTT, 25 μM Apo substrate [GST-SaPC90]), with 4 μL of either compound 
or vehicle control and incubated for 20 minutes. The reaction was terminated by the addition 
of 80 μL stopping buffer (110 mM EDTA, 50 mM Tris (pH 8.0)). The biotinylated GST-
fusion proteins were then captured using anti-glutathione-S-transferase antibody (Sigma-
Aldrich Inc., MO, USA). 96 well white plates (Greiner Bio One, Germany) that had been pre-
treated overnight at 4°C with 50 μL of anti-glutathione-S-transferase antibody (Sigma-Aldrich 
Inc., MO, USA) diluted 1:40,000 in TBS were blocked for 2 hours at 37°C with 1% (w/v) 
BSA in TBS. Before the reaction, plates were prewarmed at 37°C for 30 minutes. Twenty 
microliters of the completed biotinylation reaction was added to the antibody capture plates in 
triplicate wells. The plate was sealed with parafilm to prevent evaporation and incubated for 1 
hour at 37° to allow antibody capture of the GST fusion proteins. The reaction mix was then 
discarded and the plates washed 5× in Wash buffer (TBS + 0.1% Tween-20). Fifty microlitres 
of Eu-Streptavidin , diluted 1:1000 into Wash buffer was then added to each well and the 
plate covered by parafilm before incubation for 30 minutes at 37°C. (Each step following the 
addition of Eu-streptavidin was protected from light by covering with aluminium foil.) The 
unbound Eu-streptavidin was then removed and wells again washed 5× with wash buffer 
before addition of 50μL of DELFIA enhancement solution to facilitate dissociation of the 
Europium ion. Dissociated Europium was measured using time resolved fluorescence at 340 




2.2.4 Molecular Biology Techniques 
2.2.4.1 Preparation of chemically competent E. coli cells 
Overnight cultures of cells in LB media were prepared and subcultured the next day 
into LB medium (330 μL of overnight culture into 10 mL of LB). The cell cultures were 
grown at 37 ºC for 1.5 – 2 hours until they reached an OD600 measurement of 0.6. The 
growing culture was then subcultured 5 mL into 100 mL of pre-warmed LB media in a 1 L 
flask and was grown at 37 ºC for 1.5 hours. The cells were then pelleted by centrifugation at 
5000 x g for 5 minutes at 4 ºC and resuspended in 10 mL/pellet of transformation buffer 1 (30 
mM potassium acetate, 100 mM RbCl, 10 mM CaCl2, 50 mM MnCl2 (4.H20), 15% glycerol) 
and incubated on ice for 5 minutes. The cells were then pelleted by centrifugation at 4000 x g 
for 5 minutes at 4 ºC and resuspended in 1 mL/ pellet of transformation buffer 2 (10 mM 
MOPS, 10 mM RbCl,  75 mM CaCl2, 15% glycerol) and incubated on ice for 5 minutes. The 
cells were then aliquoted and stored in pre-chilled 1.5 mL microcentrifuge tubes at -80 ºC. 
 
2.2.4.2 Transformation of chemically competent E. coli cells 
Competent cells were thawed on ice and 1-5 μL of plasmid DNA added to a 50 μL ml 
aliquot before being incubated on ice for at least 30 minutes. This was followed by heat shock 
treatment at 42°C for 90 seconds followed by further 5 minutes incubation on ice. Pre-
warmed SOC media, 900 μL, was added to each transformation and the cells were incubated 
for 1 hour at 37 ºC with shaking. Cells were then pelleted by centrifugation at 2600 x g for 1 
min and the pellet was resuspended in 100 – 200 μL of supernatant. Cells were immediately 







2.2.4.3 Agarose Gel Electrophoresis 
Analysis of DNA and separation of DNA fragments was performed using Agarose gel 
electrophoresis. Gels were prepared with 1-2% (w/v) Agarose in TAE buffer. 6x DNA 
loading buffer was added to DNA samples before loading and samples were electrophoresed 
100V in TAE buffer. Gels were stained in 1x GelRed, 0.1 M NaCl solution for at least 10 
minutes. DNA was visualised on a blue light transluminator for gel extraction or imaged 
using the Chemidoc XRS (Bio-Rad, California, U.S.A.)  
 
2.2.4.4 Plasmid preparation  
A 5 mL overnight culture of the desired bacterial strain was prepared at 37°C, or 
relevant permissive temperature for replication. Plasmid DNA was extracted as per 
manufacturer’s instructions using the QIAGEN plasmid Mini Kit. When extracting from S. 
aureus a pre-lysis incubation in the presence of 250 μL buffer P1 containing 10 μg 
lysostaphin was undertaken for 10 minutes at 37 degrees. Plasmid concentration was 
quantified using the nanodrop 2000 and quality determined by A260/280 ratio of 1.8-2. 
 
2.2.4.5 Plasmid purification 








2.2.4.6 Gel extraction 
Gel extraction was performed using the QIAGEN gel extraction kit as per 
manufacturer’s instructions. 
2.2.4.1 Sanger sequencing  
Sanger sequencing was undertaken by preparation of a 12 μl reaction containing 
plasmid or PCR product DNA in milliQ H2O with 10 pmol of sequencing primer to AGRF for 
their Purified DNA service and sequenced as per AGRF guidelines (Sanger Sequencing 
Sample Submission Guide (GSEQDOC00166) v1.8). Sequencing was performed using 
Applied Biosystems 3730 and 3730xl capillary sequencers with Big Dye Terminator (BDT) 
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We report the synthesis and evaluation of 5-halogenated-1,2,3-triazoles as inhibitors of biotin 
protein ligase from Staphylococcus aureus. Whilst the inhibitory activity of the compounds 
against SaBPL was comparable to previous 1,4-disubstituted-1,2,3-triazoles, the halogenated 
compounds exhibited significantly improved antibacterial activity over their non-halogenated 
counterparts. Importantly the 5-fluoro-1,2,3-triazole compound 4c had antibacterial activity 





There is an urgent need to discover new therapeutics to combat antibiotic resistant bacteria.
1
 
Target based approaches to antibiotic discovery have been somewhat limited by poor 
translation of compounds with potent in vitro activity into bio-actives with whole cell 
antibacterial activity.
2,3,4
 This is often due to the formidable bacterial cell wall and/or 
membranes that present as barriers, preventing compounds from permeating into the cell and 
accessing intracellular drug targets. Bacteria also employ efficient efflux pumps to eliminate 
cytotoxic compounds from the cell. One approach to improve whole cell activity is through 
halogenation of compounds that are otherwise cell impermeable.
5
 This has been successfully 
demonstrated with the fluoroquinolones, where replacement of the hydrogen on C6 of the 
quinolone moiety improved whole cell potency ~100-fold.
6,7
 Similar approaches using 
halogenation have also been reported to improve anti-biofilm activity of  phenazines and 
quinolones.
8-9
 Due to its small size and high electronegativity, the fluorine atom is an 
attractive modification that can improve the binding affinity, membrane permeability and 
metabolic stability.
10
 As such, 20% of available drugs are fluorinated.
11
 
Biotin protein ligase (BPL) is a promising drug target that has been the subject of antibiotic 
drug discovery programs by several groups.
2, 12-21
 BPL serves as the sole enzyme responsible 
for the biotinylation, and subsequent activation, of biotin-dependent enzymes. The clinically 
important bacterial pathogen Staphylococcus aureus possesses two such biotin-dependent 
enzymes, namely acetyl-CoA carboxylase and pyruvate carboxylase, which catalyze key 
reactions in the important metabolic pathways of fatty acid biosynthesis and gluconeogenesis 
respectively.
14
 BPL catalyzes protein biotinylation through ligation of biotin 1 and ATP to 
form biotinyl-5ʹ-AMP, 2 (see Figure 1).
14
 Replacement of the labile phosphoanhydride linker 
in 2 with more stable bioisosteres has produced inhibitors that target BPL from bacterial 




 and Mycobacterium tuberculosis.
21,20 
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These pieces of work have recently been reviewed.
13
 However, there are precious few 
examples of BPL inhibitors with whole cell anti-staphylococcal activity. One example of a 
bioactive BPL inhibitor is biotinol-5ʹ-AMP 3 (Figure 2) that reduces the growth of S. aureus 
and M. tuberculosis with minimal inhibitory concentrations (MIC) of 2 and 2.5 μg/mL 
respectively,
19
 thereby providing in vitro proof of concept that pharmacological inhibition of 
BPL is a strategy for new antibacterials. Recently we reported 1,4-disubstituted-1,2,3-
triazoles as a novel class of BPL inhibitor that selectively targets the BPL from S. aureus over 
the human homologue.
12,13, 17
 This biotin triazole class is exemplified by 4a (Figure 3) that 
has the in vitro potency and selectivity over the human homologue necessary for a pre-clinical 
candidate, but poor whole cell activity.
12
 For example, 8 μg/mL of 4a only reduced the 
growth of S. aureus ATCC 49775 by 60% of non-treated controls. 
12, 18
 Inhibition of cell 
growth by > 90% is a minimum requirement for a lead compound. Attempts to improve 
antibacterial potency by shortening and simplifying the 1,4-disubstituted-1,2,3-triazole 
pharmacophore (see 5a-k, 5m, 5o, Figure 3)
13
 have had modest success. Here we present 
halogenated derivatives of two pharmacophores 4a and 5a-o as the first examples of 1,4,5-
trisubstituted triazole BPL inhibitors. Specifically, the hydrogen on C5 of the triazole 
heterocycle is replaced with iodine, fluorine or chlorine as in compounds 4b, 4c and 4d, 
respectively. Whole cell activity of these compounds was determined using antimicrobial 
susceptibility assays, with further microbiological testing and biochemical assays performed 
to confirm the mechanism of action was consistent with the inhibition of BPL. We show that 
halogenation of the triazole linker improved whole cell antibacterial activity whilst 
maintaining selectivity for SaBPL, providing a new approach to the development of 
chemotherapeutics to combat S. aureus.  
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Figure 1. Reaction mechanism of biotin protein ligase. 
 
 
Figure 2. Chemical structure of biotinol-5ʹ-AMP. 
 
 
Figure 3. Chemical structure of BPL inhibitors. (B) Benzoxazolone triazole series. (C) 




RESULTS AND DISCUSSION 
 
Series 1: compounds 4a-d (Figure 3A) 
The synthesis of the 1,4-disubstituted-1,2,3-triazole 4a
12
 and the 1,4,5-trisubstituted-1,2,3-
triazoles 4b-d was carried out as summarized in Scheme 1. 5-iodo-1,2,3-triazole 4b was 
synthesized from biotin acetylene 8
12
, which was firstly elaborated to biotin 1-iodoacetylene 
10 under CuI and N-iodomorpholine.  Biotin 1-iodo acetylene 10 was reacted with azide 9
12
 
in the presence of CuI as a catalyst and TEA as an amine ligand to afford 5-iodo-1,2,3-triazole 
4b with 36% yield.
25
 Iodinated 4b was subsequently converted to fluorinated 4c and 
chlorinated 4d by halogen exchange reaction based on the optimised conditions reported by 
Worrell et al.
26
 In particular iodide 4b was treated with 5 equivalents of either potassium 
fluoride or potassium chloride in MeCN/H2O (1:1) mixture and reacted in the microwave 
reactor at 180ºC for 10 minutes to give 5-fluoro-1,2,3-triazole 4c and 5-chloro-1,2,3-triazole 










Fluorination of compound 4a improved whole cell activity without cytotoxic effects. 
Antimicrobial sensitivity assays were performed upon S. aureus clinical isolate ATCC 
49775 to quantitate the antibacterial potency of 4a-d (Figure 4A).
16
 Whole cell activity was 
determined by measuring the optical density of the bacterial cultures spectrophotometrically 
at 620 nm after 24 hours of treatment with 4a-d. As previously reported,
27
 parent compound 
4a only reduced the optical density of the culture by ~40%. This low level of activity was 
insufficient to determine an MIC. In contrast, fluorinated analogue 4c was bioactive against S. 
aureus and inhibited measurable growth of the bacteria with an MIC of 8 μg/mL (16 μM). 
This was the first example of a biotin triazole with potent antibacterial activity. This data 
provides the first proof of concept data to support halogenation of BPL inhibitors as a route 
towards improved whole cell bioactivity against S. aureus. Interestingly, the effect was 
specific for fluorination as the 5-iodo (4b) and the 5-chloro (4d) analogues did not improve 
antibacterial activity against S. aureus. To verify that the mechanism of antibacterial action of 
4c was due to the inhibition of BPL, antibacterial susceptibility assays were performed upon 
S. aureus RN4220 engineered to recombinantly over-produce the BPL target (Figure 4B) .
13
 
A concomitant decrease in whole cell activity is expected upon over-expression of a drug 
target, should a compound’s mechanism of action be directly through that target.
13, 21
 In 
support of this, an 8-fold increase in the MIC was observed for the BPL inhibitor biotinol-5ʹ-
AMP 3 as a result of BPL overexpression (Supporting information Figure S4). Consistent 
with 4c binding directly to the BPL target, over-expression of BPL also significantly reduced 
antibacterial potency of the inhibitor, with an MIC increase of greater than 16-fold and only 
~60% growth reduction observed at the highest concentration tested (approx. 100μM). 
Finally, cytotoxicity assays were performed with HepG2 liver cells on inhibitors 4b-d. No 
cytotoxicity was measured at the highest concentration tested (approx. 80μM) (Table 1). 
Together these results suggested that halogenation of BPL inhibitors may provide one avenue 
towards improved whole cell bioactivity against S. aureus.  
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Figure 4. Inhibition of S. aureus growth in vitro. (A) Compounds, 3 (orange), 4a (brown), 4b 
(blue), 4c (red), and 4d (green) were tested against S. aureus strain ATCC 49775. (B) 
Compound 4c was tested for antibacterial susceptibility against S. aureus RN4220 in the 
presence and absence of overexpressed SaBPL. S. aureus RN4220 harbouring pCN51-BPL 
(solid line), pCN51 (dashed line) or no vector (dotted line) are shown. 
 
Antibacterial activity was not a result of increased inhibitory activity in compound 4c  
 To determine if the observed improved whole cell activity of 4c was due to increased 
binding activity against the BPL target, in vitro binding and enzyme assays were performed 
(Table 1).  The bimolecular association and dissociation constants were investigated for 4a-d 
through Surface Plasmon Resonance (SPR) binding assays using SaBPL immobilized onto a 
sensor chip. 
16, 27-28
 All four compounds displayed rapid association and dissociation rates that 
were unable to be quantified by the SPR software (Supporting information Figure S3). 
Accordingly, the KD values were measured using a steady state affinity model. There was no 
significant difference between the affinity of 4a (KD = 8.4 μM) or the halogenated analogues 
4b-d binding to SaBPL (Table 1). The indistinguishable and fast dissociation rates observed 
for all inhibitors rules out increased occupancy of 4c on the BPL target (a function of slow 
dissociation kinetics) as a possible mechanism for increased whole cell potency. Next, an in 
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vitro biotinylation assay was employed to measure the inhibition of compounds 4b-d against 
recombinant BPLs from S. aureus and Homo sapiens. The enzymatic incorporation of 
radiolabeled biotin onto an acceptor protein, the 90 amino acid biotin-acceptor domain from 
pyruvate carboxylase (SaPC90), was measured in the presence of varying concentrations of 
inhibitor. Halogenated analogues 4b-d all had similar activities as the non-halogenated parent 
against SaBPL, with 4a being the most potent inhibitor  (Ki = 0.23 μM) (Table 1). The 
iodinated (0.41 μM) and the fluorinated (0.42 μM) analogues 4b and 4c were the most potent 
halogenated analogues, whilst the chlorinated analogue 4d proved to be the weakest 
compound in the series (Ki = 0.90 μM). All of the compounds tested were inactive against 
human BPL (Ki > 10 μM) highlighting that the halogenated analogues still maintained the 
reported selectivity observed with 4a.  This is important as it suggests that the modified 
triazole is still well accommodated by the SaBPL but not the human homologue. Together the 
SPR binding and in vitro protein biotinylation assays demonstrate that the fluorine of 4c 
played no direct role in binding, so the improved whole cell activity of 4c is not the result of 

























4a H 8.4 ± 1.0 0.23 ± 0.01 >10 >100 >80 
4b I 3.8 ± 1.5 0.41 ± 0.02 >10 >100 >80 
4c F 7.1 ± 3.4 0.42 ± 0.05 >10 16 >80 
4d Cl 10.1 ± 1.8 0.9 ± 0.11 >10 >100 >80 
* Previous enzymology and X-ray crystallography studies have demonstrated that biotin 
triazole 4a is a competitive inhibitor against biotin 1.
12
 Therefore, inhibition constants (Ki) 




Finally, a crystal structure of 4c in complex with SaBPL was determined to define the 
mechanism of binding (Figure 5). The resulting data was compared to the published 
structures of SaBPL in complex with biotin 1 or biotinyl-5′-AMP 2, as well as the parent 
compound 4a (PDB 3V7S)
12
 (Figure 5A). Both 4a and 4c adopted similar binding modes 
with the biotinyl and benzoxazolone moieties occupying the biotin and nucleotide pockets, as 
expected. Importantly for this study, the fluorine of 4c did not directly contribute any new 
bonding interactions with SaBPL compared with 4a. This result was consistent with the in 
vitro assays described above. Previous crystallography studies on SaBPL in complex with 1 
and 2 have established that conformational changes accompany ligand binding and these are 
necessary for inhibitor binding. The same conformational changes were also observed for 
both 4a and 4c. In particular, residues T177-K131 undergo a disordered to ordered transition 
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when in complex with biotin.
27,30
 This feature, known as the biotin-binding loop, encases the 
active site to prevent ligand dissociation and positions the side chain of W127 in the active 
site such that it can participate in a π-π stacking interaction with the adenyl group of ATP. 
Both 4a and 4c induced these same disordered-to-ordered conformational changes resulting in 
ordering of the biotin-binding loop. Hydrogen-bonding between the triazole heterocycle and 
amino acids in the BBL are apparent in both structures, namely between triazole N2 and the 
side chain of R125, and triazole N3 with R122 (Figure 5B-C). Further interactions were 
observed between the triazole and side chains of D180 and K187. The main differences 
between the 4a and 4c structures were apparent with the side chain of W127. For SaBPL in 
complex with 4a, the indole ring of W127 adopted the same conformation as observed in the 
co-structure with biotin 1 and a biotinyl-5-AMP 2 that facilitates ATP binding. In the co-
complex with 4a, the conformation of the indole sidechain defines a T-shaped π interaction 
with the triazole heterocycle. However, for 4c, the side chain of W127 was tilted, thereby 
disrupting the protein-triazole interaction. This was offset by a new T-shaped π interaction 
between W127 and the benzoxazolone group (Supporting information Figure S1). The 
volume and area of the binding pocket of SaBPL were also increased as 5-fluoro triazole 4c 
was bound into the binding site of the enzyme. (Supporting information Table S1). These 
data suggest an induced fit model of ligand binding occurs involving the biotin binding loop, 
and the BPL active site  has enough flexibility to accommodate a tri-substituted biotin-triazole 




Figure 5. Comparison of co-crystal structures. (A) 4a (green) and 4c (magenta) were 
superimposed to reveal the different binding pose of benzoxazolone ring. (B) Binding Pocket 
of SaBPL in complex with 4a (PDB 3V7S). (C) Binding pocket of SaBPL in complex with 






Series 2: compounds 5a-o, 6a-o, 7a-o (Figure 3B) 
A second series was investigated to determine if the improved whole cell activity observed 
for 4c could be replicated through halogenation of the smaller benzyl-biotin triazole BPL 
inhibitors.
13
  Substitution of the hydrogen at C5 on the triazole linker with either fluorine or 
iodine was performed upon the benzyl biotin triazoles 5a-o
13
. The synthesis of 1-benzyl-5-
proto-1,2,3-triazoles 5a-o,
13
 1-benzyl-5-iodo-1,2,3-triazoles 6a-o, and 1-benzyl-5-fluoro-
1,2,3-triazoles 7a-o was accomplished as outlined in Scheme 2-3. The 5-iodo-1,2,3-triazoles 
6a-l and 6n were synthesized according to the same procedure described for the synthesis of 
compound 4b (Scheme 2). However, this method is a two-step reaction requiring the 
preformation of biotin 1-iodo acetylene 10 and occasionally yields a considerable ratio of 5-
proto triazole as a side product. For instance, compound 5l was isolated as a side product 
along with compound 6l after the two-step reaction (Scheme 3). The 5-iodo-1,2,3-triazole 6m 
was synthesized by reaction of biotin acetylene 8
12
 with 4-trifluoromethylbenzyl azide in the 
presence of LiI, Cu(ClO4)2, and TEA in THF (Scheme 3).  This reaction proceeds by an in 
situ conversion of the alkyne to the iodoalkyne.
31
 Synthesis of 5-fluoro-1,2,3-triazoles 7a-n 
were carried out using the same conditions as for preparation of 4c (Scheme 1) except the 
reaction time was reduced from 10 min to 5 min. The 5-iodo-1,2,3-triazoles 6a-n were 
separately treated with potassium fluoride in MeCN/H2O (1:1) mixture and reacted in the 
microwave for 5 min to give the corresponding 5-fluoro-triazoles 7a-n in yields of 64-81%. 
Increased reaction time reduced the observed yields due to decomposition of the starting 
materials. For example, the yield of 7c was increased from 33% to 76% as reaction time was 
decreased from 10 min to 5 min. Carboxylic acids 6o, 7o were prepared by hydrolysis 





Scheme 2. Synthesis of benzyl triazole series 
 
 






Bioassays of 5a-o, 6a-o, and 7a-o (Figure 6) 
To measure the antibacterial and inhibitory potencies of the new analogues, antimicrobial 
sensitivity assays were performed alongside biochemical assays with derivatives 5a-o, 6a-o, 
7a-o. The anti-bacterial assays performed here employed S. aureus RN4220 as our earlier 
microbiology data revealed this strain to be more sensitive to BPL inhibitors than S. aureus 
ATCC 49775. For example, literature compound 3 was 32-fold more active against RN4220 
than ATCC 49775. In this series containing fifteen benzyl substituents, nine iodinated (6a, b, 
f-h, j-m) and six fluorinated compounds (7a, e, f, h, j, m) displayed greater whole cell 
antibacterial bioactivity than their non-halogenated counterparts (Figure 6A, Table 2). The 
activity of the compounds was likewise tested in an in vitro protein biotinylation assay. A new 
BPL enzyme assay was employed using a GST tagged biotin domain (GST-SaPC90) as the 
biotin acceptor protein. Biotinylated protein was captured on white 96-well plates coated with 
anti-GST antibody and quantitated using Europium-conjugated streptavidin and time resolved 
fluorescence. This eliminated the need for costly radiolabeled biotin and retains the ability to 
accurately characterize inhibitory potency with both assays giving comparable Ki values for 3 
as a test compound (Supporting information Table S2). Concomitant improvements of both in 
vitro inhibition and whole cell bioactivities due to halogenation were observed for five 
examples in this series, namely 5-7b, e, h, l and m, where the non-halogenated parent 
compounds were inactive in both the enzyme (Ki > 10 μM) and microbiological assays (MIC 
> 64 μg/ml) but halogenation greatly improved potency in both cases. For example, iodination 
of the inactive 4-CF3 5m (Ki > 10 μM, MIC > 64 μg/ml) yielded derivative 6m (MIC 4 
μg/ml), that was one of the most potent of the antibacterials. Similarly, analogues of the 3-I 
5h, iodo-6h (Ki 0.38 μM) and fluoro-7h (Ki 0.86 μM), were amongst the more potent BPL 
inhibitors with anti-staphylococci activity (MIC 4 μg/ml) despite a lack of bioactivity for the 
parent compound. However, like observed with 4a to 4c, four examples in this series showed 
increased whole cell activity without a corresponding decrease in Ki (5-7f, g, j, k). This was 
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highlighted with derivatives of 4-Cl 5g and 4 t-Bu 5k where iodination only improved Ki by a 
modest 2-fold but this translated into a significant improvement in whole cell activity (MIC 
inactive 5g vs 6g 16 μg/ml; inactive 5k vs 6k 8 μg/ml). Likewise, halogenation of 3-Cl 5f and 
2-OMe 5j did not significantly alter the Ki but greatly improved anti-staphylococci activity 
over their non-halogenated parents, with iodo 6f also being one of the most potent 
antibacterials (MIC 4 μg/ml) in this series. Importantly for this work, no reduced whole cell 
activity was observed as a result of halogenation. These datum indicated that halogenation of 
C5 on the triazole linker is a valid approach for improving whole cell antibacterial activity of 


































Figure 6. Effect of halogenation at the C5 position on (A) MIC against S. aureus RN4220 and 
(B) Ki against S. aureus BPL.  × (H), ● (2-F), ■ (3-F), ▲ (4-F) ● (2-Cl), ■ (3-Cl) ▲ (4-Cl), 




Compound 5c shows alternate binding poses in the SaBPL active site. 
The possible modes of binding for the benzyl triazoles in the active site of SaBPL were 
analyzed using a combination of crystallography and docking studies. To facilitate this, the 
co-crystal structure of SaBPL in complex with compound 5c, identified as the most potent 
unhalogenated BPL inhibitor of the benzyl-biotin-triazoles
13
 (Supporting information Figure 
S2A), was determined and served as a template for further docking studies. The crystal data 
revealed that 5c induced the same disorder to ordered conformational change in the biotin-
binding loop described earlier. However, high B-factors were observed for both main chain 
and sidechain components of W127- Ser129 indicating high protein flexibility in this region. 
In addition, the indole ring of the W127 side chain was tilted out of the plane necessary for 
ATP binding. Well-defined electron densities were observed for the biotinyl and triazole 
moieties of 5c, which placed the inhibitor in the biotin-binding pocket as expected. However, 
the electron density for the appended benzyl group could not be resolved. This observation 
suggested that the benzyl substitution may adopt more than one binding conformation in the 
BPL active site. Docking studies were then performed to investigate possible modes of 
binding for the benzyl group.  In silico analysis predicted that the benzyl group could occupy 
one of two adjacent binding pockets; one generated by K187 with BBL residues H126-
Ser129, and a second site encompassed by K187, K176, D180 and I321. Further docking 
analysis with halogenated analogues 6c and 7c demonstrated SaBPL could accommodate the 
substitutions on C5 of the triazole heterocycle, again with two alternative binding poses 
(Supporting information Figure S2B-C). The multiple binding poses adopted by these benzyl 
triazoles could explain the lack of a clear structure activity relationship from the biochemical 











ID R X Ki – SaBPL (μM) 
MIC - RN4220  
μg/mL (μM) 
5a  H H N/D >64 (>172) 
6a   I 2.86 ± 0.13 16 (32) 
7a   F 2.50 ± 0.13 64 (164) 
5b 2-F H >10 >64 (>164) 
6b   I 0.67 ± 0.09  16 (31) 
7b   F 1.32 ± 0.26 > 64 (>157) 
5c 3-F H 0.28 ± 0.02 >64 (>164) 
6c   I 0.54 ± 0.08  > 64 (>124) 
7c   F 1.77 ± 0.15 > 64 (>157) 
5d 4-F H 0.6 ± 0.1 > 64 (>164) 
6d   I 3.86 ± 0.17 > 64 (>124) 
7d   F 4.16 ± 0.29 > 64 (>157) 
5e 2-Cl H >10 >64 9>157) 
6e   I 0.39 ± 0.03 > 64 (>120) 
7e   F 1.15 ± 0.07 8 (18) 
5f 3-Cl H 0.39 ± 0.04 16 (39) 
6f   I 0.48 ± 0.03 4 (7) 
7f   F 1.40 ± 0.05 8 (18) 
5g 4-Cl H 1.1 ± 0.07 >64 (>144) 
6g   I 0.65 ± 0.06 16 (30) 
7g   F 3.26 ± 0.13 > 64 (>150) 
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5h 3-I H >10 >64 (128) 
6h   I 0.38 ± 0.01 4 (6) 
7h   F 0.86 ± 0.06 4 (7) 
5i 4-I H 0.56 ± 0.06 >64 (>128) 
6i   I 0.43 ± 0.07 > 64 (>102) 
7i   F 1.02 ± 0.25 > 64 (>124) 
5j 2-OMe H 0.56 ± 0.05 >64 (>159) 
6j   I 0.80 ± 0.03 16 (30) 
7j   F 0.55 ± 0.04 32 (76) 
5k 4-tBu H 1.22 ± 0.07 >64 (>149) 
6k   I 0.66 ± 0.11 8 (14) 
7k   F 0.73 ± 0.05 > 64 (>143) 
5l 2-NO2 H > 10 > 64 (>153) 
6l   I 0.80 ± 0.06 8 (14) 
7l   F 0.78 ± 0.07 > 64 (>147) 
5m 4-CF3 H >10 >64 (>145) 
6m   I 2.75 ± 0.20 4 (7) 
7m   F N/D 8 (17) 
5n 4-COOMe H N/D >64 (>149) 
6n  I 1.54 ± 0.08 >64 (>113) 
7n  F >10 >64 (>140) 
5o 4-COOH H 0.67 ± 0.06 >64 (>154) 
6o  I 0.23 ± 0.07 >64 (>118) 








The 5-halogenated-1,2,3-triazoles reported here display greater bioactivity against the 
clinically important bacterial pathogen S. aureus than their respective parent compound series. 
In particular substitution of the hydrogen on C5 of the triazole linker of 4a with fluorine led to 
the first example of a biotin triazole inhibitor of SaBPL where an MIC could be quantitated 
against S. aureus. The precise mechanism for the improved whole cell activity observed with 
the fluorinated derivatives over their non-halogenated parent could be due to several factors. 
Amongst these are increased permeability across the bacteria membrane, increased resistance 
to bacterial efflux pumps, increased resistance to metabolic enzymes that degrade the 
compound, or higher inhibitor occupancy on the BPL target inside the bacterial cell. As the 
latter is a function of the dissociation rate between the protein target and compound, we 
employed SPR analysis to probe the kinetics of the biomolecular interaction. The fluorinated 
analogue exhibited no difference in binding kinetics to its non-halogenated equivalent, so 
higher occupancy of the target by the halogenated analogue is unlikely. Similarly, it is 
possible that the addition of a carbon-fluorine bond in the molecule improves upon the 
metabolic stability inside the bacterial cell, due to the higher energy requirement to hydrolyse 
a C-F bond compared to its C-H counterpart 
32
 . However, we suggest this is unlikely to be the 
causative factor as the triazole heterocycle is already highly resistant to metabolic enzymes
33
. 
We argue that higher intracellular concentrations of inhibitor as a result of increased uptake 
and compound accumulation is the most likely mechanism for the observed improvements in 
whole cell activity.  
One mechanism for increased compound uptake would be through increased membrane 
permeability. In support, fluorination of drugs has been shown to enhance free energy of 
partitioning and improve passive diffusion across lipid membranes 
5
. Future studies will seek 
to address the mechanisms of biotin-triazole import and efflux in S. aureus, as well as other 
bacterial pathogens. Quantitating cellular uptake of small molecules can be investigated 
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utilizing technologies sensitive enough to measure intracellular concentrations, such as 
LC/MS-MS. This has been previously reported for M. tuberculosis using BPL inhibitors 
34
. 
This approach would also address compound metabolism in bacteria, confirming the 
metabolic stability of the biotin triazoles. A recent study probed the physiochemical properties 
necessary for chemicals to accumulate in Gram-Negative organisms, and defined certain rules 
that facilitated the conversion of a Gram-positive active compound to one with broad-
spectrum activity.
35
 The properties that correlated with accumulation were an amphiphilic and 
rigid structure, with low globularity, and containing a primary amine.
35
 Further work is 
required to determine if the halogenation effect reported here is due to changes in key 
physiochemical properties. This bears exploring and a broader compound series may serve to 
address these questions. As the improved whole cell activity appears to be independent of 
increased inhibitory potency against BPL, halogenation of triazole heterocycles may offer a 
promising method to improve bioactivity of other compounds utilizing this linker
36-37
. Such a 
study would offer valuable insight into whether the effect observed here is specific to the 
biotin-triazole class. As compound entry poses one of the most challenging barriers to 
antibacterial drug discovery,
2,3,4
  a better understanding of the mechanisms of cell entry and 
efflux in bacteria will drive the development of new antibiotics more than the optimization of 
affinity for individual targets. Structure activity relationships, as detailed here, comprise an 





General Materials and Methods. 
All reagents were obtained from commercial sources and are of reagent grade or as 
specified. Solvents were also obtained from commercial sources, except for anhydrous THF 
and anhydrous DMF that were dried over solvent purifier (PS-Micro, Innovative Technology, 
USA). Reactions were monitored by TLC using precoated plates (silica gel 60 F254, 250 μm, 
Merck, Darmstadt, Germany), spots were visualised under ultraviolet light at 254 nm and with 
either sulphuric acid-vanillin spray, potassium permanganate dip or Hanessian’s stain. 
Column chromatography was performed with silica gel (40-63 μm 60 Å, Davisil, Grace, 
Germany). HPLC was performed on HP Series 1100 with Phenomenex Gemini C18 5 µM 
(250 x 4.60 mm) for Analytical. Microwave reactions were performed on a CEM Discovery 
SP with external IR temperature monitoring. Reactions were stirred for 5 min in a sealed 
container at ambient temperature, followed by 5 min stirring with increased microwave power 






F NMR spectra were recorded on a Varian Inova 500 MHz or a Varian Inova 
600 MHz. Chemical shifts are given in ppm (δ) relative to the residue signals, which in the 
case of DMSO-d6 were 2.50 ppm for 
1
H and 39.51 ppm for 
13
C, CDCl3 were 7.27 ppm for 
1
H 
and 77.00 ppm for 
13
C. High-resolution mass spectra (HRMS) were recorded on an Agilent 
6230 time of flight (TOF) liquid chromatography mass spectra (LC/MS) (Δ < 5 ppm).    
General Procedure for CuAAC  
Copper nano powder (40 mol %) was added to a stirring suspension of biotin acetylene 8
12
 
(1.0 equiv) and corresponding azide (1.5 equiv) in CH3CN:H2O (2:1) (1 mL per 60 mg of 8). 
The reaction was sonicated for 15 min and stirred at room temperature for 17 hours. The 
reaction mixture was then concentrated under reduced pressure and the residue purified by 
column chromatography on silica gel. See individual experiments for details. 
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General Procedure for Synthesis of 5-Iodo-1,2,3-triazoles 
To a solution of 1-iodoalkyne 10 (1.0 equiv) and corresponding azide (1.0-1.2 equiv) in dry 
DMF (1 ml per 10 mg of 1-iodoalkyne) was added CuI (0.05 equiv) and TEA (2.0 equiv) and 
the mixture was stirred at ambient temperature for 1 day. The mixture was quenched with 
10% NH4OH and extracted with DCM twice. The combined organics were dried over 
anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was 
purified by column chromatography on silica gel. See individual experiments for details. 
General Procedure for Halogen Exchange of 5-Iodo-1,2,3-triazole 
To a round-bottomed microwave vial was added 5-iodo-1,2,3-triazole (1.0 equiv) and 
potassium halide (5.0 equiv). The solids were washed off of the side with acetonitrile (1 ml 
per 50 mg of triazole) and then de-ionised water (1 ml per 50 mg of triazole). The vial was 
placed into the microwave reactor set at a pressure of 200 psi and heated at 180 C for 5-10 
min based on 
1
H NMR. After the vial was cooled to room temperature, the mixture was 
diluted with EtOAc and the organic layer was extracted with a Pasture pipette. The resulting 
aqueous layer was extracted three additional times and the combined organics were dried over 
anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified 
by column chromatography on silica gel. See individual experiments for details. 
General Procedure for Synthesis of Benzyl Azides 
A solution of the benzyl halide (1 equiv) and sodium azide (1.3 equiv) in DMF (1 mL per 
50mg of benzyl halide) was stirred at ambient temperature for 5 hours. The reaction mixture 
was diluted with ether and wash with water three times. The organic layer was dried over 
anhydrous sodium sulfate and concentrated under reduced pressure. See individual 





General Procedure for Hydrolysis of Ester 
To a mixture of ester (1.0 equiv) in THF:MeOH:H2O (3:1:1) (1 mL per 10 mg of ester) was 
added LiOH (2.2 equiv) and the mixture was stirred for 17 hours. The resulting mixture was 
acidified with 1 M HCl to pH = 4. The mixture was diluted with DCM:MeOH (9:1) and 
washed with 0.5M HCl, water, and brine. The organic layer was dried over anhydrous sodium 
sulfate and concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel. See individual experiments for details. 
 
Recombinant protein production 
The cloning and purification of recombinant BPL from Staphylococcus aureus and Homo 






In vitro biotinylation assays 
3
H biotin assay 
Quantification of BPL catalyzed 
3
H-biotin incorporation into the biotin domain substrate 
was performed as previously described.
12, 16, 39
 A reaction mixture was prepared containing 50 
mM Tris HCl pH 8.0, 3 mM ATP, 4.94 μM biotin, 0.06 μM 
3
H-biotin, 5.5 mM MgCl2, 100 
mM KCl, 0.1 μM DTT and 10 μM biotin domain of S. aureus pyruvate carboxylase. To 
determine inhibitory activity, BPL activity was measured in the presence of varying 
concentrations of compound. All compounds were dissolved in DMSO and then diluted into 
the reaction buffer to give a final concentration of 4% DMSO. BPL reaction was initiated by 
the addition of enzyme to give final concentrations of 6.25 nM for SaBPL and 140 nM for 
HsBPL. After 10 minutes at 37 ºC, 90 μL of stopping buffer (110 mM EDTA and 50 mM Tris 
HCl pH 8.0) was added to terminate the reaction and a 100 μL aliquot of the reaction mixture 
was added to the wells of 96-well HTS multiscreen plate containing an Immobilon-P® 
(Merck Millipore) membrane that had been pre-treated with 50 μL of 70% ethanol. 400 μL of 
MilliQ-H2O and followed by 200 μL of TBS. Quantitation of protein-bound radiolabelled 
biotin was determined by liquid scintillation counting. The IC50 value of each compound was 
determined from a dose-response curve by varying the concentration of inhibitor under the 
same enzyme concentration. The data was analysed with GraphPad prism (version 6) using a 
non-linear fit of log10 [inhibitor] vs. normalised response. The Ki, the absolute inhibition 










Where [S] is the substrate concentration ([biotin] = 5 μM) and KM is the affinity of the 




Europium-streptavidin based enzyme assay 
A 96-well assay using Europium labelled streptavidin and time-resolved fluorescence was 
developed to measure BPL activity. An in vitro biotinylation reaction was performed for at 
least 10 minutes at 37 °C in a 20 μL reaction mix containing 50 mM tris pH 8.0, 3 mM ATP, 
5.5 mM MgCl2, 25 μM GST-SaPC90, 0.1 μM DTT, 5 μM biotin and purified BPL (SaBPL 6 
nM) .BPL catalysed reactions were stopped with the addition of 80 μL stopping buffer (50 
mM Tris pH 8.0, 110 mM EDTA) and 3 x 20 μL aliquots were added to the well of a white 
lumitrac-600 96-well plate that had been previously coated by overnight incubation at 4 °C 
with an anti-GST antibody (50 μL per well) at 1:40000 dilution, followed by blocking for 2 
hours (200 μL per well) with 1% BSA in TBS at 37 °C and incubated at 37 °C for 1 hour. The 
plate was then washed 5 times (200 μL per well) with TBS containing 0.1% Tween-20. 
Europium labelled streptavidin was diluted to 0.1 μg/mL in TBS containing 0.1% Tween-20. 
The streptavidin probe (50 μL per well) was incubated for 30 minutes at 37 °C followed by 
washing 5 times in TBS 0.1% Tween-20 followed by another 5 washes in sterile water. 
Enhancement solution (Perkin Elmer) (50 μL) was added per well and incubated for 10 
minutes before reading the plate using time-resolved fluorescence using 340 nm excitation 
and 612 nm emission filters with a Perkin Elmer
®
 Victor X5 multilabel reader. Data was 
analysed as described for 
3




Surface Plasmon Resonance 
SPR was performed using a Biacore
TM
 S200 instrument (GE healthcare). S. aureus BPL 
was immobilised on a CM5 sensor chip by standard amine coupling chemistry. The 
carboxymethyl groups on the chip were activated by the addition N-ethyl-Nʹ-(3-diethylamino-
propyl) carbodiimide and N-hydroxysuccinimide. BPL (120 μg/mL) in 10 mM sodium acetate 
buffer (pH 5.8) was coupled onto the surface, and 50 mM Tris pH 8.0 was injected to block 
any unreacted sites. Typically, 7,000 resonance units of BPL were immobilised on the sensor 
chip. One channel was left blank which was subtracted from the sample channel to allow 
analysis methods to distinguish between actual and non-specific binding. Experiments were 
conducted at 25 ºC with a running buffer containing 10 mM HEPES pH 7.4, 150 mM NaCl, 
0.005% surfactant p20 and 5% (v/v) DMSO. For compounds that were poorly water soluble, 
samples were initially dissolved in DMSO and diluted in running buffer so that the final 
concentration of DMSO was 5%. To correct for variations in DMSO concentration during the 
preparation of these compounds, a solvent correction curve was included in the analysis by 
preparing a series of test solutions between 4.5% and 5.8% DMSO. Binding experiments were 
performed by injecting the analyte solutions into the instrument across the sensor surface of 
all flow cells at a flow rate of 30 μL/min with a contact time of 120 seconds followed by a 
dissociation time of 300 seconds. Zero concentration samples were used as blanks. The time-
dependent binding curves of all flow cells were monitored simultaneously. The results of 
compounds 4a-d showed fast on and off rates outside the range of kinetic quantification, so 
KD values were determined by transforming time-dependent binding curves into an affinity-
steady state 1:1 model using Biacore
TM
 S200 evaluation software (GE healthcare).  
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Antibacterial Activity Evaluation 
Antibacterial activity was determined by a microdilution broth method as recommended by 
the CLSI (Clinical and Laboratory Standards Institute, Document M07-A8, 2009, Wayne, Pa.) 
using cation-adjusted Mueller-Hinton broth (trek Diagnostics Systems, U.K.). Compounds 
were dissolved in DMSO. Serial two-fold dilutions of each compound were made using 
DMSO as the diluent. Trays were inoculated with 5 x 10
4
 CFU of each strain in a volume of 
100 μL (final concentration of DMSO was 3.2 % (v/v)), and incubated at 35 ºC for 16-20 
hours. Growth of the bacterium was quantified by measuring the absorbance at 620 nm. 
SaBPL-4c X-ray crystallography methodology 
Crystals used for micoseeding were prepared via the hanging drop method at 4 °C, with 500 
μL of reservoir solution (50 mM sodium HEPES pH 7.5, 14% (w/v) PEG 3350, 1% (w/v) 
tryptone) and a hanging drop comprised of 2 μL protein solution (5 mg/mL SaBPL-H6, 1.2 
mM BPL199, 6.7% DMSO, 50 mM Tris-HCl pH 7.5, 50 mM NaCl, 1 mM DTT, 5% (v/v) 
glycerol) and 3 μL reservoir solution. To prepare SaBPL-4c crystals, 1 mg/mL apo 
SaBPL-H6, 790 μM 4c, 4% (v/v) DMSO, 50 mM Tris-HCl pH 7.5, 50 mM NaCl, 1 mM DTT 
and 5% (v/v) glycerol were incubated overnight at 4 °C. The incubation was filtered through a 
0.2 μm Nanosep MF centrifugal device (Pall Corp.) and protein was concentrated to 
5 mg/mL. Crystals were prepared at 4 °C using the hanging drop vapor diffusion method, 
with a 500 μL reservoir comprised of 12% (w/v) PEG 8000, 0.1 M Tris-HCl pH 7.5 and 10% 
(v/v) glycerol.
12
 To prepare the hanging drop, 0.8 μL of reservoir solution was mixed with 0.2 
μL microseeds of SaBPL-H6 in complex with a known inhibitor and 1 μL of protein solution. 
A single crystal was looped and cryoprotected with reservoir solution containing saturated 
sucrose, prior to flash freezing with liquid nitrogen. X-ray diffraction data were collected at 
the Australian Synchrotron’s MX2 Micro Crystallography beamline, using an ADSC 
Quantum 315r Detector. The diffraction data were integrated using XDS
40
 and the intensities 
were merged and scaled using Aimless
41




 was used 
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to perform molecular replacement, using a single protein chain from PDB 3V7R
12
 as a search 









 and manual model building was undertaken in 
COOT
46
. Statistics for the data and refinement are reported in Supporting Information Table 
S3. 
Assay of cytotoxicity 
Mammalian HepG2 cells were suspended in Dulbecco-modified Eagle’s medium 
containing 10% fetal bovine serum, and then seeded in 96-well tissue culture plates at either 5 
000, 10 000 or 20 000 cells per well. After 24 hours, cells were treated with varying 
concentrations of the test compound such that the DMSO concentration was consistent at 2 % 
(v/v) in all wells. After treatment for 24 or 48 hours, WST-1 cell proliferation reagent (Roche) 
was added to each well and incubated for 0.5 hours at 37 ºC. The WST-1 assay quantitatively 
monitors the metabolic activity of cells by measuring the hydrolysis of the WST-1 reagent, 
the products of which are detectable at absorbance 450 nm. 
 Docking studies 
Docking experiments were performed using ICM software version 3.8-5 (Molsoft L.L.C., 
San Diego, CA, USA). Proteins for docking were retrieved from RCSB protein data bank: 
3V7S
12
 and SaBPL-4c. Then formal charges were assigned, protonation states of histidines 
were adjusted, and hydrogens, histidine, glutamine, and aspargine were optimized using the 
protein preparation procedure implemented in ICM.
47
 The original bound ligand and all water 
molecules were removed from the binding site before docking. The binding site was defined 
as the cavity delimited by residues with at least one non-hydrogen atom within a 4.0 Å cutoff 
radius from the ligand 4a or 4c. The pocket was represented by 0.5 Å grid maps accounting 
for hydrogen bonding, hydrophobic, van der Waals, and electrostatic interactions. The 
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ABBREVIATIONS 
SaBPL, Staphylococcus aureus biotin protein ligase; SaBPL-H6, Staphylococcus aureus 
biotin protein ligase containing 6 histidine tag; BPL, biotin protein ligase; BBL, biotin 
binding loop; SPR, surface plasmon resonance, SaPC90, 90 amino acid biotin-acceptor 
domain from pyruvate carboxylase; KD, equilibrium binding constant; TBS, tris buffered 
saline; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
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Figure S1. (A) 2D interaction diagram of 4a and SaBPL. (B) 2D interaction diagram of 4c and 
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Figure S2. (A) X-ray crystallography of compound 5c bound to SaBPL revealed density surrounding 
the biotinyl moiety and triazole ring but lacking for the benzyl ring. (B-C) Docking results of 6c-7c in 
the binding pocket. (B) The top-scoring conformation (yellow) and the second top-scoring 
conformation (blue) of 6c. (C) The top-scoring conformation (magenta) and the second top-scoring 
conformation (green) of 7c.  The docking studies showed that benzyl ring would be positioned in the 
ribose binding site or the outer open mouth site. 





Figure S3. SPR sensograms (left) and concentration vs response plots (right) of compounds 4a-d 
binding to SaBPL. (A) SPR sensogram and concentration vs response plot of 4a binding to SaBPL. 
(B) SPR sensogram and concentration vs response plot of 4b binding to SaBPL. (C) SPR sensogram 
and concentration vs response plot of 4c binding to SaBPL. (D) SPR sensogram and concentration vs 
response plot of 4d binding to SaBPL. Concentrations of compounds 4a-d used were: 0.2 μM (red), 
0.4 μM (green), 0.8 μM (blue), 1.6 μM (magenta), 3.1 μM (cyan), 6.3 μM (yellow), 12.5 μM (purple), 
25 μM (grey) and 50 μM (orange).      
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Figure S4. Mechanism of action studies. S. aureus RN4220 + pCN51-NcoI control (dashed line) and 
pCN51-BPL overexpression (solid line) vectors susceptibility to (A) literature BPL inhibitor biotinol-
5′-AMP and (B) non BPL targeting antibiotic amoxicillin. Assays were performed in triplicate and 




Table S1. Comparison of binding pockets. The volume and area of binding pocket of 4c-SaBPL was 
increased in order to accommodate 5-fluoro triazol 4c. The icmPocketFinder macro was used to 





) Hydrophobicity Buriedness 
SaBPL-4a (PBD 3V7S) 679.9 635.2 0.5932 0.8844 
SaBPL-4c 800.6 706.9 0.5645 0.8758 
 
Table S2. Comparison of Ki values as determined by enzyme assay with radiolabelled biotin 
compared to assay utilising GST fusion of SaPC90 for antibody capture and detection with Eu-
streptavidin conjugate. 
Compound Ki radiolabelled biotin (μM) Ki GST-fusion (μM) 
3 0.016 ± 0.01 0.004 ± 0.001 
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Table S3. Data collection and Refinement Statistics for SaBPL in complex with inhibitors 
Data collection
a
 SaBPL-4c SaBPL-5c 
Wavelength (Å) 0.9537 0.9537 
Resolution range (Å) 39.67 - 2.397 (2.482 - 2.397) 39.5 - 2.71 (2.807 - 2.71) 
Space group P 42 21 2 P 42 21 2 
Unit cell a, b, c (Å) 94.241, 94.241, 131.192 93.6 93.6 130.7 90 90 90 
α, β, γ (°) 90, 90, 90  
Total reflections 84981 (8264) 57903 (5804) 
Unique reflections 22814 (2233) 15757 (1587) 
Multiplicity 3.7 (3.7) 3.7 (3.7) 
Completeness (%) 95.52 (95.26) 95.97 (99.06) 
Mean I/sigma(I) 13.86 (1.07) 11.08 (1.94) 
Wilson B-factor 57.05 63.68 
R-merge  0.06603 (1.2) 0.07975 (0.6741) 
R-pim 0.038 (0.79) 0.04545 (0.3941) 
CC1/2 0.999 (0.454) 0.996 (0.696) 
CC* 1 (0.79) 0.999 (0.906) 
 
R-work (%) 20.77 (37.00) 0.1833 (0.3350) 
 
R-free (%) 25.40 (42.72) 0.2261 (0.3883) 




  macromolecules 2613 2605 
 
  ligands 35 27 
 
  water 32 19 
 
Protein residues 322 322 
 
RMS(bonds) 0.007 0.008 
 
RMS(angles) 0.94 1.03 
 
Ramachandran favored (%) 98 95.94 
 
Ramachandran allowed (%) 2.7 4.06 
Ramachandran outliers (%) 0.3 0 
Rotamer outliers (%) 0.0 1.05 
Clashscore 8.42 6.35 
Average B-factor 66.60 66.02 
 
  macromolecules 66.500 65.83 
  ligands 78.00 90.63 
  solvent 64.80 75.21 
 a
Diffraction data were collected from one crystal 
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Abstract 
Biotin protein ligase (BPL) inhibitors are a novel class of antibacterial agent that can target 
clinically important pathogens such as drug resistant Staphylocococcus aureus. In S. aureus, 
BPL is responsible for catalysing the attachment of biotin onto important metabolic enzymes 
such as acetyl-CoA carboxylase and pyruvate carboxylase, as well as acting as a 
transcriptional repressor that regulates the genes involved in biotin homeostasis. Whilst 
antibacterial BPL inhibitors with in vitro antibacterial activity have previously been 
described, the full effects of these inhibitors on S. aureus have never been experimentally 
explored. Here we report the synthesis of 9, a new BPL inhibitor that shows potent 
antibacterial activity (MIC90 = 0.5μg/ml) against a panel of clinical S. aureus isolates and no 
associated toxicity against HepG2 or HEK293 cells (EC50 >250 μg/ml). Using this compound 
we further probed the effects of BPL inhibition on S. aureus, demonstrating that 9 not only 
inhibits the catalytic function of BPL but also promotes DNA-binding activity and serves as a 
co-repressor in vivo. Further resistance studies using 9 also led to the discovery of mechanism 
of resistance using a missense mutation in BPL.  This mutation, (D200E) prevented 
dimerization in vitro and reduced repressive capabilities in an in vivo β-galactosidase assay. 
This is the first in vivo evidence of a BPL inhibitor acting through transcriptional repression 
as well as catalytic inhibition and provides insight into the molecular mechanism of 




The need for new antimicrobial agents to combat the growing threat of resistance is currently 
not being met, with only 5 new classes of antibiotics introduced since 2000 [1-3]. Strains that 
are now resistant to all classes of clinically approved antibiotics have been reported for 
Staphylococcus aureus, Enterococci and Mycobacterium tuberculosis [4]. If new 
antimicrobial agents are not identified, the inability to treat these infections is predicted to 
result in 10 million deaths every year by 2050 [5]. Unfortunately few new antimicrobial 
agents are in the drug development pipeline [3], with high risk and low financial reward 
discouraging investment in this area [1-3, 6]. Despite this, there is a desperate need for new 
products with novel mechanisms of action that are not subject to existing resistance 
mechanisms. Therefore new drug targets must be explored.  Better understanding of these 
drug targets and their modes of action in vivo are also required to combat resistance. Here we 
utilise structure guided design to discover a novel antibacterial agent targeting biotin protein 
ligase (BPL) from Staphylococcus aureus. Using this compound we probe the mechanism of 
action and the potential for resistance. 
BPL is an essential protein in S. aureus required for enzymatic biotinylation of biotin-
dependent enzymes, and repression of certain target genes implicated in biotin homeostasis. 
This bi-functionality makes BPL a promising new drug target [7]. In S. aureus BPL catalyses 
the attachment of biotin onto two biotin-dependent enzymes, namely, acetyl-CoA carboxylase 
(ACC) and pyruvate carboxylase (PC). This occurs through two partial reactions. In the first 
partial reaction BPL binds biotin (1, Fig 1) and ATP with ligation of these ligands yielding 
the reaction intermediate biotinyl-5′-AMP (2, Fig 1). Hydrolysis of biotinyl-5′-AMP then 
facilitates the attachment of the biotin prosthetic group onto ACC or PC [8] (figure 1). These 
enzymes have important roles in S. aureus. ACC catalyses the first committed step in fatty 
acid synthesis, whilst PC replenishes the TCA cycle with oxaloacetate. Both ACC and BPL 
have been identified as essential for in vitro growth in genetic knockout studies performed on 
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S. aureus [6, 9-11] and, consequently, been the target of drug discovery programs. The 
antibacterial efficacy of ACC inhibitors has been demonstrated in vivo (reviewed [12, 13]) 
and BPL inhibitors have shown efficacy in vitro [14-19]. PC, whilst dispensable  for in vitro 
growth, has been shown to be important in virulence in a mouse model of bacteraemia, [20] 
with several TCA cycle genes also important for infection in a nematode model [21]. As 
protein biotinylation is essential for the activity of ACC and PC, inhibition of BPL can impact 
their respective functions in cell replication and pathogenesis (reviewed [7]).  
 
 
Figure 1. Reaction mechanism of biotin protein ligase.  Equation 1, biotin (1) interacts with ATP in 
the binding pockets of BPL to produce and adenylated reaction intermediate, biotinyl-5′-AMP (2). 
Equation 2, biotinyl-5′-AMP interacts with the specific lysine on the biotin domain of biotin 
dependent enzymes to biotinylate the protein.  
 
In addition to protein biotinylation activity, BPL from S. aureus also acts as a transcriptional 
repressor [19, 22]. S. aureus BPL (SaBPL) belongs to structural class II BPLs which contain a 
helix-turn-helix N-terminal domain responsible for DNA-binding (reviewed [22, 23]). Protein 
dimerization is believed to be a pre-requisite for DNA binding to the operator sites present in 
certain target genes [24]. BPL dimerization, and consequent DNA-binding, is induced by the 
presence of the co-repressor biotinyl-5′-AMP (2, Fig. 1) [25, 26][Satiaputra et. al, 
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unpublished]. A series of well-characterized conformational changes that are required to 
facilitate DNA binding accompany biotinyl-5′-AMP binding. Following biotin binding, 
residues 118–129 (the biotin binding loop, BBL) undergo a disordered to ordered change that 
allows ATP binding. The adenosine binding loop (ABL) formed by residues I224 and A228, 
also undergo structural changes, to accommodate the binding of the adenylate moiety [27].  
The protein then undergoes a transition from monomer to dimer. Homo- dimerization 
involves sidechain interactions between residues R122 and F123, that localize within the 
biotin binding loop from one subunit, with D200 of the neighbouring subunit [28]. Upon 
homodimer formation, the two N-terminal DNA binding domains are then optimally 
positioned for their interaction with DNA [27]. Protein dimerisation can also be induced by 
chemical analogues of biotinyl-5′-AMP [26, 29]. In S. aureus, BPL represses the expression 
of the biotin biosynthesis operon, the biotin transport protein BioY, as well as a putative fatty 
acid ligase operon yhfT-yhfS [24][Satiaputra et. al, unpublished]. Pharmacologically inducing 
the repressor state would therefore induce biotin starvation through reduced de novo synthesis 
and import. Hence, as part of the antibacterial mechanism of action, maintenance of homo-
dimerization and repressor function is desirable. 
Previous attempts at BPL inhibition for antibacterial compounds have been met with varied 
success. As BPL is a ubiquitous enzyme selective inhibition of BPL from pathogenic bacteria 
over the human homologue is essential. Initial attempts using mimics of biotin as antibacterial 
agents were subject to poor selectivity and efficacy due to the highly conserved nature of the 
biotin binding pocket and relatively low affinity [14]. Subsequent design of BPL inhibitors 
has focused upon replacement of the labile phosphoanhydride of 2 with more stable 
bioisosteres. The first of these analogues employed a non-hydrolysable phosphodiester, as in 
biotinol-5′-AMP 3 (Fig. 2) [26, 29]. This compound showed promising in vitro and whole cell 
activity against both S. aureus (Ki = 18 nM, MIC 1-4μg/ml) and M. tuberculosis (Ki = 52 nM, 
MIC 0.5-2.5μg/ml). [29] However, the human isozyme was similarly inhibited (Ki = 182 nM) 
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though no associated toxicity was observed against HepG2 cells (CC50 > 200μg/ml) [29]. We 
[14, 17, 18, 29, 30] and others [15, 16, 31] have explored alternative bioisosteres to create 
more selective antibacterial agents. One promising approach utilised a 1,4-disubstituted 1,2,3-
triazole linker (4, Fig 2)  with inhibitory activity against SaBPL (Ki = 1.17 ± 0.3 μM) and 
selectivity over the human homologue (Ki > 10 μM) [17]. Removal of the ribose (5, Fig. 2) 
(Ki = 0.66 ± 0.15 μM) and further replacement of the adenine with a benzoxazolone moiety (6, 
Fig. 2) yielded a compound with potent activity (Ki = 90 nM) against S. aureus BPL with the 
required selectivity against the human BPL (Ki > 10 μM) [17]. Whilst the biotin triazole offers 
a useful pharmacophore for chemical optimisation [17, 18] whole cell antibacterial activity 
has not been sufficient, with the most potent exemplar producing only 80% inhibition of cell 
growth at 8μg/ml. Sulfonyl linkers have also been explored to create mimics of 3 targeting the 
BPL from E. coli and M. tuberculosis. [15, 16, 32] Noteworthy is Bio-AMS (8, Fig. 1), with 
potent whole cell efficacy against M. tuberculosis including drug resistant isolates (MIC 0.16-
0.78 μM). However, this compound shows no activity against S. aureus.  Here we report that 
removal of the ribose heterocycle from literature compound 8 improves whole cell activity 





Figure 2: Structure of lead compounds guiding synthesis of inhibitors against SaBirA  
(3.) derivative of reaction intermediate with non-hydrolysable phosphodiester linker, biotinol-5-AMP, 
(4.) next generation of inhibitor with increased selectivity containing 1,2,3-triazole linker (5.)  
improved structure of 1,2,3-triazole with removed ribose moiety (6.) Modification of the 1,2,3-triazole 
4 substituting the adenine moiety for benzaloxazolone. (7.) Modification of the 1,2,3-triazole 4 
substituting the adenine moiety for benzyl ring. (8.) Bio-AMS, containing acylsulfonamide linker and 





Materials and methods 
General bacteria culture, molecular biology reagents and protein methods:  
All chemicals and reagents were purchased as analytical grade or higher. Unless otherwise 
stated, all bacterial strains were purchased from the American Tissue Culture Collection. All 
molecular biology enzymes (DNA polymerase and restriction enzymes) and buffers were 
supplied by New England Biolabs. Oligonucleotides were purchased from Geneworks Ptd 
Ltd. BPL protein expression and apo-purification was performed following previously 
described protocols [33, 34]. Apo-purification was performed by incubating bacterial lysate 
purified biotin domain-GST fusion from S. aureus [35] (SaPC90) at 30°C for 1 hour, as 
described previously [28]. Protein concentration was determined using Bradford assay. Apo-
purified protein was confirmed by nESI-MS and by Western blot analysis as described 
previously [28]. Detail of apo-purification and apo-protein verification is provided in 
Supplementary section.   
Protein Crystallography: Alignment of X-ray crystal structures was performed using the 
structural analysis program, UCSF Chimera. Superimposition of SaBPL in complex with 
either compound 9 (Prof. Matthew Wilce, Monash University, this study) or 2 (PDB ID# 
3RIR) was performed using this program. The result of this superimposition is presented in 
Figure 3.  
In vitro Biotinylation assay: A 96-well assay using Europium labelled streptavidin and time-
resolved fluorescence was used to measure BPL activity. An in vitro biotinylation reaction 
was performed for at least 10 minutes at 37 °C in a 20 μL reaction mix containing 50 mM tris 
pH 8.0, 3 mM ATP, 5.5 mM MgCl2, 25 μM GST-SaPC90, 0.1 μM DTT, 5 μM biotin and 
purified BPL (SaBPL 6 nM). BPL catalysed reactions were stopped with the addition of 80 
μL stopping buffer (50 mM Tris pH 8.0, 110 mM EDTA) and 3 x 20 μL aliquots were added 
to the well of a white lumitrac-600 96-well plate that had been previously coated by overnight 
incubation at 4 °C with an anti-GST antibody (50 μL per well) at 1:40000 dilution, followed 
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by blocking for 2 hours (200 μL per well) with 1% BSA in TBS at 37 °C and incubated at 37 
°C for 1 hour. The plate was then washed 5 times (200 μL per well) with TBS containing 
0.1% Tween-20. Europium labelled streptavidin was diluted to 0.1 μg/mL in TBS containing 
0.1% Tween-20. The streptavidin probe (50 μL per well) was incubated for 30 minutes at 37 
°C followed by washing 5 times in TBS 0.1% Tween-20. Enhancement solution (Perkin 
Elmer) (50 μL) was added per well and incubated for 10 minutes before reading the plate 
using time-resolved fluorescence using 340 nm excitation and 612 nm emission filters with a 
Perkin Elmer
®
 Victor X5 multilabel reader. 
Antibacterial susceptibility evaluation: Antibacterial activity was determined by the broth 
microdilution method as recommended by the CLSI (Clinical and Laboratory Standards 
Institute, Document M07-A8, 2009, Wayne, Pa.) using cation-adjusted Mueller-Hinton broth 
(CAMHB) (Trek Diagnostics Systems, U.K.). Compounds were diluted two-fold in CAMHB 
to a final concentration range of 64 to 0.06 μg/ml in 3.2% DMSO. To prepare the inoculum 
overnight cultures from a single colony were subcultured 1 in 1000 and grown to mid log 
phase. Trays were inoculated with 5 x 10
4
 CFU and incubated at 37°C for 20-22 hours with 
shaking. Growth of the culture was quantified by measuring the absorbance at 620 nm using a 
Thermo Multiskan Ascent plate reader after shaking for 15 seconds to disrupt any 
sedimentation. Assays were performed in triplicate.  
Concentration kill kinetics: An overnight culture of S. aureus ATCC 49775 was prepared 
and diluted to approximately 2.5× 10
5
 CFU/ml in 20 mL CAMHB containing the appropriate 
concentration of compound 9 (1×,2×,4× MIC [MIC = 0.5 μg/ml]) in a 50 ml falcon tube. 
Cultures were incubated for 24 hours at 37°C and 100μl samples taken at 0, 1, 2, 4, 8 and 24 




Cytotoxicity assay: HepG2 or HEK293 cells were seeded in 96-well tissue culture plates at 
10
4
 cells per well in 100 μl of DMEM+ (10%FCS, 1 mM sodium pyruvate and  2 mM 
glutamine). After 24 hours growth, cells were treated with varying concentrations of test 
compound. Dilutions of compound were prepared by two fold serial dilution of compound in 
DMEM, maintaining a constant DMSO concentration, 2% (v/v) for HepG2 or 0.5% (v/v) for 
HEK293. After treatment for 48 hours, 10 μl WST-1 cell proliferation reagent (Roche) was 
added to each well and incubated for 30 minutes at 37°C. The WST-1 assay quantitatively 
monitors the metabolic activity of cells by measuring the hydrolysis of the WST-1 reagent, 
the products of which are detectable at absorbance 450 nm on Perkin Elmer plate reader. 
Synergy testing: Checkerboard antibacterial susceptibility assay was constructed. In brief 
compound 9 and a clinically used antibacterial agent were 2 fold serially diluted from 4 to 
0.0625 × MIC. The dilutions were arranged perpendicularly so that 64 individual 
concentrations of antibiotic were present in an 8×8 grid.  Antimicrobial susceptibility assays 
were then performed as per above using S. aureus ATCC49775. Synergy was determined by 
Σ FIC Index < 0.5 as described in [36, 37]. 
Growth in presence of fatty acids: Antibacterial susceptibility testing was undertaken as 
above with 0, 10 and 20% FCS added to media to determine any reduction in compound 
efficacy. Erythromycin was used as a control. 
Mechanism of action-increased biotin: Antibacterial susceptibility testing was undertaken 
as above with 0, 10, 100, 1000 nM of exogenous biotin added to media to determine any 
reduction in compound efficacy.  
Mechanism of action-Overexpression system: Antibacterial activity was determined on S. 
aureus RN4220 containing either pCN51-NcoI (control) or pCN51-BPL (BPL over-
expression) vectors [18]. Compounds, dissolved in DMSO, were serially diluted from 64 to 
0.06 µg/ml in Mueller Hinton broth (3.2% (v/v) DMSO) supplemented with 10 µg/ml 
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erythromycin for plasmid selection and 25 nM CdCl2 to induce BPL expression. Log phase 
cultures of transformed S. aureus RN4220 strains, grown in the absence of compound, were 
diluted 1:1000 into media containing compound. Growth of the cultures at 37°C with shaking 
was then monitored at OD630 every 30 mins for 22 hours using an EL808™ Absorbance 
Microplate Reader (BioTek Instruments Inc, Winooski, VT, USA). S. aureus harbouring 
pCN51-BPL grown in the absence of compound served as a baseline control. The mechanism 
of action assays were performed in triplicate. 
Quantification of gene expression using QRT-PCR: S. aureus NCTC 8325 was grown 
overnight at 37 °C in biotin-depleted CAMHB. The overnight culture was then used to 
inoculate 10 mL of biotin-depleted CAMHB which was incubated until mid-log phase was 
reached. The culture was then treated by adding either biotin (10 nM) or compound 9 (10 nM 
or 3.9 μM [i.e. 4× MIC]). 500μL of the culture was collected at 0, 15, 30 and 90 minutes post 
treatment and pelleted. Cell pellets were resuspended in 100 μL of TE buffer containing 1 
mg/mL lysozyme and S. aureus lysis performed by adding 1 μL of 10 mg/mL of lysostaphin 
(Sigma Aldrich) followed by incubation at 37°C for 30 minutes. RNA extractions were 
performed using RNAeasy mini kit (Qiagen), following the manufacturer’s instructions. Total 
RNA was measured using a Nanodrop spectrophotometer (Thermo fisher scientific). 2 μg of 
total RNA was treated with 20 units of DNAse1 at 37
o
C for 1 hour using a DNAseI kit (Life 
technology), followed by inactivation using 2 μL RNase-free EDTA reagent (Sigma Aldrich) 







 1- step QRT-PCR kit (Life technologies) with 0.2 nM of oligonucleotides. 
A total of 10 ng of RNA was used as a template in the qRT-PCR reaction and a total of 0.1 ng 
of RNA was used as a template in 16s rRNA amplification. The reaction and data analysis 
were performed using the Quantstudio
TM
-Dx real-time PCR instrument and software 
(Thermofisher). Relative expression was normalized against 16s rRNA and corrected to t = 0. 
For each experiment, at least 3 independent biological replicates were obtained and each PCR 
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reaction was performed in triplicates.  Statistical two-tailed t-test comparison of each time 
point against t = 0 was performed using GraphpadPrism (Graphpad Software, Inc., CA, USA) 
Electrophoretic Mobility Shift Assay (EMSA): EMSA protocol was adapted from methods 
previously published in [38]. Briefly, 10 nM double-stranded oligo (containing either SabioD 
or SabioY operator sequence) were incubated with varying concentrations of SaBPL in EMSA 
binding buffer containing 50mM Tris pH 8.0, 50 mM NaCl, 1 mM ATP, 1 mM MgCl2 and 
10% (v/v) glycerol. To generate holo-SaBPL, 100 μM biotin was added to the EMSA binding 
buffer. Binding reactions were performed in a final volume of 10 μL and incubated for 30 
minutes at room temperature. For analysis of compound 9, 100 μM of compound was added 
to the EMSA buffer. As compound 9 was reconstituted in 100% DMSO, the final DMSO 
concentration in the binding buffer was 2.5% (v/v). A control reaction was prepared by 
adding 100μM biotin and 2.5% (v/v) DMSO to the binding reaction. The reaction was run at 
room temperature, on 4-12% TBE gradient gel in 0.5x TBE buffer (Life technologies) at 
100V for 45 minutes, followed by staining with staining solution containing 100mM NaCl, 1x 
Gel Red (Biotium). 
Spontaneous resistance rate: The spontaneous resistance rate of S. aureus NCTC 8325 was 
determined by plating the entirety of a culture with 10
9 
CFU onto CAMHB Agar containing 2 
μg/mL compound 9 (4× MIC). This was repeated with 9 separate cultures in technical 
replicate (same starting colony) to control for priming mutations in the initial colony. Plates 
were checked after 24 hours at 37°C for growth with no detectable colonies observed on any 
of the plates. As true resistance rate using fluctuation analysis [39-41] requires some colonies 
a resistance frequency was instead calculated at 4× MIC as < 10
-9
. 
Selection of resistant mutants: Mutants were selected by serial passage in 96 well format as 
previously described [42]. In brief: A 2-fold dilution series of compound 9 was plated across 
7 wells. Initial concentrations ranged from 1 μg/ml to 0.016 μg/ml, with the highest 
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concentration increasing up to 64 μg/ml as the MIC increased. On the first day approximately 
10
4
 CFU of exponentially growing S. aureus 8325 was added to each well.  The OD was 
measured at 620nm for each well and the well with the highest concentration permitting 
growth (OD620 > 0.1 used as threshold) diluted 1000 fold and used to inoculate the next day’s 
assay. This process was repeated for 18 days. From the final day’s experiment single isolates 
were purified by streaking out strains and genomic DNA extracted. The stability of the 
resistance was also tested by propagating the strains selected for 6 days on MH Agar in the 
absence of any antibiotic selection. These strains were then retested in the antibacterial 
susceptibility assay and the BPL gene of each strain sequenced to identify mutations. DNA 
extraction and sequencing procedure detailed in supplementary section.  
Native nESI-MS: Purified apo-SaBPL was buffer exchanged into 200 mM ammonium 
acetate using Vivaspin 500 MWCO 10,000 spin columns (vivaproducts, MA, USA). Holo-
SaBPL samples were prepared by pre-incubating apo-SaBPL with 500 µM biotin, 1 mM ATP 
and 1 mM MgCl2 prior to buffer exchange. Proteins were diluted to 10 µM in 200 mM 
ammonium acetate for analysis by nano-electrospray ionization-mass spectrometry (nESI-
MS). MS measurements were performed on a Synapt HDMS system (Waters, UK) with the 
sample introduced by nano-electrospray ionisation in positive ion MS mode from platinum-
coated borosilicate capillaries prepared in-house. Instrument parameters were optimized to 
remove adducts while preserving non-covalent interactions, and were as follows; capillary 
voltage, 1.5 kV; cone voltage, 60 V; trap collision energy, 20 V; transfer collision energy, 15 
V; source temperature, 50°C; backing pressure, 3.95 mbar. Detected molecular weight of 
protein or protein complex are within 1.5% / 1 MDa of acceptable error mass.  
Chromosomal integration and β-galactosidase reporter assay: SaBPL D200E was cloned 
into the established integration vector and incorporated chromosomally into the λ-attB phage 
attachment site within the E. coli reporter strain containing β –galactosidase gene under the 
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control of either SabioO or SabioY promoters,  (JD26186_birA∷CAT_SabioO and 
JD26186_birA∷CAT_SabioY, respectively). Chromosomal integration was performed by 
previously established methods [43]. Detail on the cloning of SaBPL D200E into the 
integration vector can be found in supplementary section [43]. β-galactosidase assay was 
performed on an E. coli reporter strain containing SaBPL D200E and compared against 
reporter strains containing SaBPL wild-type and the previously described mutant SaBPL 
F123G, respectively. [43]. For the assay bacteria were grown overnight in minimal media 
(0.1% casamino acid , M9 salts, 1 mM MgSO4, 1 μg/mL thiamine, 0.4% glucose) containing 
100 nM biotin. The overnight culture was pelleted and washed three times with minimal 
media containing no biotin and used to inoculate each well of the 96-well growth plate 
containing minimal media supplemented with 0.5 nM - 500 nM biotin. Cells were grown at 
37°C with gentle agitation until the optical density reached OD600 = 0.50-0.60, at which point 
the OD600 was recorded, cells were lysed and β-galactosidase activity measured as described 
previously [43]. The β-galactosidase activity from the no-promoter control strain was 
subtracted from the activity generated by the strain containing SaBPL. Results were analyzed 




Design and synthesis. 
As we have demonstrated that the ribose heterocycle is dispensable for activity, this feature 
was removed from 8 to form 9. Biochemical assays revealed the compound retained potent in 
vitro inhibitory activity (Ki = 2.4 ± 0.2 nM) but had vastly improved antibacterial activity 
against S. aureus (MIC = 0.5 μg/ml) over the literature compound 8. Whole cell activity was 
also observed with M. tuberculosis, albeit with less potency (MIC = 50 μg/ml), but no activity 
was observed against Gram-negative species. X-ray crystal structure of SaBPL in complex 
with 9 showed 9 occupies the same binding site as the reaction intermediate 2 (Figure 3, PDB 
3RIR, Figure s13). A key interaction was K187 with the carbonyl of 9, as removal of this 
C=O, as in compound 10, increased the Ki by 700-fold. Likewise, the adenine moiety was 
preferred over the benzoxazolone group of 6 as this replacement, as in compound 11, reduced 
inhibitory activity 940-fold. None of the new compounds showed inhibition against the 
human enzyme at the highest concentrations tested (Ki >10 μM). This confirmed that the 
selectivity seen in biotin triazole compounds was also obtainable with the sulfonyl linker.  












12. WT5087B/ BPL218  
 
13. BPLWT5001/ BPL198 
 
 
Chemical scheme 1. With compounds  (9.) a novel derivative of acylsulfonamide 8, giving rise to 
a potent SaBirA inhibitor   (10.) modification of 9 removing the carbonyl (11.) modification of 9 
utilising a benzoxalone mimic as seen in 5. (12, 13) modification of the pharmacophore 6 with a 












Figure 3: Structural alignment of 9-bound vs. biotinyl-5-AMP- bound SaBPL (a.) overlay of the 
binding conformation of biotinyl-5-AMP (PDB 3RIR) and 9 bound to SaBPL (this study). (b) key 
residues involved in  hydrogen bonding (red lines) and π-π stacking (W127) interactions observed in 





Antistaphylococcal Activity and Therapeutic Index 
The antibacterial potency of 9 was assessed against an extended panel of clinical S. aureus 
isolates. Against all multidrug-resistant S. aureus strains tested, 9 exhibited MICs ranging 
from 0.125-0.5 μg/ml (n=23, Table 2). Cytotoxicity assays were also performed with two 
human cell lines, namely liver HepG2, and kidney HEK293 cells. Here the growth media 
contained 10% FCS. No cytotoxicity was observed at the highest concentration tested (250 
μg/ml) (supplementary information figure s1) representing a greater than 500-fold 
therapeutic window. To address concerns of serum binding reducing bioactivity in 
cytotoxicity assays [44, 45], antibacterial activity of 9 was further tested in the presence of 
foetal calf serum (FCS). No effect on MIC was observed with 10% FCS whilst testing in 20% 
FCS showed a 2-fold increase in MIC for the erythromycin control and an 8-fold increase in 
MIC for 9 (MIC = 4 μg/ml) suggesting a slightly reduced efficacy in the presence of higher 
serum concentrations (supplementary information figure s4).  
Mechanism of action, antibacterial concentration kinetics and synergy  
To demonstrate the mechanism of action of 9 was through BPL inhibition antibacterial 
susceptibility was determined in the presence and absence of either overexpressed BPL [15], 
or increased exogenous biotin. Consistent with a mechanism of action through BPL 
inhibition, overexpression of BPL resulted in an 8-fold increase in MIC of 9 (supplementary 
figure s5) and literature BPL inhibitor 3. No shift was observed for the β-lactam control 
antibiotic amoxicillin (supplementary figure s6). Additional exogenous biotin also reduced 
the efficacy of the compound, with dose responsive increases in MIC up to a 64-fold at super-
physiological concentrations (1 μM biotin) (supplementary figure s7). Kinetics of 
antibacterial activity was also determined, with viable cell counts measured following 24 
hours of treatment with 1, 2 and 4 times MIC. Growth was completely inhibited at these 
concentrations, however no reduction in cell number was observed, consistent with 9 acting  
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Table 1: MIC and inhibition data for sulfonyl compounds against S. aureus  










 >10 0.5 0.125 
10 2.34 ± 0.19 ND >64 16 
11 1.68 ± 0.17 ND >64 >64 
12 >10 ND ND ND 
13 >10 ND ND ND 
 
 
Table 2: Biological Activity and Selectivity of 9. 
 
Species Description MIC (μg/ml)  
Active species   
S. aureus  (n=22) Staphylococcus aureus (n=8) 0.25 – 0.5 
 Methicillin-resistant S. aureus (n=9) 0.25 – 0.5 
 Coagulase negative staphylococci 
(n=7) 
0.125 – 0.5 
Mycobacterium tuberculosis H37Rv 50 
Inactive species   
Streptococcus pneumoniae (n=6)  >32 
Enterocococcus faecalis (n=3)  >128 
Enterocococcus faecalis (n=3)  >128 
Enterococcus faecium (n=5)  >128 
Escherichia coli (n=1)  >128 
Cell lines  EC50 (μg/ml) 
HepG2 Liver derived cell line >250 





as a bacteriostatic agent (supplementary information figure s2).  This bacteriostatic action 
means 9 requires either host induced killing or combination therapy to clear infection. 
Consequently synergy with other clinically used antibacterial agents was performed. No 
antagonism was observed with any combination and synergy was detected for both 
methicillin and streptomycin with an FIC of  less than 0.5 [36, 37]. (supplementary 
information, table s2, figure s3). Having defined the mechanism of antibacterial action and 
determined the potential for combination therapies further characterisation of 9 was 
undertaken.  
9 induces conformational changes required for DNA binding and functions as an active 
co-repressor in vivo 
The structure of 9-bound SaBPL was compared with that of holo-SaBPL (PDB # 3RIR). Like 
with the reaction intermediate, biotinyl-5-AMP (PDB 3RIR), the crystallographic unit for 9 
bound SaBPL is a dimer with the two structures in good agreement when superimposed 
(RMSD = 1.2Å) (Figure 4). This indicates that the binding of 9 to SaBPL initiates the same 
conformational changes that are required for dimerization, correctly positioning residues 
F123, R122 and D200 at the dimerization interface. The N-terminal domains are also 
superimposed suggesting that 9 facilitates DNA binding and, therefore, functions as a co-
repressor.  
To test the effect of 9 on gene transcription, S. aureus NCTC 8325 was grown in biotin 
depleted media and treated with two concentrations of 9, either 10 nM or 3.9 μM (i.e. 4x 
MIC). Cells were harvested at 0, 15, 30 and 90 minutes post treatment and total RNA was 
prepared to analyse the level of transcript of bioD (the first gene in the biotin biosynthesis 
operon) and bioY (biotin transporter gene) using qRT-PCR. Transcriptional repression of 
bioD and bioY by 10 nM biotin was used for comparison. In bacteria treated with 10 nM 
biotin, a 111-fold decrease in bioD expression was displayed 15 minutes post-biotin addition 
and maintained throughout the time course (Fig. 5a). Addition of 10 nM of 9 however,  
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Figure 4: Structural alignment of BPL199-bound vs. biotinyl-5-AMP- bound SaBirA.  (a.) The 
structure of biotinyl-5-AMP SaBirA, residues involved in dimerization are shown (boxed diagram). 
(b.) The structure of BPL199-bound SaBirA. (c.) BPL199-bound SaBirA was aligned with biotinyl-5-










resulted in only 14-fold repression of bioD expression at 15 minutes post addition (p ≤0.0001, 
Fig. 5b), with this level of repression similarly maintained throughout the time course. 
Stronger repression of bioD was achieved by increasing the dosage of 9 to 3.9 μM (i.e. 4x 
MIC) with the level of transcripts showing a 52-fold decrease after 15 minutes, with transcript 
levels dropping further to 32-fold at 30 minutes and 71-fold at 90 minutes compared to time 0 
(p ≤0.0001, Fig. 5c). The bioY transcript exhibited less dramatic repression than bioD, with 
10 nM biotin addition resulting in only 2-fold repression at 15 minutes (p < 0.01), 5–fold at 
30 minutes (p < 0.01) and 6-fold at 90 minutes (p < 0.01) (Fig. 5d). Unlike with bioD, S. 
aureus treated with 10 nM compound 9 exhibited a similar fold-response, with bioY 
expression reduced by 1.5-fold at 15 minutes (p < 0.01), 2-fold at 30 minutes (p < 0.01) and 
6-fold at 90 minutes (p ≤0.0001, Fig. 5e). These results suggest that 9 acts as a functional co-
repressor, with repression comparable to that of the natural ligand, biotin. To further probe 
this, EMSA analysis was performed to determine whether the reduced repression of 9 was due 
to a reduction in ability to promote DNA-binding in vitro. EMSA reactions were prepared by 
first incubating apo-SaBPL with either; biotin and ATP, to allow the synthesis of biotinyl-5-
AMP (i.e. holo-SaBPL), or compound 9. The binding data showed that SaBPL:compound 9 
exhibits equipotent DNA binding to that of SaBPL:biotinyl-5-AMP (Fig. 6). SaBPL binding 
to SabioO exhibited 100% binding at 156 nM SaBPL for both biotinyl-5-AMP and 
compound 9 (Fig. 6a-b). The minimal concentration of protein required to produce 100% 
binding to the bioY probe was also 312 nM for both ligands (Fig. 6c-d). This in vitro analysis 
supports that 9 induces the same DNA binding activity as biotinyl-5-AMP and that the 






Figure 5: qRT-PCR analysis of biotin vs. 9.  S. aureus was grown in biotin-depleted Mueller-
hinton media until mid-log phase was reached and treated with either 10 nM biotin, 10 nM of  9 or 
3.9 μM (i.e. 4x MIC) of 9. The expression of SabioD and SabioY was then quantified. The amount of 
transcripts were normalized against an internal control (16s rRNA) and relative expression for each 
time point against time = 0 was calculated. The repression of SabioD following treatment with a.) 10 
nM biotin b.) 10 nM 9 and c.) 4x MIC of 9, is shown. Repression of SabioY in response to treatment 
with d.) 10 nM biotin and e.) 10 nM of 9 is also shown. Error bars represent S.E.M from independent 
biological replicates (n=3), * = p <0.05, ** = p <0.01,  *** = p >0.001, **** = p <0.0001 
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Figure 6: EMSA of biotinyl-5-AMP vs. 9. (Top) SaBPL binding to SabioO probe in EMSA reaction 
containing a.) biotinyl-5-AMP and b.) 9. (Bottom) SaBPL binding to SabioY probe in EMSA reaction 
containing c.) biotinyl-5-AMP and d.) 9. EMSA was performed in standard binding buffer (50 mM 
Tris pH 8.0, 50 mM NaCl, 1 mM ATP, 1 mM MgCl2 and 10% (v/v) glycerol) using 10 nM of a 44 bp 
double stranded oligo containing either SabioO or SabioY operator sequence and wild-type SaBPL at 
concentrations indicated. Control reactions containing biotinyl-5-AMP were prepared by adding 
0.1mM biotin, 1mM ATP and 2.5% DMSO into the binding buffer, these were compared to reactions 




Generation of resistant mutants and detection of SaBPL mutation D200E 
The capability of S. aureus to develop resistance to 9 was tested through use of both 
spontaneous resistance and serial passage approaches. To facilitate the subsequent analysis of 
these strains, S. aureus NCTC 8325 was utilised due to the availability of a reference genome 
for comparative sequence analysis. For measuring spontaneous resistance 10
9
 cells were 
plated onto media containing 4× MIC. No spontaneously resistant mutants were observed 
after 24 hours suggesting a low resistance frequency of less than 10
-9
. Consequently, 
generation of resistant strains was achieved by serial passage of seven populations of S. 
aureus NCTC 8325 in sub-inhibitory concentrations of 9 for 18 days (supplementary figure 
s8). After 18 days passage seven individual colonies were isolated and passaged on non-
selective media to verify that the mutations were genetically stable. At this point the 7 strains 
tested had an MIC 4 to 32 fold that of the parent strain (MICNCTC8325 = 0.0625 μg/ml). Strain 
NCTC8325-B7 exhibited resistance to the highest concentration (MIC = 2 μg/ml) (table 3). 
Sequencing of the BPL gene from all seven strains was subsequently undertaken to determine 
any modifications in the BPL target. NCTC8325-B7 was the only isolate which harboured a 
missense mutation in BPL. This mutation, D200E, maps in the dimerization interface between 









Table 3: MIC’s of strain NCTC8325 and derivatives against 9 after 18 days serial passage in the 
presence of suboptimal concentrations to 9. MICs were determined in triplicate. *strain B3 exhibited 
slow growth making MIC determination difficult. **strain B7 was susceptible to 4μg/ml compound 9 
but showed tolerance to 64 μg/ml. 
 
Strain MIC (μg/ml) 
NCTC 8325 0.0625 
NCTC 8325-B1 1 
NCTC 8325-B2 0.5 
NCTC 8325-B3 0.125* 
NCTC 8325-B4 0.5 
NCTC 8325-B5 0.25 
NCTC 8325-B6 1 
NCTC 8325-B7 2** 
 
Preparation of apo SaBPL D200E and polymorphisms in SaBPL 
To test the effect of the SaBPL D200E mutation, the mutation was inserted into the enzyme 
by mutagenesis and assessed in both in vitro and in vivo systems. It is worth noting that the 
enzyme previously used for characterisation of all the inhibitors to date was derived from the 
methicillin resistant strain S. aureus Mu50 which contains 3 polymorphisms between it and 
the NCTC 8325 enzyme (see figure s15). The D200 residue however is conserved in all 
strains (figure s16). As the Mu50 BPL has more conserved residues compared with other S. 
aureus strains and has previously been characterised both in vitro [7, 17, 28] and in vivo 
[Satiaputra et al, unpublished] it was decided to continue using this system for analysis. The 
recombinant protein was purified in the apo-state for further in vitro characterisation with the 
apo-state of the purified SaBPL D200E verified using native mass spectrometry. This 
indicated no biotinyl-5′-AMP had co-purified with the recombinant SaBPL. Apo-SaBPL 
(wild-type) was also purified and verified in the same manner.  
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SaBPL D200E acts by disruption of dimerization and hence transcriptional repression.  
The effect of the D200E mutation on SaBPL catalytic activity was determined by comparing 
the D200E mutant to wild type SaBPL in an enzyme assay. The affinity for biotin was 
modestly altered in the mutant with the Km for wild type 1.8 ± 0.3 μM, and D200E mutant 
BPL, 3.8 ± 0.4 μM (p < 0.05). However, the inhibitory activity of 9  was not affected with Ki 
for the wild type 4.8 ± 2.1 nM, and D200E mutant 10.9 ± 3.5 nM not significantly different (p 
= 0.18). The velocity (Vmax) of the enzymes was also not altered by the mutation. We 
reasoned due to its location that the mutation may exert its effect on the dimerization of the 
protein. The dimerisation ability of SaBPL D200E was therefore analysed using native nano-
electrospray ionization mass spectrometry. Previous studies have shown the wild type SaBPL 
is monomeric in solution, but dimerises in the presence of the reaction intermediate [25]. This 
dimerization is prevented by the presence of a F123G mutation [[28]Satiaputra et. al 
unpublished]. We similarly observed that the holo-SaBPL dimerises at concentrations as low 
as 10 μM. The D200E mutation however prevents the formation of the dimer in both the apo 
and holo state (table 4, figure s14) at the highest concentrations tested (≤ 90 μM). This 
approach provided sufficient resolution to confirm that the reaction intermediate, biotinyl-5′-
AMP, is bound in the active site, indicating the lack of dimerization is not due to inability to 






Table 4: Native ESI-MS analysis of apo and Holo SaBPL D200E and wild-type SaBPL. Summary 
of molecular weight and protein species detected by ESI-MS for SaBirA D200E and wild-type 
SaBirA. The predicted and the detected molecular weight (MW) in the absence and presence of 
biotinyl-5-AMP (MW =573 Da), as well as the oligomeric state are presented.  
 
SaBirA Sample Measured MW (Da) Complex 
components 
Calculated MW (Da) 
Apo-wild type SaBirA 
10 μM 
37892 Monomer 37892 
Holo-wild type 



























































To determine the effect of this inability to dimerise on transcriptional repression apo-purified 
SaBPL D200E was compared to the wild-type using EMSA and a previously established in 
vivo transcriptional reporter system in E. coli [Satiaputra et. al, unpublished]. For the apo 
protein both wild-type SaBPL and SaBPL D200E showed similar binding in an EMSA, with a 
minimum concentration required of 20 nM to bind bioO and 39 nM-78 nM for binding bioY 
(Figure 7). Both apo-SaBPL wild-type and apo-SaBPL D200E also failed to give 100% 
binding at the given concentrations, as indicated by the appearance of unbound probes. The 
minimal concentration of wild-type holo-SaBPL required was significantly reduced compared 
to the apo-state, with 3.12 nM for both bioO and bioY. This concentration was significantly 
lower than that of the holo-SaBPL D200E which exhibited binding at concentrations more 
similar to that of the apo-protein with 10 nM and 19 nM respectively (Fig. 8). A difference 
was also observed in the amount of probe  bound, with 100% binding of the holo-SaBPL 
wild-type to both probes at 50 nM for wild type holo-SaBPL, whilst SaBPL D200E required 
156 nM to completely bind bioO and failed to generate a complete binding to bioY at the 
highest concentration tested (156 nM, Fig. 8d). This result supported that the dimerization 
capability of the holo-SaBPL D200E, and hence interaction with SabioY, was compromised. 
To determine if this dimerization defect was biologically relevant, an in vivo β-galactosidase 
assay was employed using E. coli reporter strain.  Previously developed tools for the site 
specific integration of genetic elements into the E. coli genome were used to generate the 
required E. coli strains (figure s11) [43], with strains harbouring the wild type SaBPL and 
another dimerization mutant, SaBPL F123G [28] analysed alongside the SaBPL D200E. The 
repressor activity of the varied BPLs against S. aureus bioO and bioY promoters was 
determined by calculating the concentration of biotin required for 50% reduction of lacZ 
activity (KR). The results showed a 3.2 fold difference (p < 0.05) in biotin concentration 
required for repression of the bioO reporter between wild type (KR = 4.3 ± 1.9 nM) and the 
D200E mutant (KR = 13.9 ± 3.4 nM), similar to that seen with the F123G (KR = 15.3 ± 3.5 
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nM) (Fig. 7a).  A larger difference was observed against bioY where wild type BPL (KR = 8.2 
± 0.7 nM) repressed at vastly lower concentrations than the D200E and F123G (KR >500 nM). 
For the D200E mutant repression to basal levels was not observed even at 500 nM biotin (Fig. 
7b). This was consistent with the EMSA analysis which suggested that disruption of 
dimerization had a greater impact on binding to the bioY promoter sequence. These results 
show that although SaBPL D200E is capable of binding DNA it generates weaker interactions 
with DNA than the wild-type protein in liganded form. This suggests that S. aureus 











Figure 7: EMSA analysis of apo-SaBPL D200E vs. apo-SaBPL wild-type. a.) SaBPL wild-type 
binding to SabioO, b.) SaBPL D200E binding to SabioO, c.) SaBPL wild-type binding to SabioY 
and d.) SaBPL D200E binding to SabioY. EMSA was performed in standard binding buffer (50 mM 
Tris pH 8.0, 50 mM NaCl, 1 mM ATP, 1 mM MgCl2 and 10% (v/v) glycerol) without the addition 
of biotin. 10 nM of double stranded oligo containing either SabioO or SabioY operator sequence 









Figure 8: EMSA analysis of Holo wild-type SaBPL compared to Holo-SaBPL D200E . a.) 
SaBPL wild-type binding to SabioO, b.) SaBPL D200E binding to SabioO, c.) SaBPL wild-type 
binding to SabioY and d.) SaBPL D200E binding to SabioY. EMSA was performed in standard 
binding buffer (50 mM Tris pH 8.0, 50 mM NaCl, 1 mM ATP, 1 mM MgCl2 and 10% (v/v) 
glycerol) with the addition of 0.1 mM biotin. 10 nM of double stranded oligo containing either 
SabioO or SabioY operator sequence was used per reaction. Varying SaBPL concentration was 













Figure 9: In vivo β-galactosidase assay of SaBPL D200E In vivo assay was carried out in an E. coli 
reporter strain containing chromosomally integrated repressor and promoter constructs. LacZ units 
were calculated by subtracting the value generated by the control strain containing no integrated 
promoter construct (LacZ unit ≤ 10) from each biotin concentration. β-galactosidase assay showing the 
repression of (a.) SabioO and (b.) SabioY by SaBPL D200E (green), SaBPLF123G (black) and SaBirA 
wild-type SaBPL (yellow). No-repressor control represented in (blue). Error bars represent S.E.M 
from independent biological replicate (n = 6). 
 
 
Table 5: Summary of KR biotin obtained from in vivo β-galactosidase assay. The amount of biotin to 
reach half-maximum repression (KR) was calculated from the results generated in Figure 9, using 
Graphpad Prism. Significance of SabioO result was determined by two tailed t-test against wild type * 








SaBPL Promoter Half maximum repression 
KR biotin (nM) 
Wild type SabioO 4.3 ± 1.9 
F123G SabioO 15.3 ± 3.5 * 
D200E SabioO 13.9 ± 3.4 * 
Wild type SabioY 8.2 ± 0.7 
F123G SabioY ≥ 500 
D200E SabioY ≥ 500 














































The removal of the ribosyl moiety from the literature compound bio-AMS 8 to create 9 vastly 
improved anti-staphylococcal activity with a ≥ 400 fold decrease in MIC. This improvement 
in activity was constrained to S. aureus species and a concomitant decrease in activity in M. 
tuberculosis was observed. Small changes in this compound structure were also able to 
drastically reduce activity. This was exemplified by the other sulfonyl compounds which 
showed limited efficacy in both enzymatic and antimicrobial assays. Unlike the 1,2,3-triazole 
parent 6 the benzaloxazolone moiety was not well tolerated in the sulfonyl based compound 
11 with a greater than 700 fold reduction in Ki. This was unexpected however the crystal 
structure gives some insight into why it may have occurred. The lack of hydrogen bonding 
interactions in the adenine binding pocket without the extra interactions mediated by the π-π 
stacking with the triazole linker could feasibly reduce binding affinity resulting in weaker 
inhibition. Similarly the lack of inhibitory activity exhibited by 10 is thought to be a result of 
the removal of the carbonyl H-bonding with K187. These interactions are therefore likely key 
to binding and future development should attempt to maintain their presence with the sulfonyl 
linker.  
This study also addresses several of the underlying questions around the mechanism of action 
and resistance to BPL inhibitors. In particular the ability for 9 to act as a co-repressor through 
facilitating transcriptional repression of both bioO and bioY suggests this may play a role in 
the antibacterial activity. Interestingly whilst both biotin and 9 showed similar kinetics in the 
EMSA and in S. aureus, 9 was unable to induce repression in the in vivo E. coli system 
(unpublished observations). Knowing that 9 is capable of repressing these transcripts in S. 
aureus suggests it is incapable of entering the E. coli cell. The resistance studies further 
supported a role of transcriptional repression on antibacterial activity. The D200E mutations 
role in dimerization and repression is consistent with previous mutagenesis studies in both S. 
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aureus BPL and E. coli BPL which indicated that modification of residues involved in the 
dimerization interface can affect repressor ability. These mutations, F123G [28] and D197Y 
[46, 47]  for SaBPL and E. coli BPL respectively, drastically effect transcriptional regulation 
of their controlled genes (Satiaputra et al., unpublished [46, 47]). In particular the in vivo lacZ 
assay confirmed that this reduction in dimerization led to weaker repression of both bioO and 
bioY with the KR for biotin strikingly high for bioY (≥ 500 nM). Considering the predicted 
intracellular biotin concentration is between 10-100 nM [19, 48], the mutant strain would 
have to accumulate ≥ 5-fold intracellular biotin concentration, compared to strains with wild-
type SaBPL in order to terminate the transcription of biotin transporter protein. It would not 
be surprising if bioY is being expressed constitutively in vivo, based on these facts. It is 
reasonable to conclude that as a result of these increases in both de novo synthesis and biotin 
transport, the cells containing the SaBPL D200E mutation would accumulate more 
intracellular biotin. This presumably helps outcompete 9, occupying the active site of SaBPL. 
Supporting this is the mechanism of action assay, with increasing biotin concentrations 
reducing compound efficacy. This competitive binding mechanism is not uncommon in 
resistance development involving vitamin biosynthesis, as suggested by previous studies in 
antimicrobial resistance [12, 49, 50]. The resistance mechanism is similar to one seen for 
thiamine synthesis inhibition, where the binding site of the thiamine riboswitch ligand binding 
site is altered to prevent repression by the mimic pyrithiamine, dysregulating thiamine 
synthesis as a means of resistance [49]. It is important to note however that this mutation 
likely does not act in isolation, with stepwise increases in resistance observed in the resistant 
populations. Whilst the effect of the mutation can be elucidated, without a clearer 
understanding of the other mutations present, the exact impact of this individual mutation 




The studies outlined here using 9 have shed some light on the role of DNA binding on 
antibacterial efficacy of BPL inhibitors. Further development of this series of compounds, 
maintaining DNA binding and high potency, will hopefully lead to a valid pre-clinical 
candidate. In particular the synergistic effect seen between 9 and the antibiotics methicillin 
and streptomycin bodes well for BPL inhibitors clinical use, as does the low spontaneous 
resistance rate. As well, the single resistance mechanism elucidated here is part of a larger 
picture, with 6 of 7 strains not demonstrating mutations in the BPL target. Understanding the 
other mutations correlated with resistance in these strains as well as any additional mutations 
present in the strain NCTC8325-B7 will help immensely in further understanding the way 
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Figure s1: cytotoxicity of BPL199 was tested against both a) HEK293 and b) HepG2cell lines with 
paracetamol as a positive control. The WST-1 reagent was used to detect metabolic activity after 48 
hours treatment. No significant toxicity was observed at any concentration. Paracetamol at 6.25mM 
and 25mM respectively exhibited >60% reduction of growth (p<0.001). 
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Figure s2: concentration kill kinetics. S. aureus ATCC49775 was grown in the presence of no 
compound (blue), 1× MIC (yellow squares), 2× MIC (orange triangles), 4× MIC (red diamonds) and 
cell numbers enumerated to determine if killing was observed. 
 
Figure s3: Checkerboard assay results with BPL199 with a) Methicillin and b) streptomycin. Due to 
variability in the plate reader a consistent value of ≤2% growth in separate plates (n=3) was taken as 
optical clarity.  
153 
 
Figure s4: BPL199 antibacterial efficacy in absence of FCS (green triangles), 20% FCS (blue cross) 
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Figure s5: Mechanism of action for S. aureus against compound 9. Susceptibility of S. aureus 





Figure s6: Mechanism of action studies. S. aureus RN4220 + pCN51-NcoI control (dashed line) and 
pCN51-BPL overexpression (solid line) vectors susceptibility to a) literature BPL inhibitor biotinol-5′-
AMP and b) non BPL targeting antibiotic amoxicillin. Assays were performed in triplicate and 
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Figure s7: Effect of increased exogenous biotin concentration on antimicrobial effect of 9 against S. 
aureus ATCC 49775. No added biotin (circles), +10nM biotin (squares), +100nM biotin (triangles), 
+1μM biotin (diamonds). 
 
Advanced resistance studies 
 
Figure s8: Progression of resistance of a constantly passaged population as determined by the well 
containing the highest concentration of 9 with an OD reading of >0.1. Due to the nature of the 
experiment no replicates were obtained. *several of the populations exhibited susceptibility to 
lower concentrations of antibiotic (1-4 μg/ml) whilst growing at high (16-64 μg/mL) 
concentrations, the reason for this paradoxical effect is unknown but similar to that seen in 
several other antibiotics [1-3] 
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Modelling the effect of the mutation 
 
Figure s9: modelling the effect of the D200E mutation on the dimerization interface of SaBPL 
(Assuming lack of movement in adjacent atoms using UCSF Chimera swapaa tool). Loss of hydrogen 
bonding between the D200 and R122 of the opposing monomer results as the distance between the 
relevant residues increases to prevent steric clashes. 
 
figure s10: modelling the effect of the D197Y mutation on the dimerization interface of EcBPL 
(Assuming lack of movement in adjacent atoms using UCSF Chimera swapaa tool). Loss of one 
hydrogen bonding between the D197 and backbone of R119 of the opposing monomer results as the 








Supplementary figure verifying no biotinyl co-purified 
 
Figure s10: Confirmation of purified apo-SaBirA wild-type and apo SaBirA D200E. Western blot 
detection using Alexa 488 conjugated streptavidin was used to detect biotinylated SaPC90 domain 
after incubation with SaBPL in the presence and absence of biotin. The results for (a.) SaBPL wild-
type and (b.) SaBPL D200E are shown. A small proportion of biotin might be covalently linked to a 
non-specific lysine residue within SaBPL during purification, which results in detection of SaBirA in 





Figure S11: Integration vector containing SaBPL  D200E. SaBPL  D200E gene fused to a lac 
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Figure s12: representative dose response for Km determination enzyme assay with wild type (circles), 
and D200E (squares) SaBPL in response to increased biotin concentration. Assay was performed in 
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Figure s12: representative dose response for enzyme inhibition assay with wild type (circles), and 









Figure s13: Interactions between a) biotinyl-5′-AMP and b) compound 9 with SaBPL as determined 
by ligplot+ [4, 5], using their respective crystal structures. (PDB 3RIR, this study). Conserved 
hydrogen bonding interactions can be observed with all protein residues as well as the key π-pi 



























Figure s14. nESI-MS reveals SaBirA D200E is a mutant devoid of dimerization 
independent of ligand binding. Mass spectra of (a.) apo-wild type SaBirA at 10 μM, (b.) 
holo-wild type SaBirA at 10 μM, apo-SaBirA D200E at (c.) 1.4 μM, (e.) 11.25 μM, (g.) 22.5 
μM, (i.) 45 μM and (k.) 90 μM, along with holo-SaBirA D200E at (d.) 1.4 μM, (f.) 11.25 μM, 
(h.) 22.5 μM, (j.) 45 μM and (l.) 90 μM are shown. Proteins were purified in their apo states 
(REF protocol), whilst holo samples were prepared by incubating the apo-purified protein 
with 500 μM biotin, 1 mM ATP and 1 mM MgCl2 prior to buffer exchange and nESI-MS 
analysis. Peaks representing the oligomeric state of the proteins are marked with sphere 
symbols, with outlined light grey circles representing wild type SaBirA and dark grey circles 
representing SaBirA D200E. Monomeric protein is represented as a single sphere and 
dimeric by 2 joined spheres. The presence of the biotinyl-5-AMP ligand is represented by a 
black triangle. Transparent grey rectangles represent apo species in the holo samples due to 
the loss of ligand during buffer exchange or ionisation energy.  







Figure s15: BPL sequences of S. aureus were determined as follows: the protein cluster PCLA_885364 
containing 71 entries (which encompasses all non-redundant proteins identified as  biotin--acetyl-
CoA-carboxylase ligase in the Genus Staphylococcus) was further filtered for the clade 
Staphylococcus aureus 19988 to make a list of 26 protein sequences. These sequences were 
subsequently obtained and compared using UGENE [6] and aligned with clustal omega [7]. The 3 




Figure s16: conservation of the D200 residue across the 71 non redundant staphylococcal BPL 
sequences from the protein cluster PCLA_885364 and outgroup Bacillu subtillus. Sequences were 






Table s1: inhibition of BPL from other clinically relevant species by compound 9 
Species BPL Ki (nM) 
Acinetobacter calcoaceticus 212 ± 8.3 (n=3) 
 








Methicillin β-lactam Cell wall synthesis  0.375 Yes 
Streptomycin Aminoglycosides Protein synthesis 0.375 Yes 
Vancomycin Glycopeptides Cell wall synthesis 0.625 No 
Daptomycin Lipopeptides Cell membrane depolarisation; 
nucleotide and protein synthesis 
0.625 No 
Erythromycin Macrolides Protein synthesis 0.625 No 
Chloramphenicol Chloramphenicols Protein synthesis 0.5625 No 
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37892 Monomer 37892 
Holo-wild type 

















37916 Monomer 37905 
Holo-SaBirA 






37919 Monomer 37905 
Holo-SaBirA 






37912 Monomer 37905 
Holo-SaBirA 






37915 Monomer 37905 
Holo-SaBirA 






37915 Monomer 37905 
Holo-SaBirA 





Primers used in this study 
Primer Sequence Function source 
B481 5 -GGTTGCTAATAATGAAGGTATAGAA 
GCAATAATATGTGG-3 












5'-GGCATCACGGC AATATAC-3' attp-λ PCR screening 
primer  




5'-ACTTAACGGCTGACATGG-3' attp-λ PCR screening 
primer  




5'-GGGAATTAATTCTTGAAGACG-3' attp-λ PCR screening 
primer  




5'-TCTGGTCTGGTAG CAATG-3' attp-λ PCR screening 
primer  







Target gene Primer name Primer sequence 5'-3' Source 
S. aureus bioD qSA2716_F GCAAGGTGTGGTGATACAGG (Jiulia’s thesis) 
  qSA2716_R ACACGTGGTCATCGAGTTTG (Jiulia’s thesis) 
S. aureus 16s rRNA qSA0002_F GAACCGCATGGTTCAAAAGT (Jiulia’s thesis) 










Top strand oligo containing 







Bottom strand oligo containing 







Top strand oligo containing 







Bottom strand oligo containing 







Strain description function source 
E. coli DH5α  supEΔlac169 (p80lacZΔM15) hsdR17 










E. coli B F
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Cm
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S. aureus NCTC 
8325 
Laboratory methicillin sensitive S. aureus 
with reference genome 
parental S. 








S. aureus NCTC8325 after 18 days 







S. aureus RN4220 containing  control 
vector for mechanism of action studies 
Overexpression 
control 





S. aureus RN4220 containing  vector for 
overexpression of SaBPL for mechanism 
of action studies 
Overexpression 
vector 














JD28186 strain with N-terminal CAT cassette 












JD26186 birA::CAT strain with SaBioO lacZ 
reporter chromosomally integrated at HK022 att 
site, and placUV5-SaBPL( wildtype) cassette 











JD26186 birA::CAT strain with SaBioY-lacZ 
reporter chromosomally integrated at HK022 att 
site and placUV5-SaBPL( wildtype) cassette 













JD26186 birA::CAT strain with SaBioO-lacZ 
reporter chromosomally integrated at HK022 att 
site, and plac-UV5-SaBPL (F123-monomeric 
mutant) cassette chromosomally integrated at 













JD26186 birA::CAT strain with SaBioY-lacZ 
reporter chromosomally integrated at HK022 att 
site, and plac-UV5-SaBPL (F123-monomeric 
mutant) cassette chromosomally integrated at 













JD26186 birA::CAT strain with SaBioO-lacZ 
reporter chromosomally integrated at HK022 att 
site, and plac-UV5-SaBPL (D200E) cassette 













JD26186 birA::CAT strain with SaBioY-lacZ 
reporter chromosomally integrated at HK022 att 
site, and plac-UV5-SaBPL (D200E) cassette 





Plasmid Description  Source 
pGEMT-
SaBPL(6xHis) 




pGEMT plasmid containing saBPL D200E with 6x his-
tag 
This study 
pIT4_TL_152002 Chromosomal integration plasmid  (λ-attP, Tc
R
, R6Kγ  
ori, ccdB, pUC ori) 












Chemical synthesis of compound 9. 
 
Synthesis of 2-(4-(6-amino-9H-purin-9-yl)butyl)isoindoline-1,3-dione 
To a suspension of 6-Aminopurine (1.1 G, 8.82 mmol) in N,N-dimethylformamide (11 mL) was added 
potassium carbonate (1.8 G 13.23 mmol, 1.5 eq) and N-(4-bromobutyl)phthalamide (2.75 G, 9.7 
mmol, 1.1 eq) and the mixture was stirred at 70 °C overnight. The mixture was allowed to cool down 
to room temperature and partitioned between ethyl acetate and water. The aqueous phase was 
extracted with ethyl acetate. The organics combined were washed with brine (x2) and water (x1), dried 
over sodium sulphate anh., filtrated and evaporated under reduced pressure. The solid obtained was 
triturated from diethyl ether affording the title compound as a pale yellow solid (2.5 G, 84%).  
 
1H NMR (500 MHz, DMSO-d6): δ 8.12 (s, 1H, ArH), 8.07 (s, 1H, ArH), 7.84 (m, 4H, ArH), 7.16 (s, 
2H, NH2), 4.17 (t, J = 6.7 Hz, 2H, CH2), 3.61 (t, J = 6.7 Hz, 2H, CH2), 1.83 (dd, J = 14.7, 6.9 Hz, 2H, 
CH2), 1.56 (dt, J = 13.8, 6.9 Hz, 2H, CH2). 
13C NMR (125 MHz, DMSO-d6): δ 167.9 (2xCO), 155.9 (C), 152.3 (CH), 149.5 (C), 140.8 (CH), 
134.3 (2xC), 131.6 (2xCH), 123.0 (2xCH), 118.7 (C), 42.4 (CH2), 36.8 (CH2), 26.7 (CH2), 25.1 (CH2) 
ppm. 
MS HRMS (ESI) calcd for C17H16N6O2 (M
+














Synthesis of 9-(4-aminobutyl)-9H-purin-6-amine 
To a suspension of 2-(4-(6-amino-9H-purin-9-yl)butyl)isoindoline-1,3-dione (2.5 G, 7.43 mmol) in 
ethanol (125 mL) was added hydrazine hydrate (3.5 mL, 114.45 mmol, 15 eq) and the mixture was 
stirred at reflux overnight. The mixture was allowed to cooled down to room temperature and 
concentrated under reduced pressure. A solid was formed which was filtrated and washed with 
dichloromethane. Trituration from methanol afforded the title compound (1G, 67%) as a colourless 
solid. 
 
1H NMR (500 MHz, DMSO-d6): δ 8.12 (s, 1H, ArH), 8.11 (s, 1H, ArH), 7.14 (s, 2H, NH2), 4.11 (t, J 
= 7.1 Hz, 2H, CH2), 3.06 (br s, 2H, NH2), 2.51 (t, J = 6.9 Hz, 2H, CH2), 1.79 (dd, J = 14.9, 7.3 Hz, 2H, 
CH2) and 1.28 (dd, J = 14.9, 7.3 Hz, 2H, CH2). 
13C NMR (125 MHz, DMSO-d6): δ 155.9 (C) 152.3 (CH), 149.5 (C), 140.8 (CH), 118.7 (C), 42.8 
(CH2), 41.0 (CH2), 30.0 (CH2) and 26.9 (CH2) ppm. 
MS HRMS (ESI) calcd for C9H15N6 (M−H
+
): 207.1313, found 207.1513. 
 
 
Synthesis of tert-butyl N-(4-(6-amino-9H-purin-9-yl)butyl)sulfamoylcarbamate 
A solution of 9-(4-aminobutyl)-9H-purin-6-amine (1.6 G, 7.75 mmol, 1 eq) trietylamine (2.1 mL, 15.5 
mmol, 2 eq) and A (2.6 G, 7.75 mmol 1 eq) in dichloromethane (15 mL) was stirred at room 
temperature overnight. The solvent was removed under reduced pressure. Purification by flash 
chromatography (5% methanol:dichloromethane) afforded the title compound (664 mg, 23%) as a 
colourless solid. 
 
1H NMR (500 MHz, DMSO-d6): δ 10.77 (s, 1H, NH), 8.12 (s, 1H, Ar), 8.11 (s, 1H, ArH), 7.55 (br s, 
1H, NH), 7.16 (s, 2H, NH2), 4.12 (t, J = 7.0 Hz, 2H, CH2), 2.90 (dd, J = 13.0, 6.7 Hz, 2H, CH2), 1.82 
(m, 2H, CH2), 1.41 (m, 2H, CH2) and 1.38 (s, 9H, tBu) ppm. 
13C NMR (125 MHz, DMSO-d6): δ 155.9 (CO), 152.3 (C), 150.6 (CH), 149.5 (C), 140.7 (CH), 118.7 
(C), 81.0 (C), 42.4 (CH2), 42.2 (CH2), 27.7 (3xCH3), 26.7 (CH2), and 25.8 (CH2) ppm. 
MS HRMS (ESI) calcd for C14H24N7O4S (M−H
+






Synthesis of the sulphonamide precursor 
A solution of tert-butyl N-(4-(6-amino-9H-purin-9-yl)butyl)sulfamoylcarbamate (664 mg, 1.72 mmol, 
1 eq) in dichloromethane (12 mL) cooled down to 0 °C was treated with trifluoroacetic acid (1.2 mL, 
15.7 mmol, 9 eq) and stirred at room temperature. After 2 h trifluoroacetic acid (1.2 mL, 15.7 mmol, 9 
eq) was added. After being stirred at room temperature overnight the solvent was removed under 
reduced pressure. The title compound was obtained as a colourless solid (641 mg, 59%) and was used 
without further purification. 





A suspension of the sulfonamide precursor (641 mg, 2.225 mmol, 1 eq), CsCO3 (520 mg, 2.7 mmol, 
1.2 eq) and B (844 mg, 2.4 mmol, 1.1 eq) in DMF (2.8 mL) was stirred at room temperature overnight. 
The solvent were removed under reduced pressure and the crude was purified by flash 
chromatography (10-20% MeOH-DCM) affording the title compound (500 mg, 45%) as a colourless 
solid. 
 
1H NMR (500 MHz, DMSO-d6): δ 11.26 (s, 1H, NH), 8.13 (s, 1H, ArH), 8.11 (s, 1H, ArH), 7.59 (t, J 
= 5.7 Hz, 1H, NH), 7.20 (s, 2H, NH2), 6.50 (s, 1H, NH), 6.38 (s, 1H, NH), 4.30 (dd, J = 7.6, 5.2 Hz, 
1H, CH), 4.204.07 (m, 3H, CH2+CHH), 3.123.04 (m, 1H, CHH), 2.88 (dd, J = 12.9, 6.7 Hz, 2H, 
CH2), 2.80 (dd, J = 12.4, 5.1 Hz, 1H, CHH), 2.57 (d, J = 12.4 Hz, 1H, CHH), 2.18 (t, J = 7.4 Hz, 2H, 
CH2), 1.911.73 (m, 2H, CH2), 1.671.55 (m, 1H, CHH), 1.551.36 (m, 5H, CH2+CH2+CHH) and 
1.351.21 (m, 2H, CH2) ppm. 
13C NMR (125 MHz, DMSO-d6): 171.5 (CO), 162.8 (CO), 155.9 (C), 152.4 (CH), 149.5 (C), 140.8 
(CH), 118.7 (C), 61.1 (CH), 59.2 (CH), 55.4 (CH), 48.6 (CH2), 42.4 (CH2), 42.2 (CH2), 35.0 (CH2), 
28.0 (2xCH2), 26.8 (CH2), 25.8 (CH2) and 24.3 (CH2) ppm. 








Synthesis of 2,5-dioxopyrrolidin-1-yl 5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanoate 
D-Biotin (5.0 G, 20.5 mmol) and N-hydroxysuccinimide (2.3 G, 20.5 mmol, 1.0 eq) were dissolved in 
hot DMF (150 mL). 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloric salt (4.7 G, 2.4.6 
mmol, 1.2 eq) was added, and the solution was stirred overnight at room temperature. The mixture was 
partitioned between ethyl acetate and water and the aqueous phase was extracted with ethyl acetate 
(x3). The organics combined were dried over sodium sulphate anh., filtrated and evaporated under 
reduced pressure. The solid obtained was triturated from diethyl ether affording the title compound 
(4G, 57%) as a colourless solid. 
1H NMR (500 MHz, DMSO-d6) δ 6.41 (s, 1H, NH), 6.35 (s, 1H, NH), 4.514.20 (m, 1H, CHH), 
4.204.07 (m, 1H, CHH), 3.11 (dd, J = 12.3, 6.5 Hz, 1H, CHH), 2.872.78 (m, 5H, CH2+CH2+CHH), 
2.67 (t, J = 7.4 Hz, 2H, CH2), 2.58 (d, J = 12.2 Hz, 1H, CHH), 1.65 (dt, J = 15.2, 7.7 Hz, 3H, 
CH2+CHH), 1.551.46 (m, 1H, CHH) and 1.43 (dd, J = 12.4, 6.4 Hz, 2H, CH2) ppm. 
13C NMR (125 MHz, DMSO-d6): 170.2 (2xCO), 168.9 (CO), 162.6 (CO), 61.0 (CH), 59.2 (CH), 






Table 1.  Data collection and refinement statistics (molecular replacement) 
 
 SaBPL +  BPL199 
Data collection
a
 MX1 Beamline  
Australian Synchrotron 
Space group P 42 21 2 
Cell dimensions  
    a, b, c (Å) 92.54, 92.54, 128.98 
    α, β, γ  ()  90.0, 90.0, 90.0 
Resolution (Å) 45.93 - 2.392 (2.478  - 2.392) 
Rsym or Rmerge 0.02762 (0.4816) 
I / σI 15.65 (1.49) 
Completeness (%) 99.94 (99.96) 
Redundancy 2.0 (2.0) 
  
Refinement  
Resolution (Å) 45.93 - 2.392 
No. reflections 22803 
Rwork / Rfree 0.2069/0.2607 
(0.3157/0.3536) 
No. non-hydrogen atoms  
    Protein 2610 
    Ligand/ion 34 
    Water 43 
B-factors  
    Protein 78.80 
    Ligand/ion 95.80 
    Water 58.70 
R.m.s. deviations  
    Bond lengths (Å) 0.017 
    Bond angles () 1.56 
a
Diffraction data were collected from one crystal for each structure 
. *Values in parentheses are for highest-resolution shell. 
 
[AU: Ramachandran statistics should be in Methods section at the end of Refinement subsection.] 
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Loss of functional pyruvate carboxylase is a major contributor for resistance to 
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Abstract 
Biotin protein ligase (BPL) inhibitors are a novel class of antibacterial agent that have in vitro 
efficacy against the clinically important pathogen Staphylococcus aureus. In S. aureus BPL is 
a bifunctional protein, acting catalytically to attach biotin to biotin-dependent enzymes, and 
serving to transcriptionally regulate biotin synthesis and transport genes. Previously we 
reported the generation of 7 isolates with decreased susceptibility to a potent BPL inhibitor, 
BPL199 (compound 9, chapter 5). Here we report further investigation of the resistance 
mechanisms employed in all 7 strains using whole genome sequencing. The most common 
mutation associated with resistance was a loss of functional pyruvate carboxylase (PC), which 
occured in 5 of 7 strains. Of the strains without this loss of PC, one contained a missense 
mutation in the disulphide stress effector yjbH. Using transposon disrupted S. aureus we 
demonstrated that deletion of either PC or yjbH reduced susceptibility to BPL199. 
Characterisation of cross-resistance with other classes of antibiotics in the 7 original strains 
was also undertaken. All 7 strains exhibited reduced susceptibility to other BPL inhibitors. 
The yjbH mutant strain also exhibited slight cross-resistance to β-lactam antibiotics, but not 
any other classes of antibiotics. Together these results suggest 2 distinct mechanisms of 






There is a dire need for new antibacterial agents to combat antibiotic resistant infections. 
Staphylococcus aureus is one pathogen that has developed resistance to β-lactam treatments 
[1], glycopeptide and lipopeptide antibiotics [2], forcing clinicians to consider alternative 
treatments that often have significant associated toxicities [1, 3, 4]. As a result, discovering 
new antibacterial agents that are not subject to existing resistance mechanisms is essential for 
future healthcare. One promising target for a novel antibacterial class is the essential protein, 
biotin protein ligase (BPL). BPL is both the enzyme responsible for attaching biotin onto 
biotin-dependent enzymes, as well as a biotin-dependent transcriptional repressor [5]. These 
bifunctional activities of BPL position the protein as the key regulator of all biotin-mediated 
events in S. aureus. Two biotin-dependent enzymes are present in S. aureus, namely acetyl-
CoA carboxylase (ACC) and pyruvate carboxylase (PC), which catalyse the first step in fatty 
acid synthesis and replenish the tricarboxylic acid (TCA) cycle respectively. Without the 
biotin prosthetic group neither ACC nor PC are capable of performing their important 
metabolic functions. In S. aureus BPL also serves to repress the biotin synthesis (bioO), biotin 
transport (bioY) and a putative fatty acid synthesis (yhfTS) operons.[6](satiaputra et al., 
unpublished). Genome wide knockout studies have demonstrated the essential nature of BPL 
and ACC in S. aureus for growth in vitro, [7, 8] and a requirement for PC and the TCA cycle 
for in vivo virulence [9, 10]. BPL inhibition therefore offers a promising approach for 
antibacterial drug discovery with the ability to inhibit growth and survival both in vitro and in 
vivo (reviewed [5]). Small molecule inhibitors that target BPL’s enzymatic activity have also 
been reported with antibacterial activity against S. aureus [11-13] as well as Mycobacterium 
tuberculosis [14, 15]. We have also recently published the development and characterisation 
of a potent antibacterial, BPL199, designed as a non-hydrolysable analogue of the BPL 
reaction intermediate [chapter 5]. Our data showed that BPL199 functions as both an inhibitor 
of biotin ligase activity as well as a co-repressor, inducing transcriptional repression with 
similar potency and kinetics as biotin [chapter 5].  
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Characterising potential resistance mechanisms early in the antibiotic discovery phase is 
essential to prevent wasting resources on lead compounds and targets with high resistance 
rates [16-18]. Compounds that target multiple metabolic pathways generally show lower 
spontaneous resistance rates than compounds with single targets making them more suitable 
for mono-therapy [19]. Consistent with this observation, no spontaneous resistant mutants of 
S. aureus NCTC8325 were isolated when grown on media containing BPL199 at 4× MIC  
[chapter 5], suggesting multiple mutations were required for high level resistance. Subsequent 
serial passage in suboptimal concentrations of the antibiotic was undertaken with 7 
populations. This allowed for more gradual acquisition of resistance, allowing cells to 
accumulate the multiple mutations required for growth at 4× the MIC [chapter 5]. The strains 
isolated from these 7 populations were characterised, with 4 to 32-fold increases in MIC 
consistent with the low resistance rate observed [chapter 5]. To investigate mutations in the 
BPL target the gene encoding BPL, birA, was sequenced in all 7 isolates. A single strain was 
identified to harbour a missense mutation, D200E, which is present in the dimerisation 
interface of BPL. As dimerisation is required for DNA binding, and subsequent 
transcriptional repression of  BPL regulated genes [6, 20], the mutation was hypothesised to 
play a role in disrupting this process. Biochemical characterisation of the mutant protein 
confirmed D200E only modestly inhibited the catalytic activity but had a drastic effect upon 
protein dimerization and, consequently, repressor activity [chapter 5]. We proposed that the 
resulting increase in expression of the biotin transporter would allow increased scavenging of 
exogenous biotin to compete against BPL199. Whilst the D200E mutant provided one 
possible resistance mechanism, the lack of BPL mutations in the other strains indicated it was 
not responsible for resistance in all cases. Here we report whole genome sequencing of the 
clones from the advanced resistance study to elucidate additional mutations associated with 
resistance to BPL199. This study provides the first insights into possible resistance 
mechanisms to a novel class of antibiotic.  
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Materials and methods 
Bacterial strains, growth media and antibacterial agents.  
Bacterial strains used in this study are listed in table 1. Cation adjusted Mueller Hinton II 
(Becton, Dickinson and Company, MD, USA) was used to propagate S. aureus. BPL199 was 
synthesised by Dr Beatriz Bianco-Rodriguez as per the protocol described in [chapter 5]. 
Other antibacterial agents were obtained from sigma Aldrich. 
NCBI BLAST search was used to determine the homologue of genes identified in the WGS in 
S. aureus NCTC 8325 in strain USA300 (JE2). Available strains containing transposon 
disruption of the genes were then sourced from BEIResources.org. The following reagents 
were provided by the Network on Antimicrobial Resistance in Staphylococcus aureus 
(NARSA) for distribution by BEI Resources, NIAID, NIH: Staphylococcus aureus subsp. 
aureus, Strain USA300 (JE2), Transposon Mutants NE754, NE896, NE1022, NE788 and 
NE792. 
Genomic DNA purification and Whole Genome sequencing 
Genomic DNA was isolated with the Wizard Genomic DNA purification kit (Promega, 
Wisconsin, USA) according to the manufacturers’ guidelines. Bacteria were treated with 10 
μg of lysostaphin (Sigma- Aldrich Inc, MO, USA) and 1mg/ml lysozyme prior to lysis. 
Quantity of DNA ranged from 15ng/μL-60ng/μL. Genomic DNA from parental strain NCTC 
8325 and isolates B1-B7 was submitted to ACRF (Cancer Genomics Facility, Adelaide, South 
Australia) for library preparation and sequencing. Whole genome sequencing was performed 
with 150bp paired end reads on Illumina Miseq. Number of sequences for each strain ranged 






The Fastq reads were analysed using the Breseq analysis pipeline software [21]. The parental 
NCTC 8325 strain that had not undergone antibacterial selection was mapped to the reference 
genome (NC_007795.1) and the differences were applied to generate a new reference 
sequence using gdtools. The de-multiplexed reads from isolates B1-B7 were then mapped to 
this new reference and mutations identified.  Greater than 98% of reads from each isolate 
mapped to the reference genome. Manual inspection of the resulting HTML files was used to 
determine true positives. Amongst those manually excluded from further analysis was a 
missense mutation in rsbU which is not transcribed in NCTC8325 [22], mislabelling of 
P626L (as P579L) due to a non-standard start codon and removal of mutations identified in all 
strains (including the parental NCTC 8325) that did not reach the threshold required for 
inclusion into the new reference genome. 
Antimicrobial susceptibility testing/ cross resistance 
Antimicrobial susceptibility assays were performed using a broth microdilution method as 
recommended by CLSI (Clinical and Laboratory Standards Institute, Document M07-A8, 
2009, Wayne, Pa.). Antibacterial compounds were diluted two-fold in Cation adjusted 
Mueller Hinton Broth (CAMHB) to a final concentration range of 64-0.06μg/ml in 3.2% 
DMSO. To prepare the inoculum, an overnight culture of S. aureus was subcultured 1:1000 
into fresh media and grown to mid log phase. 96-well microtitre plates were inoculated with 5 
x 10
4
 CFU and incubated at 37°C for 20-22 hours with shaking. Growth of the culture was 
quantified after shaking for 15 seconds to disrupt any sedimentation by measuring the 
absorbance at 620 nm or 630 nm using either: a Thermo Multiskan Ascent plate reader or 




Kinetics of growth 
Growth curves were obtained by subculturing an overnight culture 1:1000 and incubating 
cells at 37°C to an approximate OD600 of 1 before a further 1:1000 dilution to yield an 
approximate initial inoculum of 10
5
 cells in 100 μL. Cultures were grown in technical 
duplicate and three independent biological replicates for 24 hours in a 96 well plate at 37°C. 
Growth of the cultures at 37°C with shaking was then monitored at OD630 every 30 mins for 
24 hours using an EL808™ Absorbance Microplate Reader (BioTek Instruments Inc, 
Winooski, VT, USA). Growth curves were analysed by the method described in [17]. In brief 
the log of the ODs from OD 0.1-0.3 was plotted against time and log(2)/gradient was 





Distinct resistance mechanisms to BPL199 
Whole genome sequencing was employed to characterise the mutations arising in the 7 strains 
obtained from the advanced resistance studies, [chapter 5] alongside the non-treated NCTC 
8325 control (table 1). Sequencing was performed with 150bp paired end reads on the 
Illumina Miseq platform, with each strain having 434,000-809,000 reads (between 22 – 40x 
coverage of genome) sufficient for detection of single nucleotide variants (SNV) [23]. The 
parent NCTC 8325 strain was compared to the reference sequence and the differences 
observed between the parental strain and reference genome accounted for in a new reference 
sequence. The resistant strains were then compared to this new parental reference genome. 
Between 2 to 4 mutations were identified in each strain. Collectively this encompassed 15 
nonsynonymous mutations in the coding regions of 11 independent genes. The majority of 
these were facilitated by SNVs, however, two instances were insertion mediated frame shifts 
and 5 were the result of a deletion, ranging from three base pairs (i.e. a single a.a. codon) to 
large scale deletions (194 to 200 bp). Four strains also contained 94 to 139 bp deletions 
between open reading frames, SAOUHSC_01476 and SAOUHSC_01477, approximately 1kb 
upstream of the putative operon containing birA (ORF SAOUHSC_01473), the gene encoding 
BPL,  which is predicted to span SAOUHSC_01476 to SAOUHSC_01471 [24].  
The only gene with non-synonymous mutations in 5 independent strains was pyc which 
encodes the biotin-dependent pyruvate carboxylase. Strains B1, B2, B4, B6 and B7 all 
contained mutations that led to premature truncation of the PC protein. These strains also 
exhibited the greatest (8-32 fold) increases in MIC (Table 1). Streptavidin blot analysis upon 
lysates to detect biotinylated protein, confirmed the loss of biotinylated PC in strain B7 
(figure s1). As previously described strain B7, the most resistant strain, contained an 
additional mutation in BPL. This was accompanied by a nonsense mutation in the fmtA gene, 





Table 1: Strains used in this study and relevant genetic and phenotypic changes associated with 
BPL199 resistance. MICs were determined against BPL199. Significance for doubling times was 








0.06 51.8 ± 2.1 N/A 
 
B1 1 69.2 ± 11.6 trkA (+1bp 285/663)(VTAK[95-98]SNC*) 
pyc Δ194bp (2761-2954/3453) 
SAOUHSC_01981 E20K 
B2 0.5 64.5 ± 1.42 * pyc 14bp insertion  (1834/3453) 
Δ94bp intergenic (SAOUHSC_01476 to 01477) 
presumed silent mutation (no rsbU)  
B3 0.12 193.6 ± 14.3 *** gdpP H442P 
yjbH Q213- 
B4 0.5 53.5 ± 5.5 pyc G361* 
Δ113bp intergenic (SAOUHSC_01476 to 01477) 
B5 0.25 68.8 ± 12.1 greA Δ111bp 
SAOUHSC _01504 P15L 
B6 1 41.9 ± 0.73 * pyc Δ200bp (917-1116/3453) 
Δ139bp intergenic (SAOUHSC_01476 to 01477) 
rpoβ P626L 
SAOUHSC_02984 (gtfA-like) R296H 
B7 2 67.1 ± 0.90 ** pyc Δ200bp (917-1116/3453) 
Δ139bp intergenic (SAOUHSC_01476 to 01477) 
fmtA K163* 
birA D200E 
JE2 0.5 ND Parent strain, USA300 JE2 
NR-47297 4 ND USA300 JE2 Δpyc (pyc::ΦNΣ) 
NR-47439 4 ND USA300 JE2 ΔyjbH (yjbH::ΦNΣ) SAOUHSC_00938 
NR-47565 0.5 ND USA300 JE2 ΔfmtA (fmtA::ΦNΣ)SAOUHSC_00998 
NR-47335 0.5 ND USA300 JE2 ΔgtfA (gtfA::ΦNΣ) SAOUHSC_02984 
NR-47331 1 ND USA300 JE2 ΔtrkA (trkA::ΦNΣ) SAOUHSC_01034 
 
Note. Isolates from B6 and B7 are suspected to be derived from the same intermediate strain, as they 






 the cell wall [25], and an intergenic deletion between SAOUHSC_01476 and 
SAOUHSC_01477. Other mutations present in strains containing the PC deletion included the 
following. Strain B1 contained a frame-shift mutation, leading to premature truncation of the 
potassium transport protein trkA and a missense mutation, E20K, in a putative sensor histidine 
kinase. Strains B2, B4 and B6 contained deletions in the same intergenic region as B7, and 
strain B6 contained two additional missense mutations, P626L in the RNA polymerase β-
subunit and R296H in a glycosyltransferase-A like gene. It is worth noting that isolates from 
B6 and B7 are suspected to be derived from the same intermediate strain, as a result of cross 
contamination, as they contain identical mutations in two separate locations in the genome. 
Two strains, B3 and B5 exhibited the lowest (2-4 fold) resistance to BPL199 and lacked any 
mutations in the PC gene. Strain B3 contained two mutations. A missense mutation in the ci-
di-AMP phosphodiesterase gdpP [26] converted histidine 442 of the presumptive catalytic 
triad in the DHH domain (supplementary figure s7) to a proline.  The other was a 3bp 
deletion which led to the loss of glutamine at position 213 in the disulphide stress effector 
yjbH [27]. Strain B5 contained a 111bp deletion in a gene predicted as a greA transcription 
factor elongation homologue and a missense mutation P15L in a putative bacterial ferredoxin, 
SAOUHSC_01504.  
To determine if there was an in vitro fitness cost associated with these mutations, growth 
curves of the strains were analysed and doubling time calculated as per [17]. All strains had 
doubling times comparable to the parental strain NCTC8325 (52 minutes) (figure 1B) except 
B3 which exhibited a significant growth defect  (doubling time, 193 minutes) preventing it 
from reaching half the maximum OD of the other strains. These data suggest that in vitro 
resistance to the BPL inhibitor is possible without significant associated fitness costs. The 
differences in the resistance profiles, growth curves and associated genomic mutations of the 
strains suggested at least two independent resistance mechanisms in the 7 strains, described 
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Figure 1: A) Susceptibility of S. aureus NCTC8325 derived strains to a BPL inhibitor BPL199 after 
serial passage in suboptimal concentrations of the antibiotic for 18 days B) Growth of strains in 
Mueller Hinton media measured half hourly. Black dashed line, parental NCTC8325; red, B1; 
orange, B2; yellow, B3;  green, B4; light blue, B5; dark blue, B6; purple, B7. Data are the average 
readings of three independent experiments. Error = SEM.  
 
Table 2:  MICs of parental strain 8325 and the 7 BPL199
r
 mutant strains to BPL inhibitors and β-
lactam antibiotics methicillin and amoxicillin. Each MIC was obtained in three independent 
experiments.  
 BPL199 biotinol- 
5'-AMP 
BPL223 methicillin amoxicillin 
NCTC-8325 0.06 1 8 2 16 
B1 1 >64            64 2 16 
B2 0.5 >64 >64 2 16 
B3 0.12 >64 16 4-8 32 
B4 0.5 >64 >64 2 16 
B5 0.25 8-16 8 2 16 
B6 1 >64 >64 2 16 







 strains showed general resistance to two other BPL inhibitors.  
To test whether antibacterial resistance was general to other antibiotics or specific to BPL199, 
all 7 strains were subjected to antibacterial susceptibility assays against a panel of antibiotics 
and 2 literature BPL inhibitors. This panel included commercially available antibiotics 
methicillin, amoxicillin, vancomycin, erythromycin and streptomycin alongside two literature 
BPL inhibitors biotinol-5′-AMP [28] and BPL223 [chapter 5]. In all but one case the 
resistance mechanisms appeared specific to the BPL inhibitors with no decrease in 
susceptibility (table 2, supplementary figure s2) to methicillin, amoxicillin, vancomycin, 
erythromycin or streptomycin (n = 1). The exception to this was strain B3 which exhibited a 2 
to 4 fold decrease in susceptibility to the two β-lactams, methicillin and amoxicillin. 
Conversely, all strains exhibited increased resistance to the two BPL inhibitors. Whereas 
parent strain NCTC8325 exhibited an MIC of 1 μg/ml against biotinol-5′-AMP all strains are 
completely resistant to this compound (MIC > 64 μg/ml) except B5 which exhibited an MIC 
of 8 μg/mL. Wild type NCTC8325 also exhibited an MIC of 8 μg/ml for BPL223, however 
B2, B4, B6 and B7 again were not susceptible. B1 (MIC = 64 μg/ml) and B3 (MIC = 16 
μg/ml) exhibited a modest decrease in susceptibility, and B5 (MIC = 8 μg/ml) showed no 
change.  
Loss of function of PC and YjbH was sufficient for a 4-fold decrease in BPL199 
susceptibility. 
Of the mutations observed, four were considered likely to induce loss of function of their 
respective genes due to truncation of the protein (trkA, pyc, fmtA, greA), whilst two encoded 
for missense mutations that were likely to drastically effect function (gdpP, yjbH). To 
determine if loss of function in any of these genes was sufficient for resistance, strains 
containing transposon disruptions in select target genes were obtained from the Nebraska 
transposon mutant library [29]. As all mutants in the library were generated in S. aureus JE2 
187 
 
(CA-MRSA, USA300) this was used as a control strain. Of the 10 discrete genes harbouring 
mutations identified in B1-B7, 5 transposon disruptions were available (trkA, pyc, fmtA, gtfA, 
yjbH). The strains were initially tested for susceptibility to BPL199 by monitoring growth for 
20 hours in the presence of varying concentrations of BPL199. Parental strain JE2 exhibited 
an MIC of 0.5 μg/ml, consistent with previous reports against clinical isolates [chapter 6]. 
Only 2 of the 5 transposon disruptions, Δpyc and ΔyjbH, led to a decrease in BPL199 
susceptibility similar to that seen in the initial advanced resistance studies with NCTC8325  
(table 3). The ability of these strains to grow in the presence of BPL199 was improved over 
the parent strain at low concentrations of antibiotic, retaining approximately 50% of 
maximum growth at 0.25 μg/ml, whilst the parental strain had greater than 90% inhibition. 
However, they were still greatly inhibited by 0.5 μg/mL at 20 hours, with only a slight 
difference in growth (figure 2A). Further  testing carried out over 46 hours showed that whilst 
the parental strain had no growth post the 20 hour time point at concentrations higher than 0.5 
μg/ml, the Δpyc and ΔyjbH strains were still growing, increasing to 50% and 25% maximal 
growth (relative to untreated control) at 46 hours (Figure 2D). At this extended time point the 
Δpyc strain was able to grow at up to 2 μg/ml (figure 2E) and ΔyjbH at concentrations up to 4 
μg/ml BPL199 (figure 2E) , the highest concentration tested. The growth curves of the two 
strains in the presence of antibiotic also differed markedly at 0.5 μg/ml (figure 2C). The Δpyc 
strain exhibited a pronounced lag phase before entering a relatively rapid log phase growth. In 
contrast, the ΔyjbH strain showed slower steady growth throughout. The fact the Δpyc strain 
was able to grow at 4× MIC suggested this mutation alone is sufficient for the 4-fold increase 
in resistance observed in the NCTC 8325 derived strains containing this mutation. Unlike the 
Δpyc and ΔyjbH disruptions, the ΔtrkA strain showed 2-fold decrease in susceptibility after 46 
hours (MIC = 1μg/ml), whilst the ΔgtfA and ΔfmtA strains exhibited no improvement in 
susceptibility. The potential mechanisms for the Δpyc and ΔyjbH mutations to have decreased 
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Figure 2: growth of wild type S. aureus USA300 (JE2) (red), and transposon mutagenesis strains:  
Δpyc (yellow), Δyjbh (purple), ΔfmtA (grey), ΔtrkA (blue), ΔgtfA (green) after A) 20 hours and  B) 46 
hours in the presence of BPL199. C-E) growth curves of strains: wild type JE2, Δpyc and Δyjbh after 
46 hours in the presence of BPL199 at C) untreated control D) 0.5 μg/ml, E) 2 μg/ml, F) 4μg/ml. 
strains were normalised to plateau of the untreated control (OD 0.75) which was consistent for all 
strains. Data are the average readings of 3 independent experiments. Error = SEM. 















































It appears that though resistance to some BPL inhibitors can appear both rapidly and 
completely (biotinol-5′-AMP, BPL223) there is a reduced rate for the antibiotic BPL199. This 
lack of complete resistance occurring in any strain is promising for the future of BPL 
inhibitors as antimicrobial agents. Coupled with the low spontaneous rate for BPL199 
[chapter 5] it suggests that although resistance may occur it is unlikely to be rapid or 
pronounced, at least in the NCTC 8325 genetic background. The mutations identified in this 
study generally have either direct links to biotin metabolism (pyc, birA) or can be linked to a 
larger cellular stress response (gdpP, yjbH, trkA). Whilst the exact mechanism of how these 
mutations lead to increased BPL inhibitor resistance is unclear, the roles of the respective 
genes provides a useful basis for identification of resistance mechanisms.  
Loss of pyruvate carboxylase was the most common mechanism employed by S. aureus to 
reduce BPL inhibitor susceptibility. A premature truncation of PC was present in 5 of the 7 
strains evolved to be resistant to BPL199, namely B1, B2, B4, B6 and B7. As the 
biotinylation domain of PC is contained within the C-terminal region, these truncated PC 
proteins were unable to be biotinylated and, hence, inactive. The transposon disrupted strain 
lacking PC (Δpyc) confirmed that PC deletion confers resistance independently of the other 
mutations in the NCTC8325 genetic background, exhibiting a four-fold decrease in MIC. As a 
result it is likely a mutation that can increase resistance to BPL inhibitors in any strain. A 
probable mechanism for this resistance is through increased biotinylation of ACC. Genetic 
knockout studies have demonstrated ACC, but not PC, is required for growth in vitro [7, 8]. 
Removal of PC from the cell therefore facilitates resistance by removing the only other 
protein substrate that (normally) competes with ACC for binding to BPL, hence, increasing 
the chance of ACC being biotinylated. This requires biotin to competitively bind to the BPL 
over the inhibitor allowing the natural reaction intermediate to form and biotinylation to 
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occur. Certain BPL inhibitors, including BPL223, used in the cross resistance study, have 
been found to have fast dissociation kinetics [chapter 5][12], and therefore have low residency 
on the BPL target. As a result, biotin can also bind more frequently, increasing the efficacy of 
such a mechanism. Increasing the residency time that inhibitors bind to the BPL target is 
therefore desirable to reduce the effectiveness of this mechanism. Whilst PC is dispensible for 
growth in vitro, its absence does impact on S. aureus virulence and in vivo growth. The loss of 
PC and TCA cycle genes has been shown to reduce virulence in murine and nematode models 
of infection respectively [9, 10]. The roles of these genes in virulence suggest that the 
resistance mechanisms identified in this study may require compensatory mutations to 
alleviate in vivo fitness costs. Despite the fact that these compensatory mutations are often not 
selected for in parallel evolution studies in vitro the mutations identified can still occur in 
clinical settings [30]. This is a result of compensatory mutations being more likely to occur 
than reversions of beneficial mutations in response to selective pressure.  
Two strains in the study (B3, B5) showed increased resistance to BPL inhibitors but 
maintained functional PC. Strain B3 in particular showed a unique phenotype, displaying 
markedly reduced growth rate. Cross resistance to two separate β-lactam antibiotics 
(methicillin and amoxicillin) was also noted in B3, indicating the mutations present in these 
strains contribute broader resistance to certain cell wall active antibiotics. Intriguingly whilst 
the strain B3 did show a 2-fold decrease in susceptibility to BPL199, it exhibited a much 
greater decrease in susceptibility to biotinol-5′-AMP (>64-fold) suggesting that the 
generalised response is more effective against the less potent inhibitor. The roles of the genes 
mutated in S. aureus B3 (yjbH and gdpP) and how they convey resistance to other antibiotics 




YjbH in S. aureus and other Gram positive bacteria has a role in the disulphide stress 
response where it shuttles the transcriptional regulator Spx to the ClpXP protease for 
degradation [27]. Loss of YjbH function therefore leads to increased Spx levels in the cell 
[27]. In this study the yjbH gene of S. aureus was found to have a 3 base pair deletion leading 
to loss of a glutamine at position 213. As loss of function of yjbH in S. aureus USA300 (JE2) 
was sufficient to decrease susceptibility to BPL199, the Q213Δ mutation is believed to 
similarly act by loss or reduction of function. This is consistent with several reports of 
mutations leading to loss of YjbH function in strains with tolerance to glycopeptide, 
antimicrobial-peptide and β-lactam antibiotics [31-33]. The Spx regulator acts through 
controlling the interaction between RNA polymerase and transcriptional regulators, binding to 
the α-CTD of RNA polymerase. As a result increasing Spx levels effects transcription of 
certain target genes [34]. In B. subtilis these upregulated genes implicated in oxidative stress, 
whilst downregulated genes are associated with purine and pyrimidine biosynthesis, amino 
acid synthesis and vitamin synthesis including the biotin biosynthesis operon [35]. In S. 
aureus, proteomic data indicates that stress response genes are similarly regulated, however 
differences in metabolic gene regulation are apparent. Indeed pyrimidine synthesis regulation 
by the Spx regulon is reported to be upregulated with increased Spx, the opposite response to 
B. subtilis [34]. We propose that the yjbH mutation observed in strain B3 leads to increased 
intracellular Spx, and subsequent induction of certain stress response genes. However the 
exact molecular details of this regulation require further investigation. 
There is also a large growth defect associated with strain B3. This is likely due to a 
combination of the yjbH and gdpP loss of function. Strains in an NCTC8325 derived 
background lacking yjbH have been described as having reduced growth and increased 
pigmentation [27] which is consistent with the growth defect observed in strain B3. This is 
not observed in S. aureus SA113 [33] and does not appear to be the case for the ΔyjbH strain 
in S. aureus JE2 (USA300)  (figure 2B), suggesting there are differences in the responses to 
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this mutation. Strains lacking GdpP and with resulting high c-di-AMP levels also show a 
small but pronounced growth defect in the S. aureus LAC (USA300) background [36] 
suggesting this mutation may also contribute to B3’s slow growth rate.  Slow growth like this 
is often associated with a persister cell type. Many antibiotics work by hijacking active 
cellular processes of growing bacteria producing a corrupted product [37]. However, persister 
cells often do not have these cellular processes active due to their slow growth, allowing them 
to avoid the antibacterial effects [38, 39]. The slow growth and cross-resistance present in 
strain B3 suggests that this strain may exhibit a persister cell phenotype.  
Determining the mutations involved in BPL inhibitor resistance allows us insight on how the 
antibiotic is affecting the bacteria and resistance mechanisms that may occur in the clinic. The 
ability for the Δpyc and ΔyjbH disruptions to convey resistance in a discrete genomic 
background suggests the mutations are applicable to multiple genetic backgrounds. However, 
the lack of effect for the other 3 disruptions (ΔgtfA, ΔtrkA, ΔfmtA) indicates S. aureus might 
take different routes to resistance in alternate genetic backgrounds. Testing of the original 
strains in an infection model would also provide vital information as to the effect of these 
mutations on virulence and whether the mutations are viable. This would be particularly 
useful for those strains with genes linked to virulence, such as B1, B2, B4, B6 and B7, and 
those with growth defects, B3. The lack of cross resistance outside of BPL inhibitors is also 
encouraging as it reduces the chance of current resistance mechanisms being able to address 
BPL inhibitors. The strain B3 is of particular interest in this respect as it exhibits traits similar 
to those seen in persister cells, exhibiting slowed growth rate and resistance to multiple 
antibiotics. Persister cells pose a serious problem for modern healthcare, being able to 
circumvent many antimicrobial treatments that would typically eradicate an infection 
(reviewed [38, 40, 41]). This makes understanding of a new potential persister cell phenotype 
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Loss of functional pyruvate carboxylase is a major contributor for resistance to 
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Figure s1: A) Coomassie stained SDS PAGE, and B) Streptavidin blot, of cell lysates from S. aureus 
NCTC 8325 (lane 2), and S. aureus B7 (lane 3). A) Both lanes show a dark band between 15 to 20 
kDa (biotinylated ACC subunit ≈ 17 kDa) However the band at approximately 130kDa (PC ≈ 130 









Figure s2: antibacterial susceptibility assays of wild type NCTC8325 and derived strains B1-B7 
against BPL inhibitors A) BPL223, B) Biotinol-5′-AMP, and β-lactams, C) Amoxicillin and D) 
Methicillin. Data is from three independent exp eriments. Error = SEM 
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Figure s3: IGV trace of RNAseq reads mapped to the USA300 genome. No significant transcription 





Figure s4 produced as result of sequence alignment of intergenic region between SAOUHSC_01476 
and SAOUHSC_01477 in several Staphylococcus species (9 S. aureus and 4 less closely related, S. 
haemolyticus, S. epidermidis, S. warneri, S. carnosus) using UGENE and muscle aligner. Sequence 
was then put into logoplot server. Location of sites was chosen to prevent extensive gap regions in the 






Figure s5 produced as result of sequence alignment of intergenic region between SAOUHSC_01475 
and SAOUHSC_01476 in several Staphylococcus species (1 S. aureus and 4 less closely related S. 
haemolyticus, S. epidermidis, S. warneri, S. carnosus) using UGENE and muscle aligner. Sequence 
was then put into logoplot server. The untranslated sequence is approximately 20-30bp for non S. 





Figure s6 Locations of mutations that have caused decreased susceptibility to vancomycin or 
daptomycin in S. aureus RpoB mapped to the E. coli RpoB (red proline is equivalent to P626L in B6). 
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Figure s7: A), sequence alignment between the DHH domain of S. aureus GdpP and DHH domain 
from SH1221 protein from Staphylococcus haemolyticus with an available crystal structure 
(PDB:3DEV). B), the catalytic site identified for the DHH domain crystal structure. The residue In red  
is the Histidine residue mutated to proline H442P in our strain, the residues in pink correspond to the 







Selection of BPL199 resistant mutants. Mutants were selected by serial passage in 96 well format as 
previously described [chapter 5]. In brief: A 2-fold dilution series of the compound was plated across 
7 wells (initially 1 μg/ml to 0.016 μg/ml) with concentration increasing as the MIC increased. On the 
first day approximately 10
4
 CFU of exponentially growing S. aureus 8325 was added to each well.  
The OD was measured at 620nm for each well and the well with the highest concentration permitting 
growth (OD620 >0.1 used as threshold) diluted 1000 fold and used to inoculate the following day’s 
culture. This process was repeated for 18 days. Single isolates were then purified from a single colony 
on agar genomic DNA extracted. The stability of the resistance was also tested by propagating the 
strains selected for 6 days on MHAgar in the absence of any antibiotic selection. These strains were 
then retested in the antibacterial susceptibility assay. 
Mauve alignment and RNAseq analysis 
To determine the possible role of an intergenic deletion, the region specified was aligned across 
several Staphylococcus species to determine if it was conserved utilising MAUVE progressive aligner. 
Further analysis of the region was undertaken by determining if there were any expressed RNA’s in 
the region by mapping the RNAseq datasets (SRX1548042, SRX1548043) from the strain USA300, 
















Code used to run whole genome sequencing analysis. 
# initally mapped every read to the reference genome 
# -j 4 refers to using 4 cores to process command 
# -r reference sequence follows 
# annotated_reference.gb= genbank file downloaded from NCBI + fasta sequence data from NCBI 
included in Genbank format 
# -o output results to mutated_outputall directory 
# path to reads ../Fastq/reads${i}-B${i}_S${i} (could have been automated) 
 
path_to//breseq-0.27.1-Linux-x86_64/bin/breseq -j 4 -r ../8325referencegenbanksequenceadded.gb -o 
mutated_outputall ../Fastq/reads1-B1_S1_L001_R1.fq ../Fastq/reads1-B1_S1_L001_R2.fq 
../Fastq/reads2-B2_S2_L001_R1.fq ../Fastq/reads2-B2_S2_L001_R2.fq ../Fastq/reads3-
B3_S3_L001_R1.fq ../Fastq/reads3-B3_S3_L001_R2.fq ../Fastq/reads4-B4_S4_L001_R1.fq 
../Fastq/reads4-B4_S4_L001_R2.fq ../Fastq/reads5-B5_S5_L001_R1.fq ../Fastq/reads5-




# then created new reference based on the mutations predicted in the mutated all results 
 
path_to/breseq-0.27.1-Linux-x86_64/bin/gdtools APPLY –r 
../8325referencegenbanksequenceadded.gb -f GFF3 -o mutatedallref.gff3 
mutated_outputall/output/output.gd 
 
#the newly created reference sequence was then used to run all of the separate sequencing results (in 
pairs) 
 
for i in 1 2 3 4 5 6 7 8; do 




#the completed outputs were manually screened for mutations (HTML document) the marginal 
predictions an unassigned data were also looked at but the differences were conserved, these were in a 
small enough quantity they could be manually excluded rather than needing to make additions to the 
mutated reference. They appear to be clustered around 2 regions of repetitive sequence identity 
making working out junctions or deletions difficulty. as they appear conserve and this region is highly 
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Chemical optimisation of BPL inhibitors as antibacterial agents 
Non-hydrolysable BPL reaction intermediate mimics have had success in inhibiting 
BPLs from a variety of organisms [1-8]. However, whole cell antibacterial activity against S. 
aureus has been difficult to achieve with these compounds [5, 6]. Improving the whole cell 
antibacterial activity of inhibitors has therefore been a major focus of compound design in this 
thesis. Using two established literature compound series as a starting point, a biotin-triazole 
and biotin sulphonamide (2, 5, figure 1), we were able to improve the antibacterial activity 
against S. aureus. These new compound series include the most potent anti-staphylococcal 
inhibitors to date.  
The first series of compounds were the Benzyl biotin-triazoles (chapter 4). Previous to 
this work the most potent and selective SaBPL inhibitor was the biotin-triazole 2, which 
despite potent inhibitory activity (Ki 90nM) did not completely inhibit S. aureus growth (i.e. 
only 80% inhibition) [5]. Benzyl biotin triazoles focused on reducing the size of this biotin-
triazole pharmacophore, and increasing affinity by appending functional groups to extend into 
the binding pocket for the ribose of ATP. These benzyl biotin-triazoles had sub-micromolar 
inhibitory activity, but, like the precursor compounds, lacked the ability to completely inhibit 
bacterial growth. Halogenation of the benzyl ring, as in BPL178 (3, figure 1), produced the 
most potent compound (Ki 280nM), however a clear structure activity relationship (SAR) was 
difficult to define. The co-crystal structure of this compound suggested the benzyl ring could 
bind in multiple conformations in the ribose pocket, providing a possible molecular 
explanation for the unusual SAR. Further stabilising one of these conformations, or extending 
the compound into another binding pocket, may be an avenue to improve potency.  
A second attempt to improve whole cell antibacterial activity was through 
halogenation on the C5 of the triazole ring (chapter 5). Whilst this generally did not improve 
on inhibition against the BPL, halogenated compounds showed vastly improved antibacterial 
activity. This included a fluorinated analogue of compound 2, (4, figure1), able to completely 
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inhibit growth of the clinical isolate S. aureus ATCC 49775 (MIC = 8 μg/ml). The in vitro 
characterisation of this inhibitor:enzyme interaction suggested that the whole cell activity was 
not due to increased target occupancy or improved inhibition of the BPL. Hence, we argue 
that increased compound accumulation was likely responsible for the improved antibacterial 
activity. It remains unclear however if this is due to passive diffusion into the cell, increased 
affinity to a transport protein, such as  the biotin transporter BioY (discussed further below) or 
an alternate mechanism such as decreased efflux. If halogenation can improve whole cell 
activity independently of the biotin-triazole pharmacophore, then trisubstitution of other 
antibacterial di-substituted triazoles [9, 10] may similarly improve activity. Such an approach 
would inform the generality of this response and potentially offer an avenue to improve whole 
cell activity for an extended range of compounds.  
Despite the improvements made to the triazole pharmacophore, inhibitory potency and 
antibacterial activity were lacking compared to the pan inhibitor biotinol-5′-AMP, (1, figure 
1). As a result, a new pharmacophore was investigated from a bio-active literature  molecule 
against M. tuberculosis reported  to lack anti-staphylococcal activity (5, figure 1) [1]. Here 
the phosphodiester group of 1 was replaced with an alternative bioisostere, a sulfonyl linker. 
By removing the ribose moiety, that we previously demonstrated to be dispensable for 
activity, a new potent inhibitor was identified, BPL199 (6, figure 1) (Ki = 2nM). This 
compound offered promising antibacterial activity (MIC 0.125-0.5 μg/ml) whilst retaining 
selectivity against the human enzyme and exhibiting no cytotoxicity against two human cell 
lines (Ki > 10 μM, EC50 > 250 μg/ml). To address the clinical potential of 6 the antibacterial 
spectrum, synergy with other antibacterials and spontaneous resistance rates were all tested. 
These data demonstrated that the compound was narrow spectrum, exhibited synergy with 
two commercially available antibacterial agents (Streptomycin and Methicillin) and had a low 
resistance rate (< 1× 10
-9
). The mechanisms of antibacterial action and resistance were also 





Figure 1: Key compounds created in this study and literature precursors 
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Mechanism of action 
Whilst in vitro evidence supported BPL as an antibacterial target [7] no study had 
demonstrated the mechanism of action of BPL inhibitors in S. aureus. In chapters 3-6 we 
demonstrated that alongside catalytic inhibition of BPL, the transcriptional repression of 
SaBPL also plays a role in the antibacterial activity of 6. Transcriptional repression induced 
by 6 led to a reduction in biotin synthesis and transport genes and, hence, would reduce 
intracellular biotin concentrations. A mutation, D200E, in the BPL of a S. aureus strain 
resistant to 6 was also identified. This mutation had no significant effect on inhibitor binding 
but prevented dimerization and the resulting repressor activity of the protein. This further 
validated transcriptional repression in the antibacterial mechanism of action.  
Despite understanding the role of the transcriptional repression capability of 6 in 
antibacterial activity, the ability of other BPL inhibitors to act as co-repressors has not been 
thoroughly explored. Work on E. coli BPL has shown certain BPL inhibitors can exhibit 
different co-repressor capabilities, despite similar affinities for enzyme binding and similar 
structures [1, 11]. It stands to reason that similar differences may occur for inhibitors binding 
the S. aureus BPL. Together with differences in cellular accumulation, differences in co-
repressor capability may serve to explain how whole cell activity can be vastly different for 
compounds with the same inhibitory activity. As there are few co-crystal structures with 
compounds that lack antibacterial efficacy against S. aureus we lack data to determine 
whether conformational changes that prevent DNA binding activity occur in the BPL when 
these compounds bind. As well, no high resolution structure of BPL in complex with DNA 
has yet been obtained. This makes interpreting the effect of any conformational changes 
challenging. Addressing these gaps in our understanding would hopefully shed light onto 




BioY transporter and mechanism of whole cell entry. 
As established in chapter 4, and discussed above, inhibitory and antimicrobial activity 
of BPL inhibitors is not always well correlated. One possible reason for this is the ability of 
the compounds to accumulate inside the cell. Currently two mechanisms for cell entry of BPL 
inhibitors are hypothesised, either, by passive transport across the cell membrane or 
recognition and transport by the biotin transporter BioY. If the latter case occurs then 
improving affinity for BioY could allow for increased efficacy of inhibitors. Studies 
performed by Dr. Al Azhar in our laboratory have demonstrated that BPL inhibitors can have 
different affinities for BioY. In particular the biotin-triazole 2 is able to bind competitively to 
BioY over fluorescent biotin, whilst biotinol-5′-AMP 1 is not [12]. If cellular uptake is 
through BioY such differences in affinity for the transporter could play an important role in 
antimicrobial activity. In an attempt to address whether BioY is required for cellular uptake, 
and whole cell activity, a strain of S. aureus with the bioY gene disrupted has been sourced. 
Preliminary studies using this strain indicate that the compound biotinol-5′-AMP is less 
effective against a strain lacking the transporter, though activity is not abolished (personal 
communications). This indicates that whilst the BioY transporter contributes to uptake this is 
not the only mechanism. Following up on this result with a larger compound series would 
provide useful insight into the role of the transporter on whole cell activity, potentially 








Resistance studies methodology 
In chapter 6, experiments were performed to address the ability of S. aureus to evolve 
resistance to the BPL inhibitor 6. This was achieved using evolution by continually 
subculturing S. aureus in suboptimal concentrations of inhibitor, a well-established route for 
the generation of resistance. Whole genome sequencing revealed several mutations that 
correlated with resistance, offering insight into potential resistance mechanisms. However, the 
sequencing analysis was restricted to the genome of a single isolate from each experimentally 
evolved population, limiting the information available. New technologies are now available 
that provide the potential for more in depth analysis. One example is the use of systems that 
allow for more reproducible and controllable growth conditions, such as chemostats that 
maintain constant media conditions, or morbidostats [13] that modify antibiotic concentration 
based on density of the culture. Spatial concentration gradients are another technology which 
offer a unique ability to map the evolution of drug resistance, with an evolutionary trajectory 
visible as a path to higher concentrations [14, 15]. Furthermore, improved DNA sequencing 
capability and computation power allow for the use of more isolates and larger datasets for 
analysis. This enables mapping of genetic fluctuations in populations over time, revealing 
evolutionary trajectories and dead ends [13, 14, 16-20]. Through this analysis, information 
about competing mutations, the presence of mutations that become dominant, and loss of lines 
that are unable to adapt, can all be gleaned [15, 16]. With these technological improvements 
and decreased sequencing costs, resistance studies will be able to provide valuable new 






One notable deficiency in the literature is a consensus on the number of samples 
required to gain confidence that mutations observed are representative of a larger population. 
Commonly 5 isolates are used in recent studies [13, 17, 21] though no rationale behind this 
number is provided, with personal experience indicating this is likely due to sequencing costs. 
As generating larger datasets becomes more cost effective, the amount of information that can 
be extracted from such experiments will also increase. For example population analysis can 
determine if a particular gene is overrepresented in a study, the rate of mutation is higher than 
expected, or if mutations are constrained to defined trajectories [20]. This would assist in 
certain cases, such as those presented in chapter 7, where 5 of 7 strains contained a mutation 
leading to loss of function of pyruvate carboxylase. Using a mathematical model that assesses 
the accumulation of mutations in a model system, it should be possible to determine whether a 
particular gene is statistically over-represented, given a large enough sample size. However, 
the framework for how to approach such analysis has not yet been established (reviewed 
[15]). Whilst in no way encompassing a complete model for such an analysis, the criteria 




BOX 1: parameters that may be useful for the generation of a statistical model 
surrounding the likelihood of mutations occurring in response to selection pressure. 
1. Mutation rate - (≈4-14× 10-11 per bp/generation* ≈ 0.3 per genome/ generation for S. 
aureus) [16, 22, 23]  
2. Estimate of mutational events/ population – The number of mutational events in a 
population is a function of the number of doubling events and the mutation rate. As 
population growth is largely exponential, and the initial population is significantly 
lower than the final population, the number of generations/day can be represented by 
log2 (final population density/day) ≈ number generations/ day.  
3. Genetic drift - depending on the situation this is either a static rate such as the 
dilution from one day’s passage to the next or a continuous rate of cell removal as is 
observed in chemostats. For the experiment in chapter 6 each population sampled 
1/20,000
th
 of the previous day’s overnight culture. 
4. Mutation impact - The rate of silent mutations in protein coding regions is 
approximately 20% of total mutations. At least 20% of mutational events in protein 
coding genes therefore have no effect on protein coding, reducing the impact of 
mutations [16]. 
*this may be effected by the presence of mutator strains [16] or increased mutation as a result of reactive 







Issues facing antibiotics beyond resistance 
This study also helps to highlight one emerging issue in addressing antibiotic 
resistance, that of cells that avoid antibiotic effects without developing genetic resistance. In 
particular one of the strains identified in the advanced resistance studies (B3) was capable of 
tolerating high concentrations of antibiotic but grew relatively slowly. This phenotype is 
commonly associated with so-called ‘persister’ cells which play a key role in recurrent 
infections. Persister cells are characterised as dormant phenotypic variants, present as a 
subpopulation of a bacterial population, which can survive concentrations of bactericidal 
antibiotics higher than the MIC. These are distinct from resistant populations which contain 
genetic variation that provide a higher MIC for the whole population [25, 26]. Persisters are 
often tolerant to a wide range of antimicrobial agents, surviving treatments of high doses of 
antibiotic in their dormant state before exiting this state and re-instating an infection [27, 28]. 
This makes them an issue in clinical settings. Persister cells and biofilm formation are also 
linked with the lack of nutrient availability in a biofilm setting predicted to induce a higher 
proportion of persister cells, leading to their antibiotic tolerance [29-31]. A corollary of this is 
that agents designed to target persister cells also serve to eradicate biofilm infections[29].  
Studying the mechanism of persister formation is difficult due to their transient nature. 
However, several studies have attempted to define a concerted mechanism by which persisters 
occur (reviewed [32]). Of particular interest to the work described in this thesis are the 
established links between metabolic state and the induction of persisters and biofilms. In 
particular the TCA cycle, involved in cellular energy production and biosynthesis of certain 
metabolic products, appears to be required for persister cell and biofilm formation [32, 33] 
(figure 2). In E. coli decreased numbers of persister cells are observed in strains containing 
deletions of several TCA cycle enzymes, implicating this metabolic pathway in persister 
formation [33]. Similarly in S. aureus the deletion of genes encoding succinate 
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dehydrogenase,  involved in the TCA cycle, led to reduced persister formation [34]. 
Upregulation of TCA cycle genes are also observed in biofilms [35, 36]. These data suggest 
that the TCA cycle is important for persister cell and biofilm states in E. coli and S. aureus. 
Late last year, a development in the ability to track persister cells in cultures of S. aureus 
identified that persister cells were a sub-population of cells that enter stationary phase 
prematurely [37]. The cause of this was established to be due to decreased ATP concentration 
in the cell as artificially reducing ATP levels induced the persister phenotype [37]. 
Replication of this study in E. coli suggests that ATP depletion, a hallmark of nutrient 
deprived biofilms, may be the common mechanism for persister cell formation [38].  
It is as of yet still unclear as to the exact effect PC inhibition has on TCA cycle 
activity and, through it, ATP levels in the cell. The TCA cycle provides ATP to post-
exponentially growing cells [39], suggesting inhibiting this process should increase persister 
formation. To the contrary, the deletion knock-outs of certain TCA cycle genes reduced the 
number of persisters in a population, [32-34] suggesting the opposite effect. Understanding 
exactly how reduction of PC activity affects persister formation is therefore important for 
understanding if BPL inhibition would combat this state. If BPL inhibitors can reduce 
persister formation this would allow the development of combination therapies to target these 
difficult to treat infections. Evidence to support this was provided with 6, which showed 
efficacy against an in vitro biofilm model of S. aureus (personal communications). If this can 







Figure 2: TCA cycle enzymes: aconitase acnB, α-Ketoglutarate dehydrogenase, succinyl-
CoA synthetase sucB, succinate dehydrogenase sdhA/B/C, and malate dehydrogenase mdh 
are implicated in (red) persister formation in E. coli [33] or S. aureus [34], or (green) biofilm 
formation in S. aureus [35, 36]. Bolded gene names indicate specific genes tested in knock-







The future of healthcare depends on the discovery of new antibacterial agents 
alongside new ways to manage antibiotic resistance. The work described in this thesis serves 
to both improve the antibacterial activity of BPL inhibitors as well as address some of the 
underlying questions surrounding this compound class. Two independent compound series 
with improvements on antibacterial activity are described here, an important step in the 
creation of a pre-clinical candidate. In particular the compound 6 offers the most promising 
activity described to date against S. aureus. With this compound we were also able to probe 
the mechanism of action of BPL inhibitors, identifying a role for the transcriptional repressor 
function. The resistance studies using this compound also further enhanced our understanding 
of how BPL inhibition works, highlighting how resistance may occur. The work presented 
here also provides vital information for the future development of BPL inhibitors whilst 
serving to further inform the chemical biology behind the mechanism of action and resistance 
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Appendix 1-assay development 
Introduction 
It is important to understand the mechanism of action of a drug before embarking on preclinical and 
clinical testing for both ethical and economic reasons. The ability to understand how a drug works 
allows for better prediction  of potential positive and negative interactions with other treatments, as 
well as side effects and how resistance may occur. One way to demonstrate mechanism of action is 
through overexpression of the presumed target. By overexpressing the target enzyme and observing 
decreased efficacy of the compound it is possible to validate the mechanism of action of an 
antibacterial agent. Using this method it has been demonstrated that BPL inhibitor Bio-AMS exhibits 
reduced efficacy in a strain of Mycobacterium with increased BPL expression [1]. However, a BPL 
overexpression system has not been established in S. aureus. 
For this purpose I constructed a recombinant expression vector and transformed this into S. aureus 
RN4220. By measuring the growth of the bacteria treated with BPL inhibitors in the presence and 
absence of this overexpression it was possible to either validate or invalidate the hypothesis that the 
antibacterial activity occurs through BPL inhibition. For an appropriate control, the parental vector 
lacking the SaBPL coding region was also transformed into S. aureus.  S. aureus has a restriction 
modification system which poses a high barrier to the transformation of plasmids [2]. As a result a 
shuttle vector capable of replication and selection in both E. coli and S. aureus was required. The 
vector chosen was pCN51 [3] which had several desirable traits: a large copy number origin of 
replication and ampicillin selection in E. coli, small copy number origin of replication and 
erythromycin selection in S. aureus and a cadmium inducible promoter for controlled expression of 
target proteins.  In this appendix I report the construction and validation of the overexpression system 
for BPL in S. aureus. This system was subsequently used to determine the mechanism of antibacterial 
action of several series of BPL inhibitors in the following chapters.  
 
 





Antibacterial susceptibility testing 
Antibacterial susceptibility testing was undertaken as per standard protocol (2.2.1.1) with relevant 
antibiotic and inducing agents added as specified. 
Cloning and creation of pCN51-SaBPL vector (figure 1) 
All vectors were propagated in E. coli DH5α unless specified elsewhere. 
The pCN51 vector lacked appropriate restriction sites around the multiple cloning site for cloning in 
the SaBPL-H6 gene from the pGEM-SaBPL-H6 vector. To facilitate cloning of SaBPL from pGEM-
SaBPL-H6 to pCN51 an NcoI site was inserted by amplifying the existing cadmium cassette using 
primers B458 (equivalent to 594 described in [3]) and B459 containing  NcoI site and PstI restriction 
sites. The resulting PCR product was digested with SphI and PstI and ligated into similarly treated 
pCN51, yielding pCN51-NcoI. The desired plasmid was confirmed by restriction analysis (figure 2) 
and DNA sequencing. The SaBPL over-expression vector was then constructed by ligating the 2kb 
PciI / EcoRI fragment from pGEM-SaBPL-H6 into NcoI and EcoRI treated pCN51-NcoI  Restriction 
analysis and DNA sequencing, using the primers B493 and B200, confirmed the desired vector was 
obtained (figure 3).  
 
Preparation of competent S. aureus RN4220 
Competent cells of S. aureus strain RN4220 were prepared essentially as described by Monk et al. [2], 
bolded sections represent deviations from published protocol.  Overnight cultures of S. aureus 
RN4220, 10mL, were grown in Mueller Hinton Media (CAMHB) and diluted to OD600 of 0.5 in 50 
mL of prewarmed CAMHB before being incubated at 37℃ for 30 minutes. The cells were chilled on 
ice for 10 minutes with subsequent steps performed at 4°C unless specified. Cells were centrifuged at 
4000 × g for 10 minutes and the pellets resuspended in equal volume ice cold MilliQ water. This was 
repeated twice. The washed cells were then resuspended in 5 ml, 2 mL and finally 250 μl of ice cold 




10% (w/v) glycerol. Aliquots of 60 μl were added to pre-chilled microcentrifuge tubes. Cells were 
then allowed to sit for approximately 30 minutes before being incubated for 5 minutes at room 
temperature and centrifuged at 4000 × g for 1 minute. The resulting cell pellet was resuspended in 50 
μl of a 10% glycerol, 400 mM sucrose solution.  
Transformation of competent cells 
Plasmid DNA (4μl at approximately 500 ng/μl) was added to the cells before being transferred to 
a 2mm electroporation cuvette. The cuvette was pulsed on the micropulser electroporator ™ (Bio-
Rad, California, U.S.A.) on the S. aureus setting (single pulse at 1.8 kv, with 2.5msec time constant) at 
room temperature. Time constants of approximately 1.8 msec were observed. The cells were 
immediately recovered in 1mL of prewarmed CAMHB containing 500 mM sucrose before incubation 
for 2 hours at 37 °C. 200 μL of the culture was plated onto CAMHB agar containing 10 μg/mL 
erythromycin for selection. Colonies did not appear on the plate until after approximately 36 hours 
had passed. Colonies were picked and grown in liquid culture supplemented with 10 μg/ml 
erythromycin overnight to select for true transformants. Plasmid extraction of pCN51-NcoI or pCN51-
BPL using the QIAGEN kit with an additional lysostaphin incubation step (2.2.4.4) confirmed the 
cells harboured the desired plasmid. 
Cadmium chloride overexpression protocol 
An overnight culture of RN4220 + PCN51_NcoI and RN4220 + PCN51_SaBPL was prepared with 10 
μg/ml erythromycin for the maintenance of the plasmid. The overnight culture was subcultured (10 μl 
into 5mL) into media with 10 μg/ml erythromycin and 25nM CdCl2. The cultures were incubated for 5 
hours before being subcultured 1: 1000 into media containing 50nM CdCl2 to maintain the 25nM 
CdCl2 after subsequent dilution into the testing plate.  An antibacterial susceptibility plate was then 
prepared as per standard antibacterial susceptibility protocol (2.2.1.2) with additional 10 μg/mL 
erythromycin and 25nM CdCl2, for selection and induction respectively.  Plates were incubated with 
shaking for 22 hours at 37°C and OD630 nM taken every 30 minutes using an EL808™ Absorbance 
Microplate Reader (BioTek Instruments Inc, Winooski, VT, USA) 
 





Optimising growth conditions for recombinant expression 
To verify that the plasmids or conditions themselves were not having an adverse effect on growth, the 
growth of strains containing each plasmid was compared. Initial testing of the system using conditions 
described in [3] of 1-15 μM of CdCl2 led to toxicity, with  cells unable to tolerate the CdCl2 over 
periods of time longer  than the 1 hour induction described in the paper. Using a dilution series of 
CdCl2 the appropriate concentration of CdCl2 was determined to be 25 nM as growth was hindered at 
higher concentrations counteracting the decreased susceptibility to BPL199 (figure 3). This slight 
reduction in growth appears to be dependent on BPL expression with the parental vector control not 
inhibited by 100nM CdCl2. To determine if the recombinant system was expressing sufficient SaBPL 
to observe the effect of over-expression on BPL inhibitor efficacy the literature compound biotinol-5′-
AMP was tested. S. aureus RN4220 containing the pCN51-BPL vector challenged with biotinol-5′-
AMP exhibited a shift in MIC of 16 fold (figure 4a) over the parental control, indicating 
overexpression of SaBPL reduced susceptibility to BPL inhibitors. This effect was specific to BPL 
inhibitors, as the two strains when challenged with amoxicillin  showed no observable difference in 
MIC or growth (figure 4b). 




pCN-BPL shuttle vector for overexpression of SaBPL 
 
 
Figure 1: PCN51-SaBPL-H6 plasmid  creation diagram. a) PCR was used to insert an NcoI restriction 
site into the MCS of pCN51. PCR product and pCN51 vector were digested with SphI and PstI and 
ligated to form PCN51-NcoI. b) pCN51-NcoI and pGem-SaBPL-H6 were digested using PstI/NcoI 
and PstI/EcoRI respectively. The 2kb SaBPL-H6 fragment from pGem-SaBPL-H6 was subsequently 










































Figure 2: Confirmation of successful integration of Nco1 site into pCN51 vector by restriction digest 
with NcoI and HindIII. a) From Left: 1) DNA ladder 2) PCN51 NcoI/HindIII, 3-5) pCN51-NcoI 
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Figure 3: A) dose response of S. aureus RN4220 + PCN51-NcoI (blue squares) and +PCN51-BPL 
(red circles) to CdCl2. B)  effect of cadmium chloride at non-toxic concentrations on growth of SaBPL 
expression vector (circles) and empty PCN51 vector (triangles) in presence of 0.25 and 0.125 μg/ml 
BPL199 and in absence of compound.  
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Figure 4: Mechanism of action studies. S. aureus RN4220 + pCN51-NcoI control (dashed line) and 
pCN51-BPL overexpression (solid line) vectors susceptibility to (A) literature BPL inhibitor biotinol-
5′-AMP and (B) non BPL targeting antibiotic amoxicillin. Assays were performed in triplicate and 
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Appendix 2-Chapter 6 mutations 
Deletion of intergenic region (strains B2, B4, B6, B7) 
The second most prevalent mutation, appearing in 4 of the 7 strains isolated, was a deletion in 
a conserved intergenic region. This mutation was only present in strains also containing the 
loss of pyruvate carboxylase function, though order of acquisition is unclear. There are 
several possible explanations for the role of an intergenic deletion. One possible role of the 
region was transcription of non-coding RNAs. To determine if this was the case an analysis of 
an available RNAseq dataset in S. aureus USA300 at 3 (Accession: SRX1548042) and 16 
hours (Accession: SRX1548043) was undertaken using Rockhopper [1] (Chapter 6, figure 
s3). This yielded no detectable transcription. Whilst it is possible that under specific stresses 
the region is transcribed it was considered unlikely and wasn’t further investigated. Another 
possible explanation is a regulatory region such as a transcription factor binding site. The 
location of the mutation (approximately 3 kb upstream of BPL gene) suggests a possible link 
between the deleted region and BPL expression.  
Attempts to elucidate the role of the intergenic region were undertaken bioinformatically. If 
the region contained a binding site for a transcriptional regulator the sequence would need to 
be conserved. Alignment of several S. aureus genomes in the region using MAUVE 
progressive aligner showed that the deleted region is relatively well conserved (Chapter 6, 
figure s4) in S. aureus. However, looking at other Staphylococcal species suggests that the 
region is unique to the S. aureus species. The operon structure of S. aureus has yet to be fully 
characterised so different predictions are required to try and determine co-transcribed genes. 
The genomic arrangement of the genes suggests the presence of a four gene operon which 
would be 1000bp downstream of the conserved deleted region. However closely related 
staphylococcus species, S epidermidis, S. carnosus, S. haemolyticus and S. warneri, have a 
larger predicted operon containing 5 genes only 200bp downstream of the deleted region. This 
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larger operon has been disrupted in S. aureus by acquisition of a 200bp intergenic region 
distancing SAOUHSC_01476 from the four genes including birA (BPL). Whilst feasible that 
a new transcription start site and promoter binding region was acquired with this intergenic 
region it seems possible that the SaBPL operon still includes the SAOUHSC_01476 gene. 
The larger operon structure is also supported by microarray data linking the regulation of the 
equivalent of SAOUHSC_01476-01471 in S. aureus strain MSSA476 [2] though this has not 
been validated by other techniques. Based on both this ancestral operon prediction and the 
microarray data it seems likely that the intergenic deleted region could affect BPL expression 
in some way. If the deletion removed a DNA recognition motif then it is feasible that it could 
lead to an increase in BPL and reduced BPL199 susceptibility. This could occur by either 
removal of a repressor protein or by structural rearrangements that facilitate expression. 
Previously we have demonstrated that increased BPL expression conveys a level of resistance 
to BPL199 with an overexpression strain RN4220 [Chapter 5]. This suggests that increased 
BPL may be a viable resistance method in vitro. Further investigation into the effect of the 
intergenic region in isolation however would be required to make any conclusions as to its 
role in resistance. 
Mutations additional to the PC and intergenic deletions (strains B6, B7) 
Strains 6 and 7 each contained two additional mutations [(gtfA, rpoB) and (birA, fmtA) 
respectively]. As the PC and intergenic deletions were identical in these two strains it is 
considered likely that cross contamination of the populations occurred during the experiment 
as the simplest explanation for such an event is shared evolutionary history [3]. This gives us 
some insight into the order that the mutations occurred, with the additional mutations almost 
certainly occurring after the PC and intergenic deletions. Based on comparison with strains 
B2 and B4, which contained only the PC and intergenic deletions, the additional mutations 
reduced susceptibility to BPL199 a further 2-fold in B6 and 4-fold in B7.  B7 also exhibits an 
unusual phenotype with increased tolerance at 64μg/ml (Chapter 6, Figure 1A). The 
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mutations involved in the strains therefore have an additive effect upon resistance either 
dependent or independent of the previous mutations. The potential roles for each mutation are 
discussed below. 
BPL D200E (strain B7) 
The strain B7 had the most pronounced resistance to BPL199 and contained two mutations 
separate from the commonly shared PC and intergenic deletions. As discussed above one of 
these mutations one was a missense mutation in BPL (D200E) that altered the reduced 
repression of biotin biosynthesis (bioO) and transport (bioY) genes in an E. coli lac Z 
expression system [chapter 5]. It was therefore suggested that resistance to BPL inhibitors 
was mediated by increasing intracellular biotin. This resistance mechanism was similar to one 
seen for thiamine synthesis inhibition, where the binding site of the thiamine riboswitch 
ligand binding site is altered to prevent repression by the mimic pyrithiamine, dysregulating 
thiamine synthesis as a means of resistance [4]. The presence of the PC loss of function 
mutation however indicates the potential that D200E is instead a compensatory mutation. The 
DNA binding function of BPL requires a homo-dimer, the formation of which is thought to be 
disrupted by un-biotinylated substrate (ACC or PC) either through protein-protein interactions 
[5] or removal of the co-repressor, biotinyl-5′-AMP [6]. In the strain B7 we have mutations 
which reduce the amount of un-biotinylated substrate through removal of one of the 
biotinylated proteins. This could feasibly disrupt the stoichiometry of BPL dimerization 
leading to increased repression of biotin synthesis and transport genes, the subsequent 
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fmtA (strain B7) 
A premature stop codon present in the penicillin binding protein FmtA was also observed in 
B7. As the ΔfmtA strain in genetic background JE2 showed no decrease in susceptibility to 
BPL199, any effect granted by this mutation either requires the NCTC 8325 genetic 
background or prior mutations. FmtA is a putative penicillin binding protein and has been 
reported to be induced upon treatment with cell wall active antibiotics such as β-lactams as 
part of the cell wall stress stimulon [7]. Inactivation of the gene has been demonstrated to 
affect the structure of the peptidoglycan [8] with FmtA recently characterised as having 
esterase function removing d-ala from wall teichoic acids [9]. Hence, the disruption of FmtA 
activity may have broad effects on cell surface charge and possibly lead to induction of genes 
that respond to such changes in cell membrane structure [10]. 
Additional mutations in strain B6 include a putative Glycosyltransferase gtfA and the 
RNA polymerase β-subunit rpoB.  
As strain B6 only showed a 2-fold difference in MIC against BPL199 compared to strains B2 
and B4, the mutations individually are unlikely to convey resistance to BPL inhibitors. This 
was supported by the fact that a loss of function mutation in GtfA does not affect the 
resistance to BPL199 in the transposon disrupted USA300 strain. The gtfA gene is proposed 
to have roles in glycosylation of factors from the secA/Y secretory system. However, there is 
little evidence on how this may affect resistance. Indeed, the mutation (R296H) converts 
arginine to histidine, conserving charge suggesting the mutation may not have a large impact 
on function. Combined this suggests that the mutation in RpoB may be responsible for the 
shift in MIC observed.  
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RpoB mutations are capable of widespread transcriptional changes that could facilitate 
resistance. 
Mutations in RpoB have been implicated in resistance to several different antibiotic classes 
[11, 12] and stress response regulation [13]. In particular, studies have demonstrated that in S. 
aureus mutations in RpoB, evolved in response to Rifampicin treatment, can convey cross 
resistance to the glycopeptide antibiotics daptomycin and vancomycin [11, 12, 14] (Chapter 
6, figure s6). Due to the initial selective pressure these mutations largely occur in the 
rifampicin binding pocket however there are mutations outside of this pocket, suggesting that 
the location is not constrained. The ability to effect cell wall active antibiotics that do not 
interact directly with RNA polymerase sets a precedent for mutations in RpoB to play a role 
in resistance to cell wall active antibiotics like BPL. Determining the exact method by which 
this occurs is not possible without extensive studies into S. aureus RpoB structure. However, 
one possible mechanism that could lead to increased resistance to cell wall active antibiotics 
is through activation of the cell wall stress stimulon. One of the major activators in the cell 
wall stress response is the transcription factor spx [15] with increased Spx levels implicated in 
β–lactam and glycopeptide tolerance [16, 17]. There is evidence in the literature of mutations 
(P519L and R484H) in RpoB conveying a protective effect in strains lacking the Spx 
transcription factor, indicating that RpoB mutants can induce Spx independent activation of 
the Spx regulon [13]. Further supporting a role of the Spx regulon in BPL resistance, the 
strain B3 has a mutation in YjbH (discussed in the main text) which is responsible for 
degradation of Spx. It is possible that both the YjbH loss of function and RpoB missense 
mutation serve a similar function, allowing the activation of the Spx regulon by either 
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Strains lacking in PC deletions B3 and B5. 
GdpP phosphodiesterase (strain B3)  
The other gene mutated in B3 is gdpP which encodes a cyclic-di-AMP (c-di-AMP) 
phosphodiesterase [18]. Relatively newly discovered as a secondary messenger c-di-AMP has 
roles in controlling potassium transport systems [19, 20] and is upregulated in stationary 
phase growth, suggesting importance in late stage growth survival [21].  Loss of function in 
GdpP leads to increased c-di-AMP levels in the cell. The GdpP mutation occurring in strain 
B3 is a missense mutation, H442P occurring after this truncation. This mutation disrupts one 
of the presumptive key residues in the DHH domain of the protein, essential for the 
phosphodiesterase activity of the enzyme (Chapter 6, figure s7). Hence, we expect that the 
mutation observed converting the histidine to a proline would abolish or drastically lessen the 
phosphodiesterase activity of GdpP and lead to increased intracellular c-di-AMP. Though 
only directly implicated in osmotic stresses transport, through binding TrkA [19] and 
regulating the sensor histidine kinase KdpD [19, 20], the exact signalling pathways c-di-AMP 
interacts with are still being discovered with recent evidence of c-di-AMP influencing the 
stringent response in S. aureus [21] and acting as a ligand for riboswitches in other bacteria 
[22]. As well loss of GdpP function reduces β-lactam susceptibility in S. aureus. Despite this, 
the mutation present in our strain is unlikely to play a role on the β-lactam susceptibility of 
the strain as β-lactam susceptibility is restored with a truncated GdpP (370aa) [23].  As further 
roles of the c-di-AMP messenger are elucidated the effects of its increase on resistance to 
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Strain B1 contains both PC loss of function as well as truncation in potassium 
transporter TrkA and a missense mutation in a putative sensor histidine kinase. 
The strain B1 has a 2-fold decrease in susceptibility to BPL199 compared to strains B2 and 
B4 that contain only PC loss of function and intergenic deletion. As well as the loss of 
pyruvate carboxylase function, strain B1 has two additional mutations that could be 
responsible for this reduction. One, an insertion in the potassium transport gating protein 
TrkA, leads to a truncation and possibly loss of function. To determine if loss of function of 
TrkA alone is able to reduce susceptibility to BPL inhibitors the ΔTrkA strain in S. aureus 
JE2 (USA300) was tested. Loss of TrkA led to slightly increased resistance suggesting that 
the truncation likely induces loss of function.  The potassium transporter TrkA is a gating 
protein for the KtrB membrane bound potassium channel. This gating is regulated by c-di-
AMP binding to one of two independent domains in TrkA, the C-terminal (RCK_C) domain 
[19]. As gdpP and trkA loss of function mutants have similar phenotypes in response to low 
potassium conditions, it is thought likely that c-di-AMP binding inactivates channel activity 
[19]. Therefore, increased c-di-AMP levels in the cell, as expected in strain B3, may have a 
similar effect to loss of TrkA function. This suggests the mutations in B1 and B3 may both 
work through reduction of potassium transport. Interestingly, the removal of TrkA has been 
shown to increase susceptibility to certain antibacterial agents in S. aureus, including 
vancomycin and several cationic antimicrobials including polymixin B [24]. This has been 
suggested to be mediated by dysregulation of membrane polarisation, increasing uptake of 
positively charged cationic antimicrobials. As BPL199 is predicted to have a negative charge 
at physiological pH the same dysregulation may decrease its uptake. Additionally the loss of 
TrkA reduces competitiveness of S. aureus JE2 in vivo [24] and in Streptococcus suis loss of 
function of gdpP negatively impacts virulence with decreased cell entry in a HepG2 based 
invasion assay and decreased virulence factor expression [25]. 
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Strain B5 –Slight resistance to Biotinol and BPL199 but not to BPL223 
The strain with the least resistance against all of the BPL inhibitors was strain B5 containing 
two mutations, a deletion in the transcription elongation factor GreA and a missense mutation 
in the S. aureus ferredoxin. Both of these genes have been identified as putative essential 
genes in S. aureus but not B. subtilis in a transposon mutagenesis study [26] suggesting that 
complete loss of function may not be tolerated though it is possible that these are false 
positives. 
The GreA transcription elongation factor in E. coli has a diverse set of genes under its control 
including several TCA cycle components. These genes were found to be upregulated in the 
absence of GreA suggesting that loss of functional GreA may upregulate the TCA cycle. 
Ultimately however there is not sufficient information to comment on the potential role of the 
GreA deletion on resistance to BPL inhibitors in S. aureus and studying the effect of the 
truncation in isolation would be required to determine if it leads to a loss or gain of function. 
Unfortunately a knockout of GreA is not available through the transposon mutagenesis library 
though an insertion at nucleotide 386/477 was tolerated in one library screen [27]. This is 
possibly due to it being essential in at least some conditions used to prepare the library though 
the fact that a c-terminal transposon insertion was tolerated indicates that this region may be 
dispensable for the essential function. The other mutation, in the bacterial ferredoxin, is a 
missense mutation converting a proline to leucine which may have some effect on the overall 
fold of the protein. Again the ferredoxin is deemed a putative essential gene in S. aureus [26] 
though it is the only member of the ferredoxin cluster not found to be essential in B. subtilis. 
Any effect due to this mutation would require further study and is likely not a direct action.  
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